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Abstract 
The recent discovery that fibroblasts can be reprogrammed directly to functional 
neurons with lentivirus has reinvigorated the belief that autologous human cell therapies 
against many neurodegenerative diseases may be achievable in the near future.  To 
increase the clinical translatability of this approach, we have developed a technique to 
perform this direct conversion without the use of virus.  We transfected fibroblasts with 
plasmids condensed into non-viral nanoparticulate carriers with a bioerodible 
peptidomimetic polymer, pCBA-ABOL. Gene delivery with pCBA-ABOL was 
exceptionally effective and nontoxic, producing high transfection efficiencies and 
enabling serial dosing of plasmid cocktails.  We delivered plasmids encoding neural 
lineage-instructive transcription factors to primary mouse embryonic fibroblasts (PMEFs), 
eliciting: drastic morphological changes, activation of endogenous neuronal transcription 
factor expression, neuronal promoter activity, and the appearance of neuronal proteins.  
Serial dosing of pCBA-ABOL complexes produced increasingly higher yields of these 
non-virally induced neurons (NiNs).  The majority of NiNs fired action potentials under 
patch clamp.  This is the first description of a method capable of directly inducing 
functional neuronal cells from fibroblasts without the use of virus. 
We then moved on to further increase the yield of NiN generation, in an effort to 
produce a sufficient quantity of neurons for cell therapies.  Informed by 
neurodevelopmental cues and by precedents set by the induced pluripotent stem cell 
(iPSC) field, we performed non-viral neuronal reprogramming in the presence of soluble 
microenvironmental factors that either inhibited GSK-3β and SMAD signaling, or 
v  
 
induced chronic membrane depolarization.  Chronic depolarization doubled the number 
of cells expressing neuronal markers produced with glutamatergic as well as with 
dopaminergic transcription factor cocktails.  Inhibition of GSK-3β and SMAD signaling 
similarly doubled the yield of glutamatergic NiNs, and enabled induction of neuronal 
markers and morphological transformation in human fibroblasts. 
In addition to soluble microenvironmental factors, the physical microenvironment 
can also strongly influence various cellular phenotypes.  This list includes many 
phenotypes related to endocytosis – the transit mechanism of nanoparticulate gene 
carriers entering cells during non-viral transfection.  As such, we set out to determine if 
patterned physical substrate topography could be used to increase non-viral transfection.  
We employed a high-throughput screen of micropitted substrate topographies, and indeed 
found that larger, denser micropits could support significantly higher transfection 
efficiencies in fibroblasts compared to smooth substrates.  The same topographies 
produced higher reverse transfection efficiencies, and greater siRNA-mediated 
knockdown of a reporter gene.  The control of transfection with substrate topography is a 
new design parameter that could find broad application in in vitro non-viral 
reprogramming strategies, as well as in the intelligent design of nucleic acid-eluting 
scaffolds in vivo.   
Encouraged by our success with direct neuronal reprogramming, and armed with 
a greater understanding of some microenvironmental mediators thereof, we attempted to 
produce non-virally-induced oligodendroglial progenitor cells (NiOPCs), which has been 
historically challenging for other investigators.  We discovered the fibroblastic 
intracellular microenvironment is a significant barrier to the function of Olig2 – a master 
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regulator of OPC phenotype – in direct reprogramming.  Fibroblasts do not express Olig2 
chaperones which are normally expressed in OPCs, causing Olig2 to become sequestered 
in the cytoplasm of transfected PMEFs.  We relieved this barrier through fusion of a 
strong nuclear localization sequence (NLS) to Olig2, which repartitioned Olig2-NLS 
from the cytoplasm to the nucleus in transfected fibroblasts.  The use of Olig2-NLS in 
iOPC reprogramming cocktails resulted in a drastic improvement in the yield of OPC-
specific marker expression.  The improvement associated with Olig2-NLS was 
insufficient to elicit significant myelin protein expression with the non-viral system, but 
the yield of virally-induced oligodendrocyte-like cells (iOLs) was improved dramatically.  
Further enhancements will be required to generate fully-reprogrammed NiOPCs, but the 
increased efficiency of viral iOPC generation is immediately useful for disease modeling 
and potentially in cell replacement therapies if human cells can be converted for the first 
time using this technique.  During direct reprogramming, CNS-specific transcription 
factors are delivered to foreign intracellular contexts as a rule, which may reduce their 
ability to function effectively; we have shown this can be a critical yet under-appreciated 
determinant of the success or failure of a direct reprogramming system. 
Taken together, the technological and intellectual advancements we describe 
herein represent significant improvements to non-viral transfection and reprogramming 
systems.  These techniques can find broad appeal to the many researchers and clinicians 
deploying these systems.  More specifically, we present significant steps towards 
realization of the dream of safe and effective autologous cell therapies against devastating 
and currently-intractable neurodegenerative diseases. 
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Chapter 1: Introduction 
1.1 Specific aims 
The objective of this dissertation is to present new methods to increase the 
effectiveness of non-viral gene transfer and cellular reprogramming, as applied to the 
direct conversion of “terminally-differentiated” fibroblasts to neurons and glia.  The 
generation of these non-virally induced neuronal (NiN), oligodendroglial progenitor cells 
(NiOPCs), and oligodendrocytes (NiOLs) is expected to lead to the first ethically-viable 
(non-embryonic) and safe (non-teratogenic and non-retroviral) autologous human cell 
sources for cell therapies against neurodegenerative disorders that currently lack curative 
treatment options.  The specific aims developed in this dissertation are: (1) the first 
demonstration of non-viral direct conversion of fibroblasts to functional neuronal cells, 
(2) the improvement of iN yields with developmentally-inspired microenvironmental 
factors, (3) the first demonstration that physical substrate topography can be used to 
enhance non-viral gene transfer, and (4) the discovery and circumvention of a fibroblastic 
intracellular microenvironmental context that strongly represses their direct conversion to 
iOPCs.  The results of these specific aims are summarized in Figure 1. 
 
Figure 1. Summary of specific aims 
SA1: Fibroblasts were directly converted to functional neurons without the use of virus. SA2: The 
efficiency of non-viral neuronal reprogramming was significantly improved with soluble 
microenvironmental factors that chronically depolarized the cells or inhibited SMAD and GSK-3β 
signaling. SA3: Micropitted substrate microtopographies that improve non-viral transfection were 
discovered with a high-throughput screening approach.  SA4: Relief of cytoplasmic sequestration of Olig2 
expressed ectopically in fibroblasts by genetic fusion with a nuclear localization sequence (NLS) greatly 
increases the induction of oligodendroglial markers during direct reprogramming. 
 
1.1.1 Specific aim 1: Non-viral direct neuronal reprogramming 
 Hypothesis 1: Non-viral neuronal transdifferentiation of fibroblasts into neuronal 
cells that fire trains of action potentials can be achieved, and can benefit from multiple 
serial doses of transcription factor-encoding plasmid DNA to produce high conversion 
efficiencies.  Poly(CBA-ABOL) is a uniquely nontoxic and effective non-viral gene 
carrier, and will be better-suited for this application than commercial reagents.  Chapter 
3: Here we demonstrated the feasibility of non-viral neuronal transdifferentiation.  We 
modified the first published lentiviral direct neuronal reprogramming technique – the 
delivery of the glutamatergic neuronal transcription factors Brn2, Ascl1, and Myt1l 
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(BAM factors) to primary mouse embryonic fibroblasts (PMEFs) – with a non-viral 
nontoxic bioreducible polymeric nanoparticle gene transfer system.  We optimized the 
polymer-to-DNA mass ratio and DNA dose to produce robust and nontoxic transgene 
expression in PMEFs.  A multiple dose transfection scheme was then developed to 
maintain high levels of transgene expression during the transdifferentiation process, and 
the effectiveness of these multiple doses was quantified by the induced expression of 
neuron-specific tubulin 1 (Tuj1) protein.  Non-virally-induced neuronal cells (NiNs) 
expressed a panel of other neuronal proteins and transgenic neuron-specific reporters.  
The most-mature NiNs were identified with a neuron-specific synapsin-RFP reporter 
lentivirus and were patch-clamped, revealing their ability to generate spontaneous and 
evoked trains of action potentials. 
 
1.1.2 Specific aim 2: Improved direct neuronal reprogramming by 
control of extracellular microenvironments 
 Hypothesis 2: Extracellular microenvironmental factors can improve NiN yields.  
Specifically, chronic depolarization or inhibition of GSK-3β and SMAD signaling will 
increase the number of NiNs generated with the BAM or ALN cocktails.  Chapter 4: 
With the proof-of-concept developed in SA1, we moved on to attempt the production of 
dopaminergic (DA) neurons, a clinically-relevant neuronal subtype with future utility in 
cell therapy against Parkinson's disease.  Accordingly, we used the methods in SA1 with 
a dopaminergic transcription factor cocktail: Ascl1, Lmx1b, and Nurr1 (ALN factors).  
DA neurons are induced with less efficiency than are glutamatergic neurons, and the 
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human cells required for translation are significantly more refractory to conversion.  
Therefore, the method developed in SA1 was modified to increase reprogramming 
efficiency for both target neuron subtypes.  Following transfection with the BAM or ALN 
factors, we significantly boosted the yield of NiNs with the inclusion of 30 mM KCl to 
chronically depolarize the cells, or with the inclusion of the small molecules LDN-
193189, CHIR-99021, and SB-431542 to inhibit GSK-3β and SMAD signaling.  The 
increased efficiency afforded by the small molecules was sufficient to encourage the 
activation of non-virally-induced neuronal markers and morphology from a human 
fibroblast source.  Taken together with our recent demonstration that lentiviral BAM 
neuron yields can be significantly increased by reprogramming PMEFs cultured on 
micrograting substrate topography, these results reveal the importance of extracellular 
physical and chemical microenvironments during multiple forms of direct iN 
reprogramming. 
 
1.1.3 Specific aim 3: Improved non-viral transfection by control of the 
physical cellular microenvironment 
 Hypothesis 3: High-throughput screening will identify micropitted topographies 
that enhance forward and reverse non-viral transfection and siRNA-mediated knockdown, 
compared to smooth substrates. Chapter 5: Here, we sought to determine whether non-
viral transfection efficiency could be improved by culture on controlled physical 
substrate topographies.  A high-throughput image analysis-based screening method was 
employed to discover substrate topographies in a combinatorial array that encouraged the 
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most efficient transfection of a GFP reporter plasmid in primary human fibroblasts.  This 
screening method used an optimized formulation of Lipofectamine 2000 – the most 
ubiquitous non-viral transfection reagent – in order to provide the most impact to the field.  
“Hits” discovered with imaging of the combinatorial topographic array were validated 
with flow cytometry, and the interaction of fibroblasts with these patterns was 
investigated with scanning electron and confocal microscopy.  The generality of 
topographic enhancement of transfection efficiency was demonstrated by the improved 
reverse transfection and siRNA-mediated knockdown of cells on patterned substrate 
topographies with Lipofectamine 2000, as well as the improved transfection of PMEFs 
with pCBA-ABOL.  When taken with our demonstration of improved viral BAM iN 
yield on microgratings, we expect that non-viral transfection for neuronal reprogramming 
performed on topography could benefit from both enhancements synergistically. 
 
1.1.4 Specific aim 4: Improved direct glial reprogramming via 
circumvention of an impermissive intracellular microenvironment 
 Hypothesis 4: Viral and non-viral iOPC generation is inefficient compared to iN 
generation, and therefore suffers from additional barriers to completion of this process.  
Cytoplasmic sequestration of Olig2 is one of these barriers, and re-localization of Olig2 
into the nucleus in reprogramming PMEFs will increase the induction of OPC and OL 
markers. Chapter 6: SA1-SA3 demonstrate and suggest new means that could be used to 
generate NiNs at greater and greater efficiencies, but one of the potential weaknesses of a 
direct-to-neuron reprogramming strategy for cell therapy is that the iNs exit the cell cycle 
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immediately upon successful conversion.  It may be also desirable to generate 
proliferative but committed progenitors, to ease the requirement for very high conversion 
efficiencies before human cell therapy can be attempted.  To investigate this possibility, 
we attempted viral and non-viral conversion of PMEFs to induced oligodendroglial 
progenitor cells (iOPCs) using Sox10, Olig2, and ZFP536 (SOZ factors).  We observed 
that Olig2 was expressed throughout the cytoplasm in PMEFs transfected with Olig2, and 
at times was excluded from the nucleus.  Genetic fusion of a strong nuclear localization 
sequence redistributed Olig2 inside fibroblast nuclei, and greatly increased the induction 
of S100β+O4+ iOPC-like cells, and the efficiency of MBP+ (myelin basic protein) iOL 
generation with virus. 
 
1.2 Organization statement 
Chapter 2 of this dissertation is a review of relevant background information.  
There are four subsequent research chapters, organized as a series of manuscripts, which 
are based on published articles, or have been prepared in a format compatible with 
submission for publication in peer-reviewed journals.  As such, there may be a degree of 
repetition in some introductory materials and experimental protocols.  The final chapter is 
a brief summary and recontextualization of the research presented herein.  
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Chapter 2: Background Information 
 
A portion of Chapter 2 appears in: Emerging links between surface nanotechnology 
and endocytosis: impact on nonviral gene delivery. Adler AF, Leong KW. Nano Today. 
2010 Dec 1; 5(6):553-569. 
 
The common thread throughout this dissertation is the use of non-viral 
transfection, with a specific aim towards safer autologous cell therapies against 
neurodegenerative disease.  First we provide background pertaining to the first phase of 
this goal – non-viral transfection.  Non-viral gene transfer vectors are a relatively mature 
and thoroughly-reviewed technology, so we place a new emphasis on the known and 
potential microenvironmental modulators of the process, which are important but under-
appreciated factors compared to the design of the vectors themselves.  We then move on 
to review the current state of gene and cell therapies applied against neurodegenerative 
disease, how the recent discovery of direct reprogramming from fibroblasts to neurons 
and glia might overcome problems associated with ES and iPSC-based therapies, and 
why the development of non-integrative methods is important for the full realization of 
this dream.  Finally, we look towards neurodevelopment and to known 
microenvironmental effectors of direct reprogramming to pluripotency, in an attempt to 
find new means to improve the yields of neurons and glia produced via the direct 
conversion of fibroblasts. 
 
  8  
 
 
2.1 Non-viral gene delivery 
Gene transfer techniques and therapies have enjoyed steady interest due to their 
current and potential application against a diversity of human illnesses [1] including 
diabetes, hemophilia, peanut anaphylaxis, and cystic fibrosis.  In an effort to increase 
transfection efficiency and specificity, researchers and physicians often turn to carrier 
systems to deliver engineered genetic material to target cells and tissues.  Generally, such 
carriers fall into one of two broad categories – viral or non-viral vectors.  Viruses are 
naturally professional gene therapists, and have been reengineered to carry a myriad of 
therapeutic gene sequences.  Despite their high efficiency, there are a number of 
drawbacks associated with viral vectors: they are typically more immunogenic than their 
non-viral counterparts, limited in DNA packaging capacity, and if randomly integrative 
can introduce significant levels of genotoxicity.  These potential issues motivate the 
ongoing search for suitable alternatives, frequently in the form of particulate polymer- 
and lipid-DNA complexes, which are less toxic, are able carry larger genes, and are 
amenable to formulation optimization to provide prolonged circulation, targeted delivery, 
and improved storage stability. 
In spite of their wide application, the mechanisms whereby DNA complexes are 
able to traverse the cellular, lysosomal, and nuclear membrane barriers to then induce 
transgene expression are only recently being elucidated, often with contradictory results 
for seemingly similar carriers.  Efficient cellular internalization of the carrier-DNA 
complex is crucial to non-viral gene transfer. Increasing consideration has been given to 
nanoscale particulate parameters including size, shape, ligand decoration, and surface 
charge. These parameters have been shown to dictate the extent and pathway of endocytic 
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uptake, and the subsequent ability of the DNA to arrive intact within the nucleus, able to 
induce transgene expression. 
While clearly important for successful non-viral transfection, particulate 
parameters do not fully account for the differences in transfection efficiency in vitro and 
in vivo; particle- and cell-substrate interactions have also been demonstrated to influence 
the uptake and expression of particulate non-viral vectors.  When delivered from a 
surface, the ability of non-viral particles to induce gene expression depends not only on 
their local concentration, but also on the tightness of their adsorption, the presence of 
extracellular matrix (ECM) proteins, and substrate surface chemistry.  Substrates with 
micro- and nano-patterned topographies could also directly influence the endocytic 
behavior and transfectability of interacting cells by inducing changes in proliferation, 
spreading, morphology, cytoskeletal arrangement, differentiation, and protein expression.   
Though potential molecular links have been described by molecular biologists, little is 
known about the functional interactions between DNA complexes, cell substrates, focal 
adhesions, and the cytoskeletal and endocytic machineries; this presents an exciting 
opportunity for the design of particles and substrates that are able to probe and exploit 
beneficial aspects of endocytic processes. 
While nanoscale particulate parameters continue to gain prominence, the 
contribution of nanoscale substrate-mediated effects on DNA complexes and cells that 
interact with them is generally ignored during non-viral gene carrier optimization.  Here 
we highlight the body of evidence supporting the importance of nanoscale particulate 
parameters for gene delivery, and also prospect routes whereby nanoscale substrate 
parameters may influence the uptake, processing, and expression of nucleic acids 
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delivered by these particles.  A full understanding of the interaction of cells with non-
viral gene carriers depends not only on an awareness of particulate parameters and their 
implications on endocytosis and transgene expression, but also on a clear knowledge of 
the substrative microenvironmental context in which the particles are presented. 
 
2.1.1 Barriers to gene transfer 
DNA complexes must overcome a series of barriers to gain access to the 
membrane surface, cytoplasmic compartment, and nucleus of a target cell, and to 
translate transgenes into protein (Figure 2).  As particles encounter each of these barriers, 
they are subject to a certain probability of success or failure in overcoming each.  The 
product of the probabilities of success for each step in the journey is reflected in the 
transfection efficiency for a given system.  Certain portions of the trip may be more 
limiting than others for a given carrier system.  If an easily-crossed barrier is not subject 
to saturation and is upstream of a bottleneck barrier, increasing the efficiency of crossing 
the upstream barrier may help to increase the number of particles or plasmids that appear 
downstream of the limiting barrier. 
 
Figure 2. Barriers to non-viral gene delivery 
(1) Transgenic DNA can be lost due to incomplete complexation with cationic polymer/lipid. (2) 
Complexes may be cleared from the circulation before they are able to bind to the cell surface. (3) Some of 
the complexes bound to the cell surface will not be internalized. (4) Following endocytosis, a portion of 
DNA may be degraded within the acidic late endosomes and lysosomes. (5) DNA successfully escaping the 
endosomal compartment may be further degraded by cytoplasmic DNAse. (6) A portion of the DNA 
reaching the nucleus may be unable to induce transcription. (7) Some of the exported mRNA may be 
incapable of translation into transgenic protein. 
 
 
This probabilistic way of thinking about non-viral gene delivery is supported by a 
study finding that noncoding DNA can enhance the efficiency of transfection by 
polyethylenimine- (PEI) DNA complexes [2].  A constant quantity of reporter plasmid 
was diluted with noncoding “junk” DNA, followed by delivery of either one population 
of particles containing both coding and noncoding DNA, or co-delivery of two different 
particle populations – one containing coding DNA and one without.  It is important to 
note that because the total amount of coding DNA remains the same in each case, the 
number of particles including coding DNA is increased in the case of particles formed 
with both coding and noncoding DNA.  The mean expression per cell was not affected, 
but the number of expressing cells was increased when a larger number of coding 
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particles were delivered.  The authors suggest that nuclear entry is a very inefficient 
process, so increasing the number of coding particles can overcome this bottleneck by 
increasing the number of opportunities for this rare event to occur. 
The formation of DNA complexes usually proceeds by condensation of anionic 
DNA with cationic lipid (lipoplex) or polymer (polyplex); these interactions must be 
strong enough to keep particles stable during exposure to charged serum components.  
The next barriers facing systemically delivered particles are extracellular, and include: 
serum proteases and nucleases, variations in pH, opsonization, and clearance during 
passage through the kidneys and liver [3].  Upon arrival near the cell, complexes must 
associate with the cell surface, either through electrostatic interactions, physical 
concentration at the cell substrate via adsorption, or by ligand-receptor binding.  
Originally, it was thought that lipoplexes could then enter target cells by direct fusion 
with the cell membrane.  It is now well-accepted that both nonspecifically- and ligand-
bound complexes enter cells principally via endocytic processes [4], which we consider 
in detail in the following section.   
After escape from the endocytic compartment, the complexes must gain entry to 
the nucleus, and unpack their DNA cargo.  Upon arrival at this step, it becomes a liability 
for carriers to bind their cargo too tightly; overbinding prohibits access by the 
translational machinery (striking an appropriate balance between protection and release 
has been reviewed by Grigsby et al. [5]).  Indeed, it is worth mentioning that translational 
inefficiencies may generally be one of the most rate-limiting obstacles in non-viral gene 
delivery.  In one excellent exploration of this barrier, the efficiency of each step in 
transfection mediated by adenovirus and lipofectamine (LF) was compared [6-7].  LF 
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was shown to require a dose three thousand times higher than that delivered by 
adenovirus to support the same level of expression.  Though LF encouraged higher levels 
of DNA uptake on a per-carrier basis, adenovirus was eight thousand times more efficient 
at completing transcription and translation of the transgenes delivered to the nucleus.  
Chemistry also appears to be important for this process; PEI polyplexes have been 
observed to unpack more efficiently compared to DOTAP lipoplexes following direct 
injection into the nucleus, lowering the translational barrier for this polyplex upon arrival 
in the nucleus [8]. 
 
2.1.2 Endocytic pathways 
A basic discussion of relevant endocytic pathways is required to describe the 
uptake of non-viral vectors.  All cells perform some form of endocytosis to maintain the 
homeostasis of intracellular species.  Endocytosis is broadly divided here into clathrin- 
and caveolae-mediated endocytosis, and fluid-phase macropinocytosis (Figure 3).  These 
three pathways are not inclusive of all the forms of endocytic uptake of non-viral carriers 
[9], but are the most studied in this context, and are our focus here. 
 
Figure 3. Endocytic pathways traversed by non-viral carriers 
Cationic particles bind to anionic heparan sulfate proteoglycans (HSPGs) and may be internalized via 
macropinocytosis (A), a form of fluid-phase endocytosis. Macropinosomes are fluid-filled vesicles formed 
by actin-driven membrane ruffling; these vesicles may fuse with degradative late endosomes, or may be 
trafficked directly to the nucleus. Non-viral vectors can also be internalized by clathrin-mediated 
endocytosis (B), which progresses by receptor clustering, formation of the clathrin coat, and actin-driven 
internalization, forming early endosomes. Some early endosomes are recycled to the cell surface, while 
others are uncoated, acidified, and progress to late endosomes and lysosomes on their way to the nucleus. 
Caveolae-mediated endocytosis (C) proceeds by oligomerization of caveolin, actin-dependent 
internalization of caveolae to form cavicles, and merger with the degradative lysosomal compartment, or 
non-degradative trafficking to the nucleus via caveosomes. Each pathway relies on microtubules for rapid 
transport of endocytic vesicles. 
 
 
Clathrin-mediated endocytosis is the most well-understood endocytic pathway 
[10], and is involved in nutrient uptake and signal transduction through internalization of 
ligand-bound receptors [3].  Low density lipoprotein (LDL), transferrin (Tf), and 
epidermal growth factor (EGF) are prototypic species transported via clathrin-mediated 
endocytosis.  Upon receptor-ligand binding, the receptors cluster in clathrin-coated pits, 
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mediated by the adapter protein AP-2 [11].  Dynamin, a GTPase, then frees the coated pit 
into the cell interior, fusing with and forming early endosomes [4, 10].  Depending on the 
cargo molecule, early endosomes are either uncoated and trafficked to acidic lysosomes 
via microtubule transport, or shuttled back to the cell surface via recycling endosomes.  
Exposure to the acidic and degradative lysosomal compartment reduces the transfection 
efficiency of non-viral vectors.  Therefore, enhanced escape from the acidic endosomes 
by the proton sponge effect [12], or by chemical and physical endosomolytic agents, have 
been pursued to help surmount this barrier [13].  Clathrin-mediated endocytosis is at 
times synonymous with “receptor-mediated endocytosis” in the literature, but this 
terminology has become antiquated with the discovery that other forms of endocytosis 
also proceed by ligand-receptor binding. 
 Caveolae-mediated endocytosis is associated with the uptake of 
glycosphingolipids, and is involved with transcytosis of serum proteins across 
endothelium [11].  Caveolae are caveolin-coated, cholesterol- and sphingolipid-enriched 
flask-shaped invaginations in the cell membrane.  These structures are relatively static 
compared to clathrin-coated pits, and generally proceed via slower uptake kinetics 
compared to clathrin-mediated endocytosis [14].  Upon dynamin- and actin-mediated 
uptake, cavicles are shuttled toward the nucleus via microtubules.  Importantly for non-
viral gene delivery, certain forms of caveolae-mediated endocytosis are thought to avoid 
the degradative lysosomal compartment [15].  Caveolae-mediated endocytosis has been 
shown to be initiated by viruses binding to and clustering integrins, resulting in their 
uptake [16] in a manner similar to that observed in the ligand-receptor binding of 
clathrin-mediated endocytosis. 
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 Macropinocytosis, a form of fluid-phase endocytosis, is the uptake of fluid and 
solutes by actin-driven ruffling of the plasma membrane.  Macropinocytosis can be 
induced by platelet derived growth factor (PDGF) activating Rho-family GTPases, which 
trigger actin assembly and internalization of surrounding extracellular fluid [11].  Long-
range transport of macropinosomes along microtubules is inhibited by nocodazole.  The 
rate of macropinocytosis of a solute is typically proportional to its concentration in 
solution (giving non-saturable kinetics).  Like caveolae-mediated endocytosis, particles 
endocytosed by macropinocytosis may bypass the lysosomal compartment, making it an 
attractive pathway for efficient non-viral gene delivery. 
 A number of studies have unambiguously implicated macropinocytosis and 
clathrin- and caveolae-mediated endocytosis as necessary processes for the uptake and 
subsequent expression of both poly- and lipoplexes. The contribution of each of these 
pathways also varies by cell type and cargo identity.  The degradative processes 
following particle uptake vary by endocytic pathway and have been shown to be 
important barriers to non-viral gene delivery. 
Clathrin-mediated endocytosis has been demonstrated to support transfection by 
lipoplexes through studies employing electron microscopy and co-localization with 
labeled transferrin [17].  Cells subject to inhibition of clathrin-mediated endocytosis by 
potassium or cholesterol depletion and those expressing dominant negative mutant Eps15 
do not internalize lipoplexes, and subsequently support lower levels of transgene 
expression (wild-type Eps15 allows docking of AP-2 to the plasma membrane, which 
goes on to assemble clathrin-coated pits)  [18].  Endocytosed lipoplexes eventually co-
localize with acidic lysosomes stained with LysoTracker, providing evidence that 
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particles taken up by this pathways are subject to low pH [19].  The use of nocodazole to 
interfere with microtubule function has also been shown to increase the nuclear 
accumulation and transgene expression of lipoplexes [20].  The authors suggest that 
because nocodazole uncouples endosomes from their trafficking to the lysosomal 
compartment [21], lipoplexes are able to skirt degradative processing following 
endocytosis, thereby increasing their transfection efficiency. 
 The ability of a non-viral vector to escape from the endosomal compartment 
determines that carrier’s transfection ability.  Polyplexes and lipoplexes are believed to 
escape endosomes using different mechanisms.  Carriers with a strong ability to buffer 
the influx of protons during endosome acidification increase the accumulation of H+ and 
Cl- ions and osmotic pressure within the vesicles, eventually leading to bursting and 
vector escape [10].  Inhibition of the activity of proton pumps decreases the transfection 
efficiency of PEI polyplexes [22], and endosomes have been observed to accumulate 
greater amounts of Cl- and swelling after delivery of highly-buffering polyplexes [12].  In 
contrast to this “proton sponge effect”, lipoplexes containing lipids that encourage 
formation of nonlamellar phases may escape endosomes through direct fusion and release 
into the cytosol [23].  Non-viral carriers must have the ability to escape the endocytic 
vesicles encountered along the endocytic pathway(s) they traverse. 
A study relying on direct microscopic visualization has elucidated the relationship 
between endocytosis and transfection efficiency of PEI polyplexes, through observation 
of the uptake of polyplexes stained with YOYO-1 (a fluorescent DNA intercalator) by 
fibroblasts labeled with FM4-64 (a lipophilic stain which fluoresces red upon binding the 
outer leaf of cell membranes) [24].  Labeled particles were observed to co-localize 
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strongly with the membrane marker for endocytosis for the duration of the transfection 
process.  Since endocytic uptake of the cell membrane and the macropinocytic uptake of 
extracellular fluid proceed by the same intracellular pathways, the polyplexes in this 
study were believed to be taken up by fluid-phase endocytosis.  Given the co-localization 
persisted through maturation of the early endosomes into lysosomes, a large fraction of 
the complexes were sequestered in the endocytic compartment, with only a small 
population escaping to the nucleus to induce transgene expression. 
 Douglas et al. noted cell-line dependent differences in the endocytic processes of 
293T, COS7, and CHO cells as the cause for varying levels of transfection using identical 
preparations of alginate-chitosan-DNA nanoparticles [25].  By measuring the variable 
inhibition of particle uptake by the clathrin-mediated inhibitor chlorpromazine and 
caveolin-mediated inhibitor genistein, the authors were able to determine that both routes 
were used for COS7 and 293T cells, whereas CHO cells endocytosed particles by a 
clathrin-independent mechanism.  Furthermore, the induction of macropinocytosis by 
phorbol myristate acetate (PMA) did not result in an increase in complex internalization 
for any cell type.  For COS7 and 293T cells, transfection was only supported by particles 
taken up by clathrin-mediated endocytosis, whereas CHO cells did not produce 
significant transgene product, possibly because they lack the mannose receptor indicated 
in the clathrin-mediated uptake of chitosan.  In this case, clathrin-mediated endocytosis 
was thought to be superior because the particles were visualized escaping the acidic 
lysosomes, presumably via the proton sponge effect, whereas particles trafficked to non-
degradative caveosomes lacked an escape mechanism and were therefore sequestered.  
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These results highlight the dependence of vector trafficking on particle chemistry and cell 
type. 
 Caveolae- and clathrin-mediated endocytosis have been demonstrated to be 
required for uptake and expression of polyplexes and lipoplexes, respectively, in a single 
study [14].  The internalization of DOTAP lipoplexes was inhibited by chlorpromazine 
and potassium depletion (clathrin-mediated) but was not affected by filipin and genistein 
(caveolae-mediated), and the uptake of PEI polyplexes was down-regulated by all four 
inhibitors.  Transfection by DOTAP particles was also abolished by inhibitors of clathrin-
mediated endocytosis, whereas transfection by PEI particles was only inhibited by 
removal of caveolae-mediated uptake.  Rejman et al. suggest that PEI polyplexes (which 
are unable to fuse directly with endocytic vesicles due to a lack of lipid content) were 
only able to avoid degradation if trafficked via non-degradative caveolae-mediated 
endocytosis.  On the other hand, the lipoplexes taken up by clathrin rapidly escaped the 
degradative pathway before acidification by direct fusion with the vesicle membranes. 
 Macropinocytosis is a major route of entry for positively charged complexes, 
particularly for those coated with arginine [26].  Membrane-bound negatively-charged 
heparan sulfates act as receptors for positively charged particles; liposomes modified 
with octaarginine co-localized with neutral dextran, a tracer of fluid-phase endocytosis 
[27].  The uptake of these particles was inhibited by amiloride, which interferes with a 
Na+/H+ exchanger required for macropinocytosis.  The lipoplexes internalized by 
macropinocytosis did not co-localize with acidic lysosomes, lending support to 
macropinocytosis as an attractive non-degradative pathway for gene delivery. 
 
2.1.3 Nanoparticulate parameters 
As has been described, non-viral vectors can be transported to the cytoplasmic 
compartment by a diversity of endocytic mechanisms.  Each of these pathways may 
support a different level of transfection mediated by a given lipo- or polyplex delivery 
system.  An emerging paradigm for the design of effective gene carriers is the 
modification of particulate parameters to encourage entry via a preferable endocytic 
pathway.  These parameters include size, shape, charge, chemistry, and ligand 
modification.  These factors are often difficult to vary independently, so the contribution 
of each can be difficult to generalize. Furthermore, endocytic processes vary by cell type, 
so the behavior of particles in one culture system may not be predictive of another.  For 
example, HepG2 cells lack endogenous caveolin and are therefore unable to internalize 
particles by caveolae-mediated endocytosis [28].  Some of the key findings of this section 
are summarized in Figure 4. 
 
 
Figure 4. Typical strategies to overcome barriers to non-viral gene transfer 
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Tuning nanoparticle chemistry, size, surface charge, shape, and ligand density can alter the endocytic 
pathway and efficiency with which nanoparticles are taken up.  Cell substrate parameters are often ignored 
in the design of non-viral transfection system. 
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2.1.3.1 Particle chemistry 
 Altering the chemistry of a particle can modulate its hydrophilicity, the tendency 
for it to fuse with endocytic vesicles, and its susceptibility to serum inhibition, all with 
implications for uptake and transfection efficiency.  For instance, a comparison of six 
phosphatidylcholine lipoplexes with varying hydrophobic chain lengths revealed that 
those with short chains mediated much higher levels of transfection in endothelial cells, 
both in the presence and absence of serum [29].  X-ray diffraction showed the particles 
supported formation of an inverted cubic phase, which is believed to resemble the 
membrane structure produced during fusion between lipid bilayers [30].  Masotti et al. 
have shown identical particle sizes or charge ratios of DMRIE/Chol, Cellfectin, 
Lipofectamine, Lipofectamine 2000, Lipofectin, and Fugene lipoplexes induce 
transfection levels that vary over many orders of magnitude in rat glioma cells [31].   
PEGylation of cyclodextrin polyplexes endowed the particles with enhanced 
stability in the presence of salt, but decreased their uptake and transfection efficiency in 
BHK-21 cells [32].  PEGylated PEI polyplexes were taken up to a similar extent as 
unmodified particles, but were unable to transfect cells as efficiently; the addition of PEG 
may have interfered with the proton sponge effect.  Using EM and fluorescence 
microscopy, the authors observed that PEGylated particles remained separate and stable 
during their journey toward the nucleus and were unable to unpack their DNA cargo, 
whereas unmodified particles aggregated into larger masses, which released their DNA 
into the cytoplasm and the nucleus.   
The molecular weight and degree of branching in PEI has been investigated in 
PEI/liposome/DNA complexes (polylipoplexes).  Branched and linear PEI induced 
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similar levels of transfection, but PEI with lower molecular weight performed better than 
the larger PEI.  Improvements in transfection efficiency with low over high molecular 
weight PEI have also been observed for pure PEI polyplexes [33].  PLGA nanoparticles 
made more hydrophilic with an increasing fraction of PVA emulsifier at their surface had 
a similar size and surface charge as more hydrophobic particles, but were taken up 
significantly less by smooth muscle cells [34]. 
 
2.1.3.2 Particle size 
 Nanoparticles are necessarily described by characteristic size parameters.  It is 
important to note that DNA complex size can be a moving target, and is not completely 
defined by a single number.  That is, particles often aggregate with time and, like 
polymers, require reporting of a polydispersity parameter for a full description of their 
size characteristics.  Caution is warranted in comparison of particle sizes measured with 
different techniques and at different hydration states.  For example, a particle’s 
hydrodynamic diameter measured in solution with dynamic light scattering may differ 
significantly from the same particle measured after dehydration and visualization by 
TEM.  The endocytic machinery and cell membrane have well-defined geometries and 
flexibility that may restrict entry of incompatibly large or small particles.  Modifications 
and procedures to create or stabilize a target nanoparticle size can direct gene carriers to 
endocytic routes that are supportive of high expression levels. 
A linear relationship between the size of DC/Chol/DOPE lipoplexes, uptake, and 
transfection efficiency was observed over a range of 300-2000 nm; this relationship held 
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true regardless of whether the particle size was changed by altering the cation to DNA 
charge ratio, or serum concentration [35].  Interestingly, particles formed in the presence 
of increasing serum concentration bound to cell membranes to the same extent, but larger 
particles were endocytosed much more efficiently.  The size of DOTAP/DOPE lipoplexes 
can also be increased by pre-incubation with free PEG in solution prior to the onset of 
transfection [36].  PEG dehydrates and destabilizes lipid bilayers, leading to increased 
aggregation, fusion, and generation of micron-size particles from 500 – 800 nm 
nanoparticles.  This increase in size led to an increase in cellular association and uptake 
of the particles in multiple cell types.  Transfection efficiency also improved for micron-
size particles, but the increase in uptake did not account for the difference observed, 
suggesting the larger particles may have been preferentially trafficked into a more 
favorable endocytic route.   
Extrusion of various multilamellar vesicles through a 100 nm filter resulted in 
lower transfection efficiency, but the identity of the cationic lipids used had a stronger 
effect on transfection in Neuro2A cells [37].  Similarly, Li et al. observed an increase in 
uptake and transfection efficiency of DOTAP and Lipotap complexes when their size was 
increased with subsequent layer-by-layer self-assembly of positively charged gold 
nanoparticles with uncomplexed DNA on the surface of the lipoplexes [38].  Altered 
endocytic trafficking should be added to the authors’ list of possible mechanisms 
whereby the larger particles increased transfection efficiency, which included elevated 
sedimentation, DNA payload, and charge-shielding.  Larger, low molecular weight PEI 
polyplexes (590 nm) have also been observed to transfect NIH-3T3, HEK293, COS-7, 
CHO, HeLa, and Jurkat cells more efficiently than small high molecular weight 
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polyplexes (156 nm), though it is unclear what contribution size made relative to weaker 
DNA condensation for the larger particles [33]. 
Prabha et al. separated a bimodal preparation of PLGA nanoparticles into 
fractions with hydrodynamic diameters of 150 and 300 nm [39].  The smaller 
nanoparticles produced 27x higher transfection efficiency in COS-7 cells, despite similar 
levels of particle uptake by mass and slower DNA release by the smaller particles.  
However, it was revealed with calculation that the smaller particles were taken up 20x 
more efficiently by number.  Therefore, it is difficult to determine if the increase in 
transfection efficiency was a result of differential trafficking, or simply due to an increase 
in particle count.  Considering that non-viral carriers are typically delivered on a per-
mass basis, increases particle count with decreasing diameter may influence transfection 
efficiency in many studies without notice.  Other polymeric systems produce similar size-
dependencies on uptake; only sub-micron polystyrene particles are efficiently taken up by 
Caco-2, HepG2, and Hepa 1-6 cells [40].  Very small (< 25 nm) particles may traffic 
through a unique non-clathrin- and non-caveolae pathway that could be interesting for 
non-viral gene delivery [41]. 
 Particle size clearly affects the extent to which particles are taken up and are able 
to transfect target cells.  Though many of the results presented here have suggested larger 
polymer and lipid particles (still in the submicron rage) are taken up more efficiently than 
smaller ones, some studies have claimed particles smaller than 100 nm offer good 
transfection efficiency, particularly when they must first pass through a capillary network 
(in vivo) [30].  Beyond controlling the extent of uptake, particle size has also been 
demonstrated to control the endocytic uptake pathway of nanoparticles [42].  In a 
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comparison of the uptake of fluorescent latex nanospheres by B16 cells, uptake was only 
observed for particles 50-500 nm in diameter, but not for 1 um particles.  Inhibitors of 
clathrin-mediated endocytosis were less effective at blocking uptake of large particles, 
whereas inhibitors of uptake by caveolae were only effective against the uptake of 500 
nm nanospheres.  Small particles (50 – 100 nm) were taken up within 30 minutes and 
appeared in the lysosomal compartment, whereas larger particles were taken up over a 
span of hours and did not colocalize with the late endosomes.  These results suggest that 
large particles may be preferentially trafficked through a slow, non-degradative, 
caveolae-mediated route, and may explain why larger lipoplexes often produce higher 
transfection efficiencies.  It would be interesting to extend these results to other 
chemistries and surface charges to determine if the size cutoffs for each pathway are 
intrinsic to a particular geometry of the endocytic machinery. 
 
2.1.3.3 Surface charge 
 Along with size, surface charge (zeta potential) is a ubiquitous particulate 
parameter that is important for the understanding of uptake mechanisms and transfection 
efficiency.  Particles that may be of an appropriate size to traverse a desired endocytic 
pathway may not be able to access that pathway if cellular binding is diminished by a 
significantly negative zeta potential.  Also, the stability of a particulate gene delivery 
system can often be predicted by its zeta potential. 
 It is generally believed that positively-charged nanoparticles perform better for in 
vitro transfection of cells through their enhanced binding to negatively-charged 
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proteoglycans on cell surfaces [27, 43].  Indeed, grafting polymerization of MMA onto 
carboxymethyl chitosan or chitosan hydrochloride can generate 150 nm nanoparticles 
with widely varying surface charge, leading to charge-dependent differences in endocytic 
uptake [44].  Particles with more-positive zeta potentials encouraged the highest rates of 
uptake in L02 and SMMC-7721 cells. 
The dependence of uptake efficiency on surface charge is extendable to particles 
carrying genetic payloads.  Optimization of a non-viral carrier often involves an 
empirical modification of the charge ratio (cationic polymer or lipid to anionic DNA) 
aimed to balance competing effects on cellular binding and uptake, DNA protection and 
release, and complex size and stability.  Despite this wide parameter space for 
optimization, carriers with positive surface charges are often the most effective.  This is 
likely due to increased binding to anionic cell surfaces, as well as more complete DNA 
complexation at high (+/-) charge ratios.  Almofti et al. demonstrated that increasing the 
DNA content of DC-Chol-DOPE lipoplexes resulted in a decrease in zeta potential [45].  
Particle size and liposome-liposome fusion were maximal at neutral charge ratios where 
the particles were unable to repel each other electrostatically, however transfection in 
A431 cells was greatest at a slightly positive charge ratio and was abolished by endocytic 
inhibitors.  EPC-Chol lipoplexes modified with octaarginine demonstrate a similar 
dependence on surface charge; increasing densities of octaarginine produce increasingly 
cationic particles, leading to an increase in macropinocytosis, uptake, and transgene 
expression [26]. 
 Though a positive zeta potential may be desirable to increase cellular uptake in 
vitro, positively charged particles may interact with negatively charged serum proteins in 
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vivo, leading to charge neutralization, opsonization, increased particle size, and clearance 
[46].  With this in mind, cationic particles can be pre-neutralized with plasma-compatible 
proteins to increase transfection efficiency [47-48].  Unlike their cationic precursors, 
BSA-neutralized particles do not accumulate extra protein or increase in size upon 
exposure to plasma, and are endocytosed more effectively than PEG-shielded liposomes 
[47].  The authors suggest this may be a consequence of the caveolae-mediated 
endocytosis of surface BSA by the albumin receptor gp60 [49]. 
 
2.1.3.4 Shape   
 Nonspherical particle shapes are only recently being evaluated for altered tissue 
distribution and cellular uptake.  This may be due to a previous lack of readily available 
techniques for the synthesis of well-defined nonspherical particles [50].  A lithographic 
method called PRINT (Particle Replication In Non-wetting Templates) has been 
developed to produce particles with various shapes and surface charges [51-52].  These 
cationic poly(ethylene glycol)-based particles with different shapes but similar zeta 
potentials have dramatically different uptake kinetics in HeLa cells.  Comparing cylinders 
with similar particle volume, 150 nm cylinders with aspect ratio of 3 were taken up much 
more rapidly than 200 nm cylinders with aspect ratio of 1.  The uptake was abolished if 
the particles were rendered anionic by conversion of protonated surface amines to amides.  
The authors also interrogated the cells with a series of endocytic inhibitors, revealing 
important roles for clathrin- and caveolae-dependent endocytosis in the uptake of small 
particles.  The high aspect ratio 150 nm cylinders may have been taken up efficiently due 
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to their utilization of all of the endocytic pathways probed.  Highly elongated lipoplexes 
have also demonstrated improved efficiency in vivo [53], but the elongated structure has 
not been clearly correlated with improved transfection efficiency in vitro [54]. 
 Alexander et al. have shown that polymeric micro-doughnuts are internalized 
much less efficiently than similarly-sized microspheres in a variety of non-phagocytic 
cell types [55].  This could be explained by the necessitation of a greater membrane 
curvature to engulf nonspherical particles of equal volumes [56].  Also, oblong 
nanoparticles with a minor axis that is smaller than nuclear membrane pores have been 
shown to transfect post-mitotic cells following cytoplasmic injection [57].  Taken 
together, these effects suggest particle shape could be engineered to investigate, avoid, or 
exploit various endocytic pathways and barriers to transfection by presentation of well-
defined lengths and curvatures. 
 
2.1.3.5 Ligand modification 
 Nanoparticles can also be targeted to specific arms of endocytosis through 
modification with species known to ligate endocytosable receptors, though this enormous 
body of work will not be the focus of this review.   These strategies are particularly useful 
for targeting cell types that uniquely- or otherwise over-express a particular receptor.  
Many of the classic endocytic ligands have been added to the surface of DNA complexes 
to increase transfection efficiency, including EGF-modified PEI polyplexes [58-60] and 
transferrin-modified lipoplexes [61-63] targeted to clathrin-mediated endocytosis.  As 
previously mentioned, heparan sulfate proteoglycans act as “nonspecific receptors” for 
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the binding of particles modified with arginine-rich peptides [64-65].  Arginine 
decoration can increase uptake by macropinocytosis [26] and clathrin-mediated 
endocytosis [66], depending on the orientation and concentration of the peptide on the 
particle surface.  Interestingly, the uptake of octaarginine-modified particles can be 
switched from macropinocytosis to a caveolae-mediated pathway by substitution of only 
two of the peptide’s residues [67]. 
 
2.2 Cell-substrate interactions 
2.2.1 Impact of substrate chemistry on transfectability 
As discussed above, cell-particle interactions are critically important for efficient 
uptake and transfection.  Through these interactions, particle morphology and chemistry 
can either enable or prohibit entry into and expression from target cells.  However, non-
viral vectors not only interact with target cells, but also with the substrates on which the 
cells are cultured.  While these particle-substrate interactions may quietly impact the 
success of many “forward” transfection systems, their effects are most apparent during 
reverse transfection (also referred to as substrate-mediated transfection).  Reverse 
transfection differs from forward transfection in that cells are seeded on top of particles 
that have been previously immobilized onto a surface, rather than adding particles to 
previously seeded cells.  Complex immobilization is thought to increase transfection 
efficiency by increasing the local concentration of DNA at the cell surface, and can out-
perform bolus delivery at times [68-70].  In one such example, Okazaki et al. found that 
reverse transfection of DNA-spermine-pullulan complexes maintained better hMSC 
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viability, and produced a more intense and sustained expression of reporter transgene 
compared to forward transfection in the presence of serum - an important consideration 
for in vivo translation [71].  Substrate-mediated gene delivery also provides a simple 
method to locally deliver genetic material from the surface of porous implants.  However, 
if the association of complexes with a substrate is too tight, endocytic uptake and 
transfection can suffer.   
The context wherein adsorbed complexes are presented to cells can be modified 
with surface chemistry and the deposition of serum or ECM proteins.  These 
modifications can alter transfection efficiency in a manner uncoupled from the extent of 
uptake, suggesting alternate processing for complexes presented in different substrative 
microenvironmental contexts.  The consequences of altering the density and tightness of 
particle adsorption, as well as the benefit of matrix proteins, are presented in Figure 5.  
Furthermore, substrate-mediated transfection may change the rate-limiting barrier to 
expression.  For instance, Bengali et al. report that internalization of lipoplexes is 
impaired but nuclear trafficking is improved in reverse compared to forward transfection.  
On the other hand, internalization of polyplexes was unaffected, but nuclear trafficking 
was impaired upon substrate-mediated rather than bolus delivery [72].  Reverse 
transfection may therefore be well-indicated for switching a bottleneck barrier to one that 
a certain particle type is more able to overcome. 
 
Figure 5. Effect of density and presentation of surface-bound complexes on the efficiency of reverse 
(substrate-mediated) transfection 
(A) Low densities of adsorbed complexes lead to low levels of particle uptake and expression upon cell 
seeding.  (B) Increasing the density of adsorbed complexes may lead to proportionally increased expression, 
but (C) over-tight immobilization of complexes renders cells unable to internalize bound complexes, and 
diminishes transgene expression. (D) Complexes co-immobilized with extracellular matrix components 
often support superior internalization and transfection by incompletely-understood mechanisms. 
 
2.2.1.1 Concentration of DNA at the cell surface 
 The concentration of DNA at the cell surface has been suggested as a limiting 
factor in non-viral gene delivery [73].  For forward transfection, the delivery of 
complexes to the cell surface is typically a diffusion-limited process, whereas reverse 
transfection can pre-load complexes at high levels onto the cell-substrate interface 
through drying, electrostatic and hydrophobic interactions, or ligand-receptor binding.  
Similar to forward transfection, increasing the amount of DNA adsorbed to a surface 
during reverse transfection increases expression levels, up to a limit.  PEI polyplexes with 
increasingly positive zeta potentials adhere in greater numbers to acellular intestinal 
submucosa that is rich in negatively charged glycosaminoglycans, leading to increased 
transgene expression in fibroblasts seeded in direct contact with the adsorbed complexes 
[74].  The size of printed lipoplex spots depends on the hydrophobicity of the substrate; 
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more hydrophobic substrates produce smaller spot sizes, higher local DNA 
concentrations, and elevated expression levels [75]. 
 
2.2.1.2 Strength and nature of complex adsorption 
Aggregation may translate to weaker binding between complexes and their 
substrate [76].  Polyplexes formed from a block copolymer of cationic poly N,N-
dimethylaminopropyl acrylamide and thermoresponsive N-isopropylacrylamide did not 
produce strong expression in forward transfection or when dried to the culture surface.  
However, heat-induced hydrophobic transition, aggregation, and deposition of the 
complexes onto the substrate produced expression levels rivaling that of PEI in 
conventional transfection; the authors suggested that dried complexes were too tightly 
attached to the surface for uptake to proceed [77].  The inclusion of an increasing amount 
of cationic peptide to lipoplex preparations also induced aggregation onto cell culture 
substrates, thereby increasing vector release, shifting to a non-lysosomal caveolar 
pathway, and enhancing transfection efficiency [76]. 
The balancing act between concentrating vector at the surface and facilitating 
cellular internalization is well-illustrated by the tethering of biotinylated polylysine 
complexes to a neutravidin-coated surface [78].  While the immobilization of particles 
increased with increasing biotinylation, the transfection efficiency was maximal for only 
a small amount of biotin functionalization; a low level of biotinylation encouraged 
complex deposition but was simultaneously permissive to internalization, whereas 
highly-biotinylated complexes were bound too tightly to the surface to be internalized.  In 
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another study, stamping PEI complexes onto a layer of cells did not result in transfection 
unless the complexes were first released by an underlying pH-sensitive polymer layer 
[79]. 
 Substrate surface chemistry can also have a marked effect on the immobilization 
and expression of non-viral vectors.  Immobilization of Lipofectamine 2000 complexes 
onto self-assembled monolayers of alkanethiols with varying endgroups allowed the 
comparison of substrate-mediated gene delivery from surfaces with controlled ionization 
and hydrophilicity [80].  Surfaces with a high ratio of anionic (carboxylic) to neutral 
(hydroxyl) groups supported the highest levels of complex immobilization and 
transfection of NIH/3T3 fibroblasts.  Hydrophobic decane surface chemistry also bound 
high levels of lipoplex, but did not transfect cells, putatively from over-tight complex-
surface interactions.  Inclusion of PEG-like moieties can also increase the transfection 
efficiency of PEI polyplexes adsorbed to monolayers of carboxylic endgroups [81].  This 
increase cannot be attributed to an increase in complex binding or release, but the size 
and shape of adsorbed complexes is markedly affected.  The ionic association of 
complexes with a substrate may be preferable to hydrophobic association, because ionic 
interactions can be displaced upon introduction of serum proteins, freeing complexes for 
internalization during reverse transfection. 
 
2.2.1.3 Co-presentation of adsorbed protein with non-viral vectors 
Protein pre-adsorbed to surfaces used in reverse transfection can aid in the 
subsequent deposition of complexes.  Adsorbed protein can also improve transgene 
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expression in a manner that is not fully explainable by increased immobilization or 
uptake.  Complexes delivered with protein may maintain conformations favorable for 
cellular uptake, or may be differentially trafficked.  Fibronectin deposited onto surfaces 
dramatically increased the reverse transfection efficiency of polyplexes in hMSCs, 
though cell adhesion and spreading were not apparently affected [69].  This suggests an 
active role of fibronectin in complex internalization.  A similar effect was demonstrated 
with co-deposition of antibodies against various integrin subunits.  Engagement of 
integrin subunits through adsorbed antibodies, particularly anti-CD29 (which engages the 
ubiquitously-expressed integrin β1 [82]), resulted in an increase in transfection efficiency 
compared to control IgG for all of the cell types analyzed [83].  Intriguingly, placing 
RGD (an integrin-binding peptide sequence) directly on the surface of adsorbed PEI 
polyplexes leads to a decrease in transfection efficiency [84]. 
 Fibronectin has been implicated elsewhere in the enhancement of substrate-
mediated gene delivery [85]; drying a layer of fibronectin, collagen, laminin, FBS, BSA, 
and collagen was demonstrated to control the extent of PEI complex deposition, cellular 
association, endocytic internalization, and transfection efficiency following reverse 
transfection, whereas transgene expression was identical for all coating types following 
forward transfection.  All coatings other than laminin mediated high levels of complex 
deposition.  With the exception of FBS, complexes were found to be highly associated 
with the remaining coated surfaces (collagen, fibronectin, and BSA).  Collagen and 
fibronectin had identically high levels of complex internalization compared to other 
coatings, but fibronectin supported a significantly higher level of transgene expression, 
suggesting differences in the trafficking of complexes internalized from collagen- and 
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fibronectin-coated surfaces.  Uptake in this system depended more heavily on caveolae- 
than clathrin-mediated endocytosis, which may be a functional manifestation of the co-
localization of fibronectin with integrin β1 and caveolin in adhesion complexes [86] 
(discussed further in the next section).  Similarly, substrates with adsorbed rather than 
dried FBS immobilized similar quantities of PEI and Lipofectamine 2000 complexes [70].  
This FBS coating boosted the transgene expression of PEI 1500-fold compared to 
delivery from an uncoated surface. Expression of Lipofectamine 2000 from FBS-coated 
surfaces was unchanged, but the number of transfected cells was increased compared to 
uncoated substrates.  Adsorption of fibronectin for improvement of substrate-mediated 
transfection has also been applied to 3D PLGA scaffolds for spinal cord regeneration [87-
88]. 
 
2.2.2 Modulation of endocytic phenotype by substrate surface 
nanotechnology 
The use of surface nanotechnology to modify particulate parameters has gained 
well-deserved attention in non-viral gene delivery, as these parameters are becoming 
increasingly well-understood modulators of uptake and transfection efficiency.  Another 
approach worth considering is the engineering of desirable endocytic cellular phenotypes 
in target cells through substrate surface nanotechnology.  A suite of parameters such as 
cell morphology, adhesion, proliferation, differentiation, and protein expression are 
tunable with substrate parameters including stiffness, chemistry, and physical topography 
(Figure 6).  Cell biology offers hints towards mechanisms that may mediate useful 
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interactions between these substrate-mediated effects on cell phenotype, the endocytic 
machinery, and subsequent transfection.  Further, perhaps the simplest method whereby 
substrate nanotopography could enhance the transgene expression of interacting cells 
would be by increasing the loading of non-viral carriers onto patterned surfaces through 
an increase in available surface area afforded by feature sidewalls.  Cells stretched over 
substrate topography may also expose an increased proportion of their basal surface, 
creating a larger area for complexes to attach and to be internalized.  In general these 
interactions have yet to be directly investigated and exploited for gene delivery.  
Advances in patterning technology have made micro- and nano-patterned substrates more 
widely available; the following is an exploratory discussion of how these substrates may 
already be affecting endocytosis and transfectability, despite a lack of explicit, functional 
studies. 
 
Figure 6. Topographical effects on cell phenotype may also impact non-viral gene transfer 
The quantity and denaturation of matrix proteins adsorbed to patterns can be increased or decreased, 
depending on the specifics of the substrate topography and chemistry. These differences in the adsorbed 
protein layer mediate alterations in a number of cell phenotypes. Cells cultured on patterned topographies 
generally have decreased spreading and proliferation, reduced integrin clustering, and smaller focal 
adhesion complexes compared to smooth controls. Actin-mediated transduction of tension from integrin-
nucleated focal adhesions to the nucleus alters the expression of a multitude of secreted and intracellular 
proteins; many of these proteins play a role in endocytosis, and therefore possibly in the endocytic uptake 
of non-viral carriers. Finally, patterned topography can control the differentiation state of many cell types, 
leading to concomitant alteration of transfectability. 
 
2.2.2.1 Protein adsorption on nanofeatures 
 Cells interact with the substrates they are cultured on through integrins.  Integrins 
are a family of transmembrane receptors that bind to an assortment of extracellular matrix 
proteins through shared RGD domains, including: fibronectin, laminin, collagen, and 
fibrinogen.  Integrin binding and clustering initiates the assembly of adaptor proteins 
vinculin, talin, paxillin, and phosphorylative activation of focal adhesion kinase (FAK), 
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comprising the focal adhesion complex [89].  FAK goes on to provoke downstream 
effects such as cell movement and cytoskeletal contractility [90].  Therefore, cell-
substrate interactions are mediated by the proteins that are deposited from solution onto 
to a given substrate, as actuated through integrin signaling.  Substrate topography and 
chemistry alter the amount and conformation of integrin ligands, and may form the 
general basis for many if not all subsequent topographical effects on cell behavior. 
 Nano- and micro-scale topographies affect the amount and conformation of 
protein binding by presenting heterogeneous surface energies, altering exposed surface 
area, or restricting wettable area [91-92].  Nanoislands prepared by polymer demixing 
with heights of 14 nm supported 50% more fibronectin binding than 45 nm islands, 
despite a negligible change in exposed surface area [93].  Furthermore, the fibronectin 
preferentially adsorbed to the valleys between 14 nm islands.  Similarly, 4 µm wide, 1 
µm tall PDMS posts encouraged the adsorption of 50% more fibrinogen compared to 
smooth control despite only an 8% increase in surface area [94].  In contrast, higher 
aspect ratio PLGA support decreased fibrinogen adsorption [95]. 
 The conformation of proteins adsorbed to surfaces also changes with physical 
patterning, which has implications for integrin binding.  Adsorption of fibronectin to a 
nano-rough tantalum surface was increased compared to smooth tantalum, and the 
adsorbed layer’s stiffness increased, accompanied by a decreased susceptibility to 
antibody interrogation, indicative of a more extended fibronectin conformation [96].  
This result is echoed for fibronectin adsorbed to colloidally-roughened silica substrates 
[97].  The rearrangement of collagen into fibers on smooth substrates can also be 
hindered by nanocolumn patterning [98], and F-actin aligns on 2 nm- but not 4 nm- tall 
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ridges [99].  Globular proteins have been shown to retain their structure and biological 
activity on small, highly curved particles, whereas large proteins are denatured when 
forced to adsorb to such geometries [100-101].  These effects may be responsible for the 
differences observed for cells interacting with ECM adsorbed or secreted onto various 
nanopatterned substrates. 
Altered protein conformation has also been directly implicated in the control of 
adherent cell behavior.  Osteoblastic differentiation of MC3TC cells can be controlled by 
substrates that influence the conformation of adsorbed fibronectin [102].  Antibodies 
against specific fibronectin epitopes alter fibronectin binding when adsorbed to different 
substrate chemistries, subsequently affecting myoblast proliferation and differentiation 
[103].  Fibroblasts can sense the conformational change of fibronectin elicited by the 
subtle replacement of a substrate polymer’s methylene groups with oxygen [104].  Cells 
are able to detect changes in substrate topography and chemistry through the high 
sensitivity of protein adsorption to these physical and chemical features. 
 
2.2.2.2 Proliferation and endocytosis 
 Rapidly dividing cells are generally more susceptible to non-viral transfection, an 
effect generally attributed to greater access to the nucleus during cell division [4].  For 
example, low rates of proliferation elicited by contact-inhibition of epithelial cells leads 
to decreased lipoplex uptake and expression [105].  The decrease in transfectability with 
cellular confluence and age could also be due in part to decreased endocytosis in these 
cells.  Indeed, late passage fibroblasts down-regulate the expression of amphiphysin-1, a 
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linker between the clathrin coat and dynamin, causing a decrease in receptor-mediated 
endocytosis that can be resurrected with reexpression of amphiphysin-1 [106-107].  
Therefore, substrates that control cell proliferation are also expected to control cellular 
susceptibility to non-viral gene delivery. 
Researchers have repeatedly noted changes in the metabolic and proliferative 
rates of cells cultured on patterned topographies.  A decrease in proliferation for cells on 
micro- and nano-structures is most common, but increases are also observed  [108].  For 
example, smooth muscle cells cultured on 350 nm wide gratings proliferated significantly 
slower, as measured by BrdU incorporation [109].  Fibroblasts cultured on quartz 
micropits with 7-25 µm diameters and 20-40 µm spacing proliferated most slowly for the 
smallest, most closely spaced pits [110].  There are some exceptions which report 
increased proliferation on patterns; connective tissue progenitor cells grown on 10 µm 
diameter, 6 µm high posts exited post-seeding lag phase days before cohorts cultured on 
smooth control PDMS [111].  Substrates eliciting elevated proliferation rates may 
therefore be beneficial for gene delivery. 
 
2.2.2.3 Differentiation and endocytosis 
The differentiation of certain cell types can be controlled with substrate 
topography and stiffness.  Naïve hMSC are sensitive to nanotopography, encouraged by 
nanogratings to more readily commit to the neuronal lineage than by a chemical 
differentiation factor (retinoic acid) delivered to cells on a smooth substrate [112].  
hMSCs are also sensitive to the stiffness of their substrate (a property that could be 
  41  
 
 
modified locally with substrate topography), preferring osteogenic, myogenic, or 
neurogenic differentiation when cultured on gels with stiffnesses mimicking that of bone, 
muscle, or brain, respectively [113].  Mouse embryonic stem cells and osteoprogenitors 
can be maintained in undifferentiated phenotypes with culture on 2.4 µm tall, 1 µm 
diameter posts discovered by high-throughput screening of hundreds of micro-
topographies [114-115]. 
 The differentiation state of a cell population can determine the transfectability and 
endocytic phenotype of those cells.  Non-viral transfection is notoriously difficult for 
neurons [116], macrophages [117], dendritic cells [118], and differentiated chondrocytes 
[119] and adipocytes [120].  Further, the expression of caveolae is up-regulated in 
terminally differentiated fat, endothelial, muscle, and transdifferentiated lens epithelial 
cells [121-122], and the uptake of LDL by clathrin-mediated endocytosis decreases with 
adipogenic differentiation of hMSCs [123].  hMSCs directed to the neuronal lineage by 
nanopatterns express less caveolin-1, and alter the expression profile of a number of 
integrin subunits [112].  In addition, the production of heparan sulfate proteoglycans (the 
ubiquitous receptors for cationic particles) is down-regulated with differentiation of 
myogenic satellite cells [124].  Given these differences in transfectability and endocytosis 
between various cell types, substrate nanotechnology-mediated differentiation is another 
tool that could be leveraged to engineer the non-viral expression of transgenes. 
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2.2.2.4 Expression of endocytic proteins 
 Irrespective of differentiation, cells cultured on patterned topography undergo 
genome-wide changes in the expression of proteins that are implicated in endocytosis.  
Changes in gene expression of cells on patterned topography are believed to be mediated, 
at least in part, by nuclear deformation.  Many different cell types have been observed to 
align and elongate with nano- and micro-grooved topography.  The lower size limit for 
this alignment may be cell type-specific, but has been demonstrated to be around 100 nm 
wide, 70 nm deep gratings for the early alignment of rat fibroblasts [125].  Smooth 
muscle cells [109] and hMSCs [112] also align and elongate on 350 nm PDMS gratings.  
Alignment of the cell membrane and cytoskeleton can translate force to the nucleus via 
intermediate filaments, and can result in nuclear alignment and deformation [126-129].  
Stress applied to the nucleus alters histone deacetylation, chromatin condensation [130], 
and centromere arrangement [131], leading to global changes in gene expression. 
 The changes in protein expression on patterned topography include those 
explicitly implicated in endocytosis such as clathrin and caveolin, growth factors and 
cytokines that have established effects on endocytosis, matrix proteins that may alter cell-
substrate interactions, and signaling proteins that are needed for endocytosis but are not 
necessarily as well understood in their mode of action.  The latter category has recently 
been elucidated in an impressive manuscript where genomic libraries of siRNA were 
assessed for effects on the endocytosis of EGF and transferrin as directly observed with 
automated confocal microscopy [132].  The 4,609 genes affecting endocytosis can be 
cross-referenced with the handful of gene array studies that have been performed on cells 
interacting with patterned topography.  For instance, human fibroblasts cultured on 
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micro-grooved quartz [126] and 13 nm polymer demixed islands [133-134] upregulated 
their expression of Grk6, integrin α6, integrin β5, the growth factor receptor tyrosine 
kinase Ryk, REP-2 (targets Rab5 to the plasma membrane for early endosome trafficking 
[135]), Jnk2, and many more; RNA interference with any of these proteins leads to 
changes in the uptake of EGF and transferrin or in the intracellular distribution of 
endosomes [132]. 
 Dalby et al. have suggested that endocytosis is altered (qualitatively) for cells 
cultured on patterned topography.  Human fibroblasts attempt to endocytose 
nanocolumns with 100 nm diameter and 160 nm height, as supported by increased 
dynamin and peripheral clathrin staining, and TEM visualization of nascent endocytic 
vesicles near columns [136].  Fibroblasts cultured on nanopits with similar dimensions 
formed clathrin tracks indicative of “high rates of endocytosis”, and upregulated the 
expression of Epsin 2 [137], a stimulator of endocytic vesicle fissure from the plasma 
membrane [138]. 
 Cytokines and growth factors are potent stimulators of cell function, and 
endocytosis is no exception.  hMSCs cultured on patterned PMMA surfaces upregulated 
the expression of EGF and FGFb [112].  EGF can stimulate uptake of its own receptor as 
well as fluid phase endocytosis [139], and FGFb has been noted to downregulate the 
expression of surface-bound heparan sulfate proteoglycans [140].  Macrophages cultured 
on increasing nanograting widths increased their secretion of TNF-α [141], an 
inflammatory cytokine that accelerates clathrin-mediated endocytosis in Sertoli [142] and 
endothelial cells [143].  The expression of signals which increase endocytosis may be up-
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regulated in cells interacting with patterns and act in an autocrine fashion, thereby 
altering the uptake of non-viral vectors. 
 
2.2.2.5 Cell spreading and endocytosis 
Cell spreading may be the best-described effect of culture on nano- and 
microtopographic surfaces.  The heterogeneous presentation of extracellular matrix 
proteins adsorbed to topography supports varying degrees of integrin engagement.  
Adhesive substrates are predicted to sustain increased spreading with patterning 
(increased adhesive surface area), whereas non-adhesive substrates are expected to 
maintain better spreading if smooth (maintaining a minimal degree of cell deformation) 
[144].  Indeed, NIH/3T3 cells cultured on rough, super-hydrophobic silicon nanospikes 
were rounded, while those on rough, hydrophilic spikes were well-spread [145].  
Fibroblasts  [146] and endothelial cells [147] cultured on 13 nm tall polystyrene islands 
were more spread than those on flat control, and those cultured on 120 nm diameter, 100 
nm depth pits in PMMA were much less spread than control [137].  This dependence of 
spreading on topography may be due to the altered ability of integrin to cluster for 
various substrates; gold nanospheres with RGD functionalization were deposited onto a 
passivated surface with well-defined spacing to study this possibility [148].  The 
nanospheres were small enough that only a single integrin could be expected to be able to 
bind to each.  Cells grown on RGD spaced 108 nm apart had delayed spreading and a 
smaller projected area, compared to those on RGD spaced 58 nm apart. 
  45  
 
 
The act of integrin engagement and spreading itself may have an immediate effect 
on endocytosis, before changes in protein synthesis could be expected (Figure 7, right).  
Caveolin-1 is a lynchpin of caveolar endocytosis, and convincing evidence has appeared 
implicating it in integrin signaling [149].  Integrin β1 colocalizes with fibronectin and 
caveolin in focal adhesions [86], and its binding results in phosphorylation of caveolin-1 
[150].  Caveolin-1 acts as a membrane adaptor protein to couple integrins to downstream 
signaling partners, and to facilitate integrin clustering by oligomerization [149].  
Caveolin-1 knockouts are unable to internalize lipid rafts after detachment, and this 
behavior can be restored with subsequent reexpression of caveolin-1 [151].  Also, a loss 
of integrin-mediated adhesion results in the dramatic internalization of caveolae [152].  
These studies demonstrate a strong link between integrin function and caveolar 
trafficking, but it is unclear what the functional implications are for the uptake of cargo 
molecules that are nearby or directly involved in this process. 
 
Figure 7. Two possible links between integrin engagement and nanoparticle uptake 
(Left) Actin filaments localized to the cell surface by integrin-containing focal adhesions bind to the 
HIP1/HIP1R complex, which recruits AP-2 to assemble the clathrin coat on nascent vesicles. Cortactin is 
thought to induce and localize the polymerization of actin at internalizing vesicles by linking dynamin and 
the actin-nucleating complex Arp2/3. Integrin disassembly and internalization is a clathrin-mediated 
process, and high rates of this activity on patterned topography could compete with or augment complex 
uptake. (Right) Integrin engagement also results in local sequestration of caveolin-1 and stabilization of 
caveolae at the cell surface. Subsequent integrin release induces caveolae internalization, but it is unknown 
what effect this may have on the uptake of nearby gene carriers. Nanotopographical control of integrin 
engagement and turnover may be a useful tool in the study of these effects. 
 
2.2.2.6 Endocytic turnover of focal adhesions 
The formation, strengthening, contraction, and disassembly of focal adhesions 
allows cells to explore and move across their substrates.  This cycle is controlled by 
substrate topography, as mediated through the availability of adsorbed integrin ligands.  
When integrins are not allowed to cluster, the small focal adhesions that form are unable 
to hold on upon contraction of the actin cytoskeleton [127], leading to a more rapid 
turnover of adhesions as the cell searches for stable contact [148].  Integrin clustering is 
likely affected by the adsorption of ECM to nano- and microtopography, producing 
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differences in the size, strength, and number of adhesions formed on different structures.  
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Tall features restrict binding to the tops of patterns, small feature size (< 70 nm) prevents 
adhesions from forming at all, and large interfeature spacing reduces integrin clustering 
[89].  Indeed, fibroblasts cultured on 50 nm diameter pits have much smaller focal 
adhesions, and normal actin stress fibers are not formed [153].  On the other hand, 
shallow 30 μm diameter PMMA pits encourage a higher number of adhesions in hM
[154].  Furthermore, 350 nm PDMS gratings decrease the expression of vinculin in 
hMSCs compared to smooth control, and lower the cells’ elastic moduli as measured
AFM, indicative of structural changes in the organization of the actin cytoskeleton [155].
These effects of topography on focal adhesion formation and turnover may be 
ive of the situation in vivo; natural 3D extracellular matrices encourage the 
formation of small focal adhesions, while flattening the same matrix into two dimen
recovers large adhesions [156].  3D fibrillar matrix also increases the rate of fibronectin 
remodeling [157].  This remodeling proceeds by caveolar endocytosis, as demonstrated 
with inhibition by low temperature, and siRNA against caveolin-1, genistein, β-
cyclodextrin, and staursporin [158].  Substrate topography introduces a degree o
dimensionality to the presentation of adsorbed proteins, and may therefore modulate this
remodeling process. 
A number of r
al adhesion complex and the endocytic and cytoskeletal machineries (Figure 7, 
left). Disassembly of focal adhesions is a clathrin-dependent endocytic process; clathrin
and AP-2 colocalize with focal adhesions, and knockdown of clathrin, AP-2, and 
dynamin activity results in lowered integrin internalization [90].  As well, recently
described proteins including cortactin, Abp1p, Hip1R, and intersectin-1 link actin-
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nucleating enzymes such as Arp2/3 to their substrates [159-160], and recruit clathri
the plasma membrane to stimulate its assembly and association with actin [161-162].  
Actin contractility has indeed been suggested to drive the internalization of cholesterol
rich lipid rafts containing cationic complexes bound to proteoglycans [163].  Interesting
inhibition of PKC with staurosporine inhibits uptake and expression of PEI complexes, 
but not their binding.  These interactions suggest differences in the strength of integrin 
binding and the speed of integrin turnover induced by substrate topography can be 
expected to alter endocytic activity.  This could manifest as a coincident uptake of 
complexes or as a downregulation of particle uptake through increased competition
the endocytic machinery by the process of integrin internalization. 
 
Neurodegenerative diseases are responsible for an enormous pro
ity and mortality.  Currently-approved treatments generally only manage 
symptoms, or at best slow disease progression.  As a consequence of the high pre
and poor prognoses of these diseases, the desire for and willingness to accept new gene- 
and cell-based therapies against neurodegeneration has been high for decades, with 
unfortunately little human benefit to show for it… yet.  The groundbreaking discove
iPSCs and the resulting upheaval of the dogmatic “irreversibility” of development has 
reignited the hope that curative autologous cell therapies for neurodegeneration can be 
realized.  However, the teratogenic capacity of iPSCs may preclude or slow their wide 
approval for use in humans.  Excitingly, the discovery of direct lineage conversion from
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2.3.1 Current standard of care and prognosis 
 Alzheimer’s, Parkinson’s, 
nd mu
erhaps 
t 
e 
sands of highly-specified neuronal subtypes, each of which 
ay the
adult somatic cells to functional neurons and glia has significantly reduced if not 
eliminated safety concerns regarding teratogenicity, but much work remains to be
produce sufficient quantities of cells for use in humans without the use of potentially 
dangerous integrative methods. In this section we review state-of-the-art gene and cell
therapies against Alzheimer's disease (AD), Parkinson's disease (PD), and multiple 
sclerosis (MS), and describe how the rapidly-developing toolbox of direct 
reprogramming may be wielded to improve now-dire therapeutic outlooks, 
intelligently-selected microenvironmental factors may aid in this cause. 
 
 There are countless neurodegenerative diseases, but
a ltiple sclerosis are, if not absolutely, among the most: costly, prevalent, 
debilitating, and deadly.  These negative outcomes are a direct consequence of p
the most defining fact of our CNS – our neurons are as old as we are because they do no
divide, and they are generally not replaced if lost (with rare exceptions – in the dentate 
gyrus, for example).  This long persistence time provides us with a degree of permanenc
about our personalities and memories, but also poses a unique medical challenge when 
these cells and circuits die.   
 There are tens of thou
m oretically be subject to a specific autoimmune or prion-mediated attack.  These 
diseases can arise as a consequence of a highly penetrant familial mutation of a single 
gene, or as a sporatic idiopathic form that is presumably polygenic or otherwise 
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multifactorial.  This diversity of etiologies makes cure development very difficul
particularly because patients are often undiagnosed until symptomatic, at which poi
neuronal death has typically progressed to a significant extent.  Even with an accurate 
and timely diagnosis, there are no curative options for these diseases, only strategies fo
improved symptom management, or to slow progression.  Developing curative treatments
is becoming increasingly important, as our population shifts to a more aged demographic, 
and patients consequently suffer more  from the neurodegenerative diseases which 
principally occur later in life [164]. 
 Current estimates are that AD
over $170 billion each year [165], with an additional 17.5 billion hours of unpaid care 
provided by friends and family yearly [166].  AD affects 10% of those over 65 years of
age, and 50% of those over 85 [167], with a mean life expectancy of 7 years following 
diagnosis  [168].  The major pathological change in AD is a loss of cholinergic neurons 
in the basal forebrain, with projections to the cortex and hippocampus [169], caused by 
accumulation of amyloid plaques.  This eventually leads to widespread cortical neuron 
death, loss of memory, dementia, and eventual loss of organ functions, and to death of t
patient.  The only approved therapies for AD are neuroprotective cholinesterase inhibitors 
and NMDA receptor antagonists [170-171], which are only effective for a period of 
months to manage symptoms in a portion of patients. 
 Parkinson’s disease is also highly prevalent in 
age of 60 suffer from PD [164].  PD costs $11 billion per 500,000 affected Americans 
each year, with 1.5 million currently-diagnosed cases [172].  PD is a selective loss of 
dopaminergic neurons in the substantia nigra pars compacta of the ventral mesencepha
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This loss lowers the dopamine levels in the dorsal striatum, with eventual deterioration of 
nigrostriatal projections  [164].  This produces a gradual deterioration of motor function 
in the patient, leading to characteristic tremors, difficulty walking, and increasing 
disability.  This eventually progresses to dementia, and a significantly increased ris
death from complications such as pneumonia [173].  Approved treatments manage 
symptoms and include: L-dopa, dopamine agonists, anticholinergics, MAO-B inhibi
(which block the breakdown of L-dopa), and deep brain stimulation (DBS) to treat 
tremors and medication-induced dyskinesia.  The effectiveness of each of these 
treatments decreases over time, with a virtually inevitable symptomatic progress
 Multiple sclerosis has a worldwide prevalence of approximately 2.3 million, w
400,000 cases in the United States, carrying an average annual cost of $28 billion [174].  
MS is an autoimmune inflammatory disease, which results from destruction of the myelin
sheath insulating neurons in the brain and spinal cord.  These lesions appear in multiple 
foci along the white matter tracts, and eventually result in death of the demyelinated 
axons, and motor deficit.  After diagnosis, ambulation difficulty begins an average of 
years later [174], and the employment rate of patients declines 3% each year [175].  
There are many presentations of the disease, including relapsing-remitting and steadily-
progressing forms.  No treatment alters the course of primary progressive MS [176].  Th
progress of relapsing-remitting MS can be slowed but not reversed with aggressive 
immunomodulation via interferons [177], inhibition of T-cell proliferation [178], 
lymphocyte sequesteration [179], etc., and relapses are managed with corticostero
[180], which does not alter the disease course.  After immunosuppression fails, patient
may elect for immunological ablation and hematopoietic stem cell transplantation in an 
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2.3.2 Gene therapies 
medications for PD, AD, and MS collectively represent 
transfo ths 
e 
ed 
 
iral 
transdu
 
effort to induce tolerance rather than attack at lesion sites, which comes with a significant 
risk of implant-related mortality [181]. 
 
Currently-approved 
rmative advances for patient comfort, and some can extend symptomless mon
and even years, but they are not curative.  The pipeline for discovering, implementing, 
and approving new drugs is extraordinarily slow and expensive, and animal models hav
not been predictive of success [182].  Current gene therapies for neurodegenerative 
disease generally aim to deliver neurotrophic factors to promote neuron survival, or 
enzymes that are known to be absent in patients with well-characterized deleterious 
genetic mutations.  As a drug delivery technique, gene therapy promises more sustain
therapeutic effects than small molecule drugs, as the gene products are produced actively
by cells over a longer period of time – potentially for the entire life of the patient. 
Viral vector-based gene therapies have largely coalesced into ex vivo lentiv
ction into hematopoietic stem cells, and delivery of adeno-associated viruses in 
vivo, which can suffer from immune responses that limit efficacy [183].  Despite this 
concern, over 1800 gene therapy clinical trials have been completed worldwide [184],
with an assortment of positive and negative outcomes.  Most positively, lentivirus has 
been used to successfully treat X-linked adrenoleukodystrophy in two patients following 
immune ablation and reconstitution with genetically-corrected hematopoietic stem cells 
[185].  Sub-retinal injection of AAV expressing a corrected RPE65 gene has also 
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improved visual acuity in 5 patients with LCA2 3 years after treatment [186-187]. 
is also beginning to show promise in the CNS.  The use of AAV is particularly attractive 
for CNS gene therapy because AAVs infect non-dividing cells, can drive long-term 
expression from subtype-specific promoters, and can be serotyped to infect a particu
neuronal or glial target [188].  The advent of recombinant AAV technology has allowed
number of human PD and AD trials to proceed [189-190], including focal delivery of 
AAV carrying neurotrophic factors (neurturin [191]) or enzymes for synthesis of 
dopamine (GAD [192], AADC [193]) for use in patients with PD [183], and deliv
NGF via infected fibroblasts to promote neuron survival in a major cholinergic center in 
patients with AD [194-195]. 
Despite these promisi
s associated with the use of viral vectors for gene therapy.  Potential 
complications include retroviral insertional mutagenesis, phenotoxicity from prolonged 
transgene overexpression, immune response against capsid components, horizontal 
transmission from bodily fluids which remain infectious for a long period of time, an
vertical transmission in the case of lentivirus [183].  For some specific examples – a tria
to treat SCID-X1 in 5 patients with gammaretrovirus to correct the IL2RG gene was 
initially promising, but 4 of the patients developed T cell leukemia due to insertional 
mutagenesis and oncogene activation [196].  A patient treated for X-CGD with retrovirus 
died after the transgene was methylated and silenced [184, 197].  With gene therapy in 
vivo, the most proliferative (and potentially dangerous) clones may have a selective 
advantage [198].  Further, hepatocytes transduced with AAV have been shown to eli
potent T cell-mediated killing response; such an immunological attack would not be 
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2.3.3 Cell replacement therapies 
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 – 
 
 
n(s) 
benign in the CNS [183].  Effective viral therapies may therefore require 
immunosuppressants [199].  There are also many examples of non-viral ge
against neurodegenerative disease [200], which typically avoid a majority of the 
genotoxicity and immune response associated with lentiviral and AAV therapy, 
respectively.  For instance, there is currently an open Phase II trial for correction
by delivery of naked plasmid DNA vaccines encoding MBP [201-202], and naked VEGF
plasmid has been injected to protect peripheral neurons in patients with diabetic 
neuropathy [203]. 
 
 The approved drugs and gene thera
replace neurons that have already been lost at a late stage of neurodegenerative disease
only alleviate symptoms of or slow their inevitable loss.  However, cell replacement 
therapies have the potential to reverse neurodegeneration by replacing those lost cells
with healthy equivalents, and as such have been a tantalizing target for decades.  As 
described in this section, “cell therapy” is distinct from cell-based delivery of viral 
transgene products, which is occasionally used in conjunction with lentiviral or AAV
neuroprotective strategies (such as a NGF delivery via infected fibroblasts).  “Cell 
therapies” in this context aim to recapitulate all or the most critical complex functio
of neurons or glia lost to degenerative processes – neurons for PD and AD, and 
oligodendroglial cells for MS. 
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 There is some shared rationale for cell therapy against AD, PD, and MS.  
Generally speaking, idiopathic non-familial neurodegenerative diseases – which are 
polygenic or multifactorial – are more prevalent than their monogenic forms.  Gene 
editing techniques, which can correct specifically-targeted (and known) diseased genes, 
are transformative for a small portion of the population with well-characterized singular 
defects, but are unable to treat the largest idiopathic proportion of the patient population.  
Neuroprotective gene therapies, as described in the previous section, can slow the 
progression of polygenic diseases, but the underlying degenerative processes continue.  
Embryonic, neural, and induced pluripotent stem cells (ESCs, NSCs, iPSCs) share a 
highly proliferative phenotype, and, with varying degrees of accuracy and efficiency, the 
ability to differentiate into functional neurons and glia.  Stem and progenitor cell-derived 
neurons and glia may be able to correct neurodegenerative disease phenotypes without an 
understanding of the unique particularities of each patient's etiology. NPCs and NSCs 
have more limited division potentials than ESCs, but can be maintained in proliferative 
state in vitro [165, 204].  Grafted neurons and glia may replace tissue function directly, 
scavenge excitotoxic neurotransmitters, and support surrounding cells by the release of 
neurotrophins.  These characteristics have allowed expansion of stem and progenitor cell 
sources to levels required for human trials, but also come with steep safety and, for 
embryo-derived tissues, ethical concerns, which may be insurmountable for widespread 
clinical translation. 
 Cholinergic neurons may be the best candidates for transplanted cell therapy in 
AD [170], but these are not the only neurons lost in AD, and as such replacement of only 
cholinergic neurons is not expected to restore full function to a patient.  Cholinergic 
  56  
 
 
differentiation from stem cells is difficult to achieve accurately, but is possible for a small 
proportion of the cells [169].  Cell therapy for AD is made more difficult by its multi-
focal nature – implanted neurons would ideally be delivered and integrated into multiple 
sites across the brain for maximum recovery of function.  Despite these hurdles, 
significant memory test recovery has been achieved after replacement of cholinergic 
neurons derived from ESCs in lesioned and aged animal models of AD [205-206].  The 
multifocal delivery required for improvement across an Alzheimerian brain could also be 
achieved by the widespread migratory capacity of neural progenitor cells [165].  iPSCs 
have also been differentiated to NSCs, and then to cholinergic neurons, and then 
implanted NSCs to provide phenotypic recovery in an animal model of AD [207]. 
 PD results from disorder of a single small region of the brain, in a well-defined 
subtype of neuron – those which secrete dopamine.  This is a best-case scenario for cell 
therapy in the CNS – delivery of relatively few cells at a single anatomically-defined 
focal point (the striatum or substantia nigra).  At minimum, implanted dopaminergic 
neurons need only to secrete dopamine onto the striatum to provide some symptomatic 
relief.  At best, implanted dopaminergic neurons would integrate with their appropriate 
afferent and efferent connections along the nigrostriatal pathway, thereby recapitulating 
the normal feedback circuits required for proper dopamine regulation.   
 Initial allogeneic transplantation of DA neurons from fetal ventral mesencephalic 
tissue into the striata of PD patients showed some clinical benefits [208-211], but the 
improvement was modest and results were mixed across several trials [212-213]. Societal 
concerns of using fetal tissue as a cell source and low yields of DA neurons from the 
tissue presented additional challenges [165].  Motivated by these results and a desire to 
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improve yields of pure DA neurons for transplantation, investigators have developed 
protocols for dopaminergic differentiation from ESCs that are much more efficient than 
other neural subtypes [169].  iPSCs have also been successfully differentiated to 
functional dopaminergic neurons, and implanted in a lesioned animal model of PD, with 
restoration of some motor function [214]. 
 Cell replacement therapy for multiple sclerosis shares some of the same 
challenges faced in cell therapy for AD, as well as some of the advantages of cell therapy 
for PD.  Like AD, MS is widespread and multifocal, with inflammatory lesions appearing 
throughout all of the white matter tracts.  However, like PD, the target cells to be 
replaced are well-defined – the oligodendrocyte progenitor cell (OPC), or myelinating 
oligodendrocyte (OL).  Though a multifocal disease, the motivation for cell replacement 
therapy in MS is very strong [215].  For progressive MS, standard medications fail in an 
early stage, with uniform downhill progression.  Transplanted OPCs or OLs can migrate 
rapidly to sites of injury and inflammation [216-217] where they can act to inhibit 
inflammation, protect neurons with neurotrophins, and participate directly in 
remyelination.  Transplanted OPCs have superior remyelination capacity than OLs [218], 
presumably because individual OPCs can each produce multiple OLs.  Various 
transplanted OPC cell sources can remyelinate model lesions in the adult CNS [219].  
Perhaps most excitingly, human iPSC-derived OPCs have been shown to migrate, 
disseminate, and myelinate across the entire neuroaxis of congenitally hypomyelinated 
animals in vivo [220]. 
 For each of these implantation strategies in AD, PD, and MS, it is not fully clear 
what implications the underlying disorder may have on long term graft survival, 
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particularly considering there may be a prion component to these diseases [221-222].  
Transgenic and lesioned animal models often do not fully capture the sensitivity 
implanted neurons may have to the disordered microenvironment in patients with non-
familial disease.  Supporting this notion, remyelination is a constantly active process in 
human MS tissues [223].  The failure of endogenous OPCs to fully myelinate axons in 
chronic MS [224] may reflect an impermissive extracellular microenvironment, 
potentially mediated by chondroitin sulfate proteoglycans and hyaluronan at lesion sites 
[225].  Despite the potential for impermissive microenvironmental effects at diseased 
implant sites, there is some evidence for the functional superiority of transplanted OPCs 
over older resident OPCs [215, 226]. 
 These results are a clear indication of the potential cell replacement therapies hold 
for regenerative medicine.  The discovery of iPSCs by Yamanaka in 2006 [227] removed 
the greatest ethical and practical barriers to stem cell access, and provided the first 
feasible opportunity to produce autologous neurons and glial cells.  Autologous iPSC-
derived neurons and glia have a clear advantage for cell replacement over fetal and 
embryonic sources, in that they should theoretically not require immune suppression 
upon implantation.  Unfortunately, the exciting functional improvements afforded by 
differentiated ESCs, NSCs, and iPSCs are tempered by a host of safety concerns.  iPSCs 
can incur genotoxic integrations when produced with integrative viral methods, and their 
autologous immunological privilege is not always absolute.  We discuss these concerns 
next. 
 The danger of uncommitted progenitors and stem cells is now appreciated as a 
real one, following human implantation trials.  In one example, a boy implanted with 
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fetal NSCs to treat a congenital ataxia developed a donor-derived tumor 4 years later 
[228].  Animal models also agree that, even with efficient differentiation techniques, 
ESCs carry the potential for phenotypic instability and can retain tumorigenicity after 
implantation [229].  Besides incomplete differentiation, inaccurate differentiation of 
ESCs and NPCs is problematic as well.  Graft-induced dyskinesias are a common 
complication following cell replacement therapies for PD, and may result from 
unintended co-transplantation of serotonergic cells [164, 230-231].  The same concerns 
arise from the use of iPSCs [232], with the added concern that the use of viruses in their 
derivation can induce copy-number variation [233] – a structural mutation that may 
underlie complex heritable diseases [234], including those of the nervous system [235] – 
and insertional activation of oncogenes [236].  Finally, it is somewhat surprising to note 
that implanted syngeneic undifferentiated iPSCs are immunogenic [237], though it 
remains to be seen if the same is true for xeno-free and fully-differentiated cells [164]. 
 Though the concerns associated with the continuously-proliferative phenotype of 
iPSCs are inherent to their identity as self-renewing stem cells, their safety profile could 
be improved through the removal of viral transduction during their creation.  As such, 
there has been a significant effort devoted to the removal of virus and vector sequences 
for the generation of more clinically-translatable iPSCs [238].  Transfection with 
episomal plasmids [239] or direct transcription factor protein delivery [240] can generate 
integration-free iPSCs, but at very low efficiencies.  Plasmid DNA transfected with 
lipoplexes [241], polyplexes [242], or electroporation [243] can also produce integration-
free iPSCs (with screening) at comparatively higher efficiencies.  Repeated transfection 
of mRNA with modified ribonucleotides avoids integration and is less immunogenic than 
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unmodified mRNA [244], and can generate iPSCs at an even higher efficiency than 
retrovirus [245].  Transposase- [246-247] and cre recombinase-based [248] 
insertion/excision of reprogramming factors can remove reprogramming factors after 
conversion has been completed, and will benefit from ongoing advancements in safe 
harbor-targeted, rather than random, insertion [249-250].  Taken together, these results 
are definitive evidence that efficient but less-safe integrative viral techniques are not 
obligate for the successful generation of iPSCs. 
 
2.3.4 Direct somatic cell reprogramming 
 We have described how cell replacement is expected to deliver improved future 
therapeutics over current “gold standard” drug-based treatments, how iPSCs are an 
ethical and immunological improvement over ESC sources for cell replacement therapies, 
and how iPSC safety can be improved with the use of non-viral reprogramming systems.  
From a therapeutic perspective, the biggest remaining problem is the unrestricted 
proliferative nature of iPSCs.  The ability to directly generate functional neurons and glia 
from an autologous adult cell source while completely avoiding a teratogenic pluripotent 
stage, preferably without the use of virus, would be the “ideal” cell source to be wielded 
on behalf of millions of patients with intractable neurodegenerative disease. 
 
2.3.4.1 Directly-inducible CNS cell types 
In 2010, Wernig et al. succeeded in delivering three neuronal transcription factors 
(TFs) – Brn2, Ascl1, and Myt1l (BAM factors) – with lentivirus, to convert mouse 
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fibroblasts directly into functional neuronal cells [251], referred to as induced neuronal 
cells (iNs). Human cells were converted subsequently with the addition of NeuroD1 
[252]. These iNs generated action potentials and formed functional synapses when co-
cultured with primary cortical neurons or glia. Like the first report of iPSC generation, 
this discovery represented a paradigm shift for cell biologists and cell therapists alike, 
demonstrating the first clear direct conversion of somatic cells from one germ layer to 
another.  As a source for cell replacement therapy, cells produced via direct somatic 
reprogramming with terminal fate-determining factors likely have a marked safety 
advantage over iPSCs, in that they do not rely on oncogenes for induction, and are not 
expected to proliferate indefinitely in vivo. 
 Since its inception, the neuronal transdifferentiation field has expanded rapidly. 
The use of new transcription factor cocktails has generated induced human dopaminergic 
neuronal cells (iDAs) which are capable of releasing dopamine and providing phenotypic 
rescue in animal models of PD [253-257], as well as cholinergic motor neuronal cells 
(iMNs) [258]. Fibroblasts from patients with familial Alzheimer’s disease [259], 
hepatocytes [260], astrocytes [257], and pericytes [261] have all been directly induced to 
a functional neuronal phenotype.  Further, cells have been infected with lentiviral 
miRNA/TF cocktails [262-263], or only with a shRNA construct targeting a single gene 
to de-restrict miRNA-mediated interference with REST function, to convert fibroblasts to 
functional neurons [264]. 
Direct neuronal reprogramming is more efficient than iPSC generation, but iPSCs 
still have the logistical (though not necessarily medical) advantage of a proliferative 
phenotype, which eases scale-up to the quantities required for animal and human trials.  
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However, accurate and efficient differentiation of ESCs and iPSCs remains a challenge, 
particularly for astro- and oligodendroglial targets [164, 265], so only a fraction of those 
expanded iPSCs would be therapeutically-beneficial as implants – “It can be summarized 
that, after a decade of research […], robust and reproducible differentiation protocols 
have not been established” [164].  For these reasons, the subsequent discovery of 
transcription factor cocktails that can reprogram fibroblasts to lineage-committed but 
expandable NPCs [266-267] and OPCs [268-269] is particularly exciting.  With defined 
growth factor support these cells can be expanded many times, and upon mitogen 
removal efficiently differentiate into functional neurons and myelinogenic glia.  iOPCs 
and iNPCs are expected to have more limited proliferation and lineage restrictions in vivo 
than iPSCs or ESCs [220, 270], and are likely much safer as a consequence. 
Beyond their utility in cell replacement therapies, these induced neurons and glia 
will also find utility as test beds for drug discovery.  Before the discovery of iNs, there 
was no way to drug diseased, aged, and accurately-specified human neurons in vitro.  
Neurons harvested post-mortem often reflect a diseased endpoint phenotype, which is 
likely not the most amenable to therapeutic intervention.  One example of the promise of 
this new modeling technique is the derivation of functional neurons from fibroblasts 
taken from patients with familial Alzheimer's disease.  These neurons recapitulated 
diseased processing of APP and Aβ [259]. Similarly, neurons generated from fibroblasts 
carrying a neuroligin-3 mutation associated with autism demonstrated a diseased synaptic 
phenotype [271]. 
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2.3.4.2 Direct neuronal reprogramming in vivo 
Some of the most recent developments in direct neuronal reprogramming have 
demonstrated direct conversion in vivo.  The success of these techniques may be 
particularly important for certain types of clinical reprogramming.  The panoply of 
neuronal subtype specificity is based not only on the molecular identity, morphology, and 
electrophysiology of individual cells, but also on their anatomic location and connectivity 
with others – these are exclusively in vivo traits which, if necessary for positive 
therapeutic outcome, may be particularly difficult to recapitulate fully with ex vivo 
reprogramming and subsequent transplantation [272].   
Encouragingly, reactive glial cells have been reprogrammed to neurons in vivo 
with lentiviral delivery of NeuroD1 in an animal model of AD [273]. Implanted pre-
infected dox-inducible fibroblasts and striatal astrocytes could also convert to neurons in 
situ [274].  Furthermore, resident postmitotic neurons could be reprogrammed with 
electroporation of Fezf2 from one subtype and cortical layer to another [275], and 
accurately reprogram the afferent/efferent connectivity of L4 neocortical neurons (which 
make local intracortical connections and do not project axons to subcortical structures) to 
that of L5B neurons (which project through the striatum to the pons and spinal cord) 
[276].  These results are proof-of principle that in vivo cues may be supportive and 
sufficient to guide more complex subtype-specific anatomical integration and function of 
iNs than can be attempted in vitro. 
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2.3.4.3 Non-integrative direct reprogramming 
To date, all the neuronal transdifferentiation success has been achieved using viral, 
and almost exclusively integrative, delivery strategies. These iNs are invaluable for 
neuronal disease recapitulation, drug discovery, and exploring the emerging biology of 
direct reprogramming. However, the concern of genotoxic integration of  viral payloads 
into the host genome hinders the clinical translatability of lentiviral iNs [164, 184, 236], 
just as it does lentiviral iPSCs, and encourages the search for efficient non-integrative 
methods to generate these cells.   
For the moment, the list of non-integrative direct reprogramming methods in the 
CNS is considerably shorter than that for iPSC generation, as the field is just beginning to 
emerge.  Cytoplasmic Sendai viruses have been deployed to generate iNPCs via brief 
expression of the Yamanaka factors, including the oncogene c-Myc [277].  Adenoviral 
delivery of Ascl1, Brn2, and Ngn2 was used to reprogram fibroblasts to iNs, without 
evidence of integration [278].  There are ongoing trials to convert resident astrocytes to 
dopaminergic neurons in a non-human primate model of PD with in vivo delivery of 
Ascl1, Nurr1, and Lmx1b via AAV [279].  iNPCs were also generated by lipofection of 
Sox2 and Pax6 plasmids into adult human fibroblasts, which could be differentiated into 
multiple neuronal subtypes, and were electrophysiologically-capable [280].  To date, our 
report of polymeric nanoparticle-mediated reprogramming of fibroblasts to iNs with 
Ascl1, Brn2, and Myt1l (described in Chapter 3), is the only published protocol for non-
viral direct generation of neurons [281].  These successes clearly demonstrate that 
various clinically-relevant cell types can be produced via direct reprogramming without 
integration, and without virus. 
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2.4 Microenvironmental effects on direct reprogramming 
 Though the published non-viral methods for iN and iNPC production are 
encouraging, the efficiency of these processes is currently lower than that of their viral 
counterparts.  Even viral direct reprogramming can suffer low conversion yields – in 
particular, induced motor neurons [258] and iOPCs [268] initially suffered from 
drastically lower efficiencies than Ascl1, Brn2, Myt1l glutamatergic neuron induction 
[251].  The field is therefore well-motivated to investigate and understand the unique 
contextual barriers to reprogramming for each specific transcription factor cocktail and 
starting cell source, as well as any barriers shared by all cells converting from the 
mesodermal to ectodermal lineage.   
 Setting aside the practical issues of transcription factor- and cell-delivery for a 
moment, the many questions faced by the field can perhaps be summarized generally as: 
Why are certain transcription factor cocktails more efficient at reprogramming the same 
cell source, and why are certain cell sources more amenable to reprogramming with the 
same factors [282]?  It could be that there are inherently "powerful" pioneer transcription 
factors, which are particularly capable at binding condensed chromatin and efficiently 
recruiting transcriptional and epigenetic-modifying machinery [283].  It could also be that 
target genes for a particular desired phenotype may be potently occluded (or primed) 
epigenetically [284] in a given starting cell source.  These "intracellular 
microenvironmental factors" have been the best-studied to this point in the short history 
of direct neuronal reprogramming.   
 Extracellular microenvironmental factors are less-understood in the context of 
direct neuronal reprogramming.  Ordinary culture systems may not provide appropriate 
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physio-chemical cues for the survival and maturation of newly born neurons [164], which 
are exposed to a variety of spatio-temporally varying electrical and soluble cues to 
prompt differentiation, maturation, and survival in vivo, not to mention any intermediate 
transient phenotypes which lay between fibroblast and neuron.  Interestingly, it is 
becoming clear that at least some of the processes of normal neurodevelopment are 
traversed by induced neurons.  For instance, the sequential activation of endogenous 
Ascl1, Brn2, Myt1l, then NeuroD1 expression in reprogramming human neurons is the 
same as that seen in vivo [285].  Furthermore, the genomic binding sites of Ascl1 in 
fibroblasts overlap closely with those in ESC-derived NPCs [272].  As such, informed 
appropriation of developmentally-inspired microenvironmental cues may provide an 
excellent entry point for the discovery of new techniques to improve direct 
reprogramming yields and to accurately guide subtype specification. In the following 
sections we explore how microenvironmental encouragement and transcription factor-
mediated forcing could act synergistically.  
 
2.4.1 The epigenome 
Cells expressing the same set of ectopic transcription factors do not always 
reprogram to the same fate – epigenetic modifications are required as well, as 
demonstrated by the reprogramming of mitotic germ cells into neurons in vivo only upon 
removal of a histone remodeling complex component [286].  The stability of a 
differentiated phenotype is the result of a combination of cis-acting factors such as 
methylation, posttranslational histone modifications, and nucleosome positioning, and 
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trans-acting factors including transcription factors, coactivators, noncoding RNA, and 
chromatin remodeling complexes [283].  Epigenetic modifications can therefore act as 
potent inhibitors to reprogramming speed and success. 
Some of the earliest evidence for the importance of epigenetic modifications in 
direct reprogramming came from studies of myogenesis in non-muscle cells via cell 
fusion or transfection.  Pretreatment of HeLa cells with 5-azaC, a global DNA 
methyltransferase inhibitor, allowed their reprogrammed via fusion with myotubes [287].  
5-azaC can also induce spontaneous muscle differentiation in fibroblasts, and the 
demethylated genomic DNA from these cells could induce muscle phenotypes in other 
cells [288].  MyoD, the "master regulator" of skeletal muscle induction was discovered 
shortly thereafter [289].  MyoD-mediated reprogramming is dependent on the 
intracellular microenvironment; on its own, MyoD is unable to fully convert cells from 
non-mesoderm lineages [290].  
These early reprogramming experiments with MyoD were indicating that the pre-
existing state of a starting cell source is crucial to the success or failure of complete 
transdifferentiation.  The induced expression of a gene is dependent on permittivity both 
in cis and in trans.  One of the most elegant examples of this came from the transfection 
of epigenetically blank or "naive" bacterial artificial chromosomes (BACs) of myogenic 
genes that are normally silent (occluded, either in trans or in cis) in fibroblasts.  Whereas 
the endogenous copies of these genes (Myf5/6) were silent, BACs transfected into 
fibroblasts induced Myf5/6 expression and a muscle phenotype, meaning the fibroblastic 
intracellular microenvironment was entirely supportive of expression in trans.  However, 
when transgenic mice were generated carrying the Myf5/6 BAC, both the endogenous 
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and BAC copies of the gene were silent.  Myf5/6 BACs transfected in at an early stage of 
development were also silenced.  These results suggest the Myf5/6 locus is cis-silenced 
during development, which is a prerequisite for maintenance of a non-muscle phenotype 
in fibroblasts [284]. 
The importance of epigenetic states has also been well-documented in the iPSC 
field.  Small molecular inhibitors of DNA methyltransferases, histone deacetylases, and 
demethylases have all been found to be able to increase iPSC generation efficiency, and 
at times to substitute for some of the Yamanaka transcription factors [291-292].  The 
ability of only a small percentage of cells to surmount all of the barriers to 
reprogramming has been a point of particular interest to the field.  There has been debate 
over two hypotheses with respect to the method whereby these rare cells become iPSCs: 
stochastic induction of pluripotency (perhaps reflecting brief access to a critical promoter 
during cell division), or deterministic acquisition of pluripotency from an "elite" cohort 
of cells.  The current state of understanding is that fibroblasts reprogram to iPSCs via 
distinct intermediate stages, each with a variable recalcitrance to progression towards the 
next [293].  One of these intermediate stages may be a hyperproliferative phenotype, 
which is acquired stochastically with Yamanaka factor induction, but once obtained 
progresses deterministically to full pluripotency, and is parent to 99% of iPSC clones 
[294]. 
The details of the epigenetic changes required for a fibroblast to become a neuron 
are not well known.  The differences in reprogramming efficiency towards various 
neuronal subtypes may reflect necessary activation of a particularly stubborn cis- or 
trans-occluded gene during reprogramming.  Interestingly, a complex combination of 
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chromatin marks identified by ChIP predicts both the permissiveness to Ascl1 binding in 
non-neuronal cells, and the efficiency of their reprogramming to iNs [282]. Fortunately, it 
seems that stable and complex cell fates can often be fully-instructed by a remarkably 
short list of master regulators (Ascl1 is sufficient to generate functional albeit slowly-
maturing neurons from fibroblasts [251], and Ngn2 alone can produce functional motor 
neurons [295], for example).  Therefore, improvements in transdifferentiation may come 
from selecting maximally-permissive starting cell sources for a given master regulator, 
and further microenvironmental destabilization of existing transcriptional programs to 
discourage converting cells from falling into undesirable valleys on Waddington's 
"epigenetic landscape" [285] during the reprogramming process. 
Necessary destabilization of starting cell programs may be why the efficiency of 
neuronal reprogramming is proportional to viral titer [285], and by extension potentially 
why non-viral methods generally produce lower yields.  Supra-physiological doses of 
ectopic reprogramming factors may outcompete endogenous transcription factors for 
ubiquitous E protein cofactors such as Tcf3, which are required for lineage-specific 
bHLH factors (like MyoD and Ascl1) to bind to DNA [283, 296].  Other factors may act 
in trans to compete with ectopic factors; Foxo3, for instance, shares many targets with 
Ascl1, and inhibits Ascl1's ability to reprogram fibroblasts [297].  High levels of Oct4 
and Klf4, with lower levels of c-Myc and Sox2, is the best combination for iPSC 
generation [292].  It is also possible that the increased iN generation efficiency with high 
levels of ectopic factor expression may reflect an improved activation of the endogenous 
loci via epigenetic remodeling, irrespective of increased levels of direct downstream 
transactivation.   
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The advent of synthetic CRISPR/Cas9 transcription factors may help to elucidate 
the relative contributions of stable activation of endogenous master transcription factor 
loci from the supraphysiological expression of the downstream targets of those factors.  
CRISPR/Cas9 transcription factors directly activate target endogenous loci, evidently 
even when occluded by heterochromatin [298], but currently induce lower overall levels 
of protein expression than is produced from conventional plasmids.  It therefore remains 
to be determined if equal amounts of endogenous and ectopic transcription factor 
expression result in greater reprogramming for those activated endogenously by 
CRISPR/Cas9, which would indicate that epigenetic de-repression of the endogenous loci 
may be one of the principal barriers to successful direct reprogramming. 
 
2.4.2 Soluble factors 
 Normal development relies on a host of soluble factors to specify and pattern the 
differentiation of all cell types.  For just a few examples: FGF, TGF, Shh, and Wnt 
signaling specify germ layers - TGFβ and BMP-4 to mesoderm, and ectodermin to 
ectoderm, often utilizing cross-antagonism to support stable fates [299].  Neural subtype 
patterning is guided in a similar way by soluble factors - for instance FGF8, TGFβ3, and 
Shh specify a dopaminergic neuronal fate from progenitors.  These developmental cues 
have been used to improve both the derivation of specific neuronal subtypes from 
progenitor cells, as well as to increase the yields of neurons induced by direct 
reprogramming.   
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 Dorsomorphin, a BMP inhibitor, drastically increased the yield of induced 
cholinergic motor neurons from human fibroblasts, and their survival depended on the 
support of the essential motor neuron trophic factors BDNF, GDNF, and NT-3 [295].  
Inhibition of BMP, SMAD, and GSK-3β (involved in TGFβ signaling [300]) with small 
molecules also improved the yield of glutamatergic neurons [301].  Interestingly, similar 
small molecule cocktails have previously worked to improve the yield of iPSCs [302] and 
induced cardiomyocytes [303-304].  For iPSCs, it is believed that the small molecules 
encourage the obligatory mesenchymal to epithelial transition (MET), but it's not known 
if a similar transition is required for iN formation [292].  Ngn2 and Ascl1 both have a 
repressive GSK-3β phosphorylation site [285], which may act to diminish their activity 
during reprogramming.  Forced post-translational modification of master regulators may 
be a fruitful area of exploration; the transactivating activity of Sox10 (the master iOPC 
instructive factor), for example, can be increased by mutating inhibitory SUMOylation 
sites [305], an effect that could potentially also be mimicked by soluble SUMOylation 
inhibitors during reprogramming [306]. 
 The complex milieu of trophic factors secreted by neurons and glia likely contain 
as-yet undefined factors that could aid in neuronal reprogramming.  Differentiation of 
ESCs is aided, for example, by co-culture with PA6 stromal cells, which improve the 
yield of dopaminergic [307] and cholinergic motor neurons [308], presumably by 
paracrine effects.  Retinoic acid (RA) is one of the better-defined of these pro-neural 
soluble factors.  RA is critical for normal neurodevelopment [309], induces neuronal 
differentiation from ESCs [310], and lentiviral addition of an RA receptor to fibroblasts 
with soluble RA supplementation can improve the subsequent yield of iNs produced by 
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Ascl1, Brn2, and Ngn2 [278].  In vivo reprogramming of resident progenitors with Ngn2 
has also been demonstrated to be sensitive to the presence of growth factors, and on the 
anatomic location the reprogramming is performed.  In the striatum, delivery of growth 
factors (FGF2 and EGF) and Ngn2 induced few neurons at the site of a stab injury, 
whereas in the neocortex Ngn2 induced a large number of immature neurons, with few 
lasting to maturity, and distinct gene expression profiles observed for each [311].  
Reduced oxygen tension compared to atmospheric (as is normally the case in vivo) also 
improves iN yield [312].  These are clear demonstrations of the strong impact that soluble 
microenvironmental cues can have on direct reprogramming.   
 
2.4.3 Calcium signaling 
Membrane depolarization could also complement efficient transcription factor 
delivery by encouraging favorable epigenetic modifications in converting cells, and 
resilient phenotypes in the resulting iNs, likely via Ca2+ signaling.  This notion is 
informed by normal developmental processes.  In vivo, electrical activity is one of the 
signals migrating progenitors and immature neurons use to recognize and stop at their 
final destination, and to initiate axono- and synaptogenesis, as coded via voltage-sensitive 
calcium influx [313].  Electrical activity also serves to balance excitatory and inhibitory 
subtype specification [314].   In vitro, hippocampal neural progenitor cells differentiate 
more efficiently upon chronic depolarization by high extracellular levels of KCl [315].  
Nurr1, a dopaminergic reprogramming factor [257], can be rapidly activated by 
neurotransmitters, membrane depolarization, and intracellular Ca2+ [316].  Furthermore, 
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prolonged membrane depolarization with KCl has been recently demonstrated to enhance 
midbrain dopamine neuron differentiation from progenitor cells via epigenetic histone 
modifications [317].  In this system, high extracellular KCl but not NaCl increased the 
number of TH+ neurons, increased DAT-mediated dopamine uptake, and increased access 
of Nurr1 to the TH and DAT promoters by dissociating MeCP2 and corepressors HDAC1 
and CoREST [317]. 
 In normal development, approximately half of all immature neurons die via 
apoptosis; this process is necessary to arrive at an appropriate final level of innervation 
density [318-319].  During this apoptotic phase, the availability of neurotrophic factors 
and afferent input determines which neurons survive and which do not [318].  Treatment 
with TTX (a sodium channel blocker) can kill 50% of neurons in culture by 2 weeks, via 
ablation of spontaneous electrical activity [320].  Applying chronic depolarization with 
high extracellular KCl can rescue 100% survival in these cultures [321], an effect that is 
believed to mimic spontaneous activity-mediated opening of voltage-sensitive Ca2+ 
channels [318, 320].  This increase in survivability does not appear to depend on 
paracrine effects; the same improvements were observed in low-density cultures [322-
323].  KCl-mediated influx of Ca2+ can transfer neurons among one of four distinct 
intracellular calcium ([Ca2+]i) states: too little [Ca2+]i to be rescued by neurotrophins, 
normal [Ca2+]i where they are subject to normal apoptotic processes, high [Ca2+]i where 
they do not require neurotrophic support, and very high [Ca2+]i which can be excitotoxic 
[324].  It appears high extracellular KCl can transport neurons to the third category [324].  
The most obvious link between intracellular Ca2+, transcription, and survival may be the 
CaMKII pathway [318]. 
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 As applied to direct neuronal reprogramming, chronic depolarization could be 
used to encourage the emergence of a particular subtype, or to improve neuronal yield in 
general via increased survivability.  Interestingly, GSK-3β is inhibited via CaMKII-
mediated phosphorylation [325].  Non-phosphorylatable GSK-3β mutants can promote 
neuronal apoptosis, whereas a peptide including the phosphorylation site protects neurons 
[325].  These results suggest there may be a close link between Ca2+-mediated survival in 
primary neuronal cultures, and small molecule-mediated improvements in induced 
neuron yields via GSK-3β inhibition.  Beyond survivability, depolarization may also act 
to encourage the activation of endogenous transcription factor loci; activators of Ascl1 
expression have been shown to induce CaMKII binding at the Ascl1 promoter, which 
may be further encouraged by high [Ca2+]i [326]. 
 
2.4.4 Cell-substrate interactions 
 Just as substrate-mediated changes in endocytic phenotypes may have 
consequences for non-viral transfection, known cell-substrate interactions can also likely 
impact both the efficiency of direct somatic reprogramming, as well as the phenotype of 
the cells produced.  Many of these effects appear to act via some of the same epigenetic 
and signaling processes operating in normal development which we have already 
described.  As such, neuro-supportive effects of physical nano- and microtopographies 
could be wielded synergistically with the delivery of appropriate lineage instructive 
transcription factors in a supportive chemical microenvironment to improve the yield and 
specification of non-viral iNs towards therapeutically-useful levels. 
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 For an example of physical microenvironmental improvement of reprogramming 
via epigenetic modification, microgratings have been shown to increase the generation 
efficiency of iPSCs, via histone deacetylase (HDAC) inhibition [327].  HDAC inhibition 
by VPA has also been shown to increase the yield of neurons differentiated from NPCs at 
the expense of the glial lineage, via upregulation of NeuroD1 [328] (one of the critical 
transcription factors for generation of human glutamatergic iNs [252]).  Similarly, iPSCs 
cultured on gratings upregulated TUJ1 and NeuroD1 expression [329].  ESCs cultured on 
nanofibers upregulated TUJ1 expression compared to smooth substrates, but required 
further encouragement by ectopic Ngn1 expression to extend neurites [330].  In another 
study, anisotropic substrate topographies produced more TUJ1+ and MAP2+ neuronal 
cells from differentiating ESCs and NPCs, whereas anisotropic substrates favored glial 
differentiation [331].  Topographic cues have also been used to: increase the yield of 
oligodendrocytes from NSCs [332], accelerate neurite outgrowth of motor neurons [333], 
and to encourage a neuronal phenotype in MSCs [112].  
 Beyond physical topography, other substrate-mediated effects may be important 
for iN generation.  ECM factors provide nanotopographical cues, but also can control the 
content of soluble and immobilized growth factors [334], which can have a potent impact 
on neuronal differentiation [335].  Scaffold-mediated encouragement of neuronal 
differentiation in NSCs can be blocked by inhibition of integrin β1 [336].  Similarly, an 
observation of increased neuronal differentiation of MSCs on soft substrates was due 
specifically to caveolae-mediated internalization of integrin β1 [337].  Taken together, 
these results suggest that the control of cell-substrate interactions may provide a potent 
means to guide and encourage direct neuronal reprogramming. 
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Chapter 3: Non-viral Direct Conversion of Primary 
Mouse Embryonic Fibroblasts to Neuronal Cells 
 
A portion of Chapter 3 appears in: Nonviral direct conversion of primary mouse 
embryonic fibroblasts to neuronal cells. Adler AF, Grigsby CL, Kulangara K, Wang H, 
Yasuda R, Leong KW. Molecular Therapy – Nucleic Acids. 2012 Jul; 1(7):e32. 
 
3.1 Summary 
Transdifferentiation, where differentiated cells are reprogrammed into another 
lineage without going through an intermediate proliferative stem cell-like stage, is the 
next frontier of regenerative medicine. Wernig et al. first described the direct conversion 
of fibroblasts into functional induced neuronal cells (iNs). Subsequent reports of 
transdifferentiation into clinically relevant neuronal subtypes have further endorsed the 
prospect of autologous cell therapy for neurodegenerative disorders. So far, all published 
neuronal transdifferentiation protocols rely on lentiviruses, which hinders their clinical 
translation. Instead, we delivered plasmids encoding neuronal transcription factors (Brn2, 
Ascl1, Myt1l) to primary mouse embryonic fibroblasts with a bioreducible linear 
poly(amidoamine). The low toxicity and high transfection efficiency of this gene carrier 
allowed repeated dosing to sustain high transgene expression levels. Serial 0.5 μg cm-2 
doses of reprogramming factors delivered at 48-hour intervals produced up to 7.6% Tuj1+ 
(neuron-specific class III beta-tubulin) cells, a subset of which expressed MAP2 
(microtubule-associated protein 2), tau, and synaptophysin. Transgenic fibroblasts 
reported NeuroD6 and doublecortin expression as early as day 6 post-transfection, and 
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Tau expression by day 12.  A synapsin-RFP reporter helped identify mature, 
electrophysiologically active cells, with 24/26 patch-clamped RFP+ cells firing action 
potentials. Some non-virally-induced neuronal cells (NiNs) were observed firing multiple 
and spontaneous action potentials.  This study demonstrates the feasibility of non-viral 
neuronal transdifferentiation, and may be amenable to other transdifferentiation processes. 
 
3.2 Rationale and Significance 
Neuronal transdifferentiation has revived the dream of future therapies that truly 
alter the course of neurodegenerative disease which currently have only palliative 
treatment options.  iNs are non-proliferative [258, 260], and are therefore far less likely to 
generate teratomas after implantation compared to iPSC-derived neurons, which can also 
produce immunogenic intermediates from syngeneic sources [237].  The successful 
demonstration of iMN [258] and iDA [254] engraftment and functional improvement in 
animal models of Parkinson’s [255-256] suggests the goal of cell-replacement therapies 
using iNs for a number of neurodegenerative diseases is within reach. This type of 
approach is made even more attractive by the difficulty of adult neural stem cell isolation 
[338].  The benefit-to-risk ratio of neuroprotective adeno-associated virus (AAV) gene 
therapy to combat PD has already been deemed high enough to warrant clinical trials 
[339], so the introduction of ethically and technically viable autologous non-viral sources 
of neuronal cells should be of great and immediate therapeutic value. The reduced risk of 
insertional mutagenesis with a non-viral approach should push the barrier to entry for a 
variety of neurodegenerative therapies even lower.  Further, the demonstration of NiN 
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generation would support the feasibility of non-viral approaches to the other known 
forms of direct reprogramming, for the generation of -cells, macrophages, 
cardiomyocytes, and hepatocytes [340-345].  In addition to cell therapy, direct neuronal 
reprogramming also provides a unique opportunity to model disease through the 
generation of neurons that recapitulate pathological phenotypes from patients with 
neurodevelopmental, psychiatric, and neurodegenerative disorders [346-347].  New 
enhancements to the reprogramming process, as we expect to discover through 
completion of this work, can also be applied to generate these model cell types at higher 
efficiencies to facilitate drug screening. 
A critical finding of viral neuronal transdifferentiation studies is that the 
epigenetic and transcriptional programs of the source cells are largely (but not 
completely) erased and rewritten in favor of a stable neuronal state [260], which persists 
even when exogenous transcription factor (TF) expression is discontinued. Endogenous 
neuronal TFs are activated and continue to be expressed after a relatively brief pulse of 
doxycycline (dox)-inducible ectopic transgene expression is shut down by dox 
withdrawal [253-254]. This, taken with the rapidness and high efficiency of iN generation, 
and the published success of non-viral iPSC generation [243, 348-351], suggested to us 
that neuronal transdifferentiation could be achieved with a clinically-advantageous 
transient non-viral gene delivery strategy, which we report herein.  We hypothesized that 
multiple doses of reprogramming factors would be beneficial to generate non-virally-
induced neuronal cells (NiNs) at high efficiencies. Predicting that non-viral 
transdifferentiation would be less efficient than the viral systems, we elected to begin 
with primary mouse embryonic fibroblasts (PMEFs) as a starting material; PMEFs are 
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putatively the somatic cell type most-susceptible to neuronal transdifferentiation [251, 
260]. 
 
3.3 Methods 
Molecular cloning and plasmid purification 
The reporter vectors pmax-GFP (3486 bp, Amaxa, Cologne, Germany) and 
VR1255C (6413 bp, Vical, San Diego, CA), which respectively express GFP and 
luciferase under control of the CMV promoter, were used for flow cytometric 
measurement of transfection efficiency. pmax-Brn2 (4154 bp), pmax-Ascl1 (3497 bp), 
and pmax-Myt1l (6359 bp), which express the mouse transcription factors Brn2, Ascl1, 
and Myt1l, respectively, under control of the CMV promoter, were generated by first 
excising the GFP coding sequence from pmax-GFP with SacI digestion, blunting by 
DNA polymerase I Klenow fragment, NheI-HF digestion (NEB, Ipswich, MA), and gel 
extraction (QIAquick Gel Extraction Kit, QIAGEN, Hilden, Germany). Then, Brn2, 
Ascl1, and Myt1l inserts were prepared by digestion of the lentiviral vectors Tet-O-
FUW-Brn2 (Addgene 27151), Tet-O-FUW-Ascl1 (Addgene 27150), and Tet-O-FUW-
Myt1l (Addgene 27152) with EcoRV and NheI-HF (NEB) and gel extraction, and were 
subsequently ligated into the empty pmax vector with T4 DNA ligase (NEB). When used 
together, these three plasmids are abbreviated as pmax-BAM. pUNO1-mAscl1 (3892 bp, 
InvivoGen, San Diego, CA) and pUNO1-mMyt1lb (6744 bp, InvivoGen), expressing 
mouse Ascl1 and Myt1l under control of the EF1α/HTLV promoter, were used in 
conjunction with pmax-Brn2, and when used together are abbreviated as pUNO-
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AM/pmax-B. A summary of these plasmid cocktails is presented in Figure 8.  Plasmids 
were propagated in Escherichia coli DH5α (Invitrogen, Carlsbad, CA) and purified with 
EndoFree Plasmid Mega and Maxi kits (QIAGEN). Plasmid DNA concentrations were 
quantified by measurement of absorbance at 260 nm with a NanoDrop ND-1000 
Spectrophotometer (Thermo Scientific, Waltham, MA). 
 
Production and purification of lentiviral synapsin reporter 
  Stbl3 bacteria (Invitrogen) were transformed with pLV-hSyn-RFP [352] 
(Addgene 22909) according to the manufacturer’s protocol. Plasmid DNA was 
propagated and purified using the EndoFree Maxiprep kit (QIAGEN). For the lentiviral 
production, HEK293T cells were seeded in 75 cm2 dishes, cultured in DMEM 
(Invitrogen) containing 10% Premium Select FBS (Atlanta Biologicals, Lawrenceville, 
GA) and 1% penicillin-streptomycin (Invitrogen), and were transfected by the calcium 
phosphate technique with the following plasmids: 16.9 μg of pMD2.G (Addgene plasmid 
12259) 31.3 g of psPAX2 (Addgene plasmid 12260) and 48.2 μg of pLV-hSyn-RFP. 
The medium was changed after 14 h. 72 h after transfection, the medium was collected in 
50 mL tubes, centrifuged, and filtered through a 0.45m filter to remove cell and 
membrane debris. The supernatant was then concentrated to 100x in Amicon Ultra 
centrifugal filter tubes, (Millipore, Billerica, MA) and the concentrated virus was stored 
at -80oC. PMEFs in 2 cm2 wells were infected with 1 µL of 100x viral concentrate in 
PMEF medium 5 days before patch clamping. 
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Poly(CBA-ABOL) synthesis and polyplex formation 
 Poly(CBA-ABOL) was synthesized by Michael polyaddition of 3.67 g N,N-
cystaminebisacrylamide (CBA) (Polysciences, Warrington, PA) and 1.26 g 4-amino-1-
butanol (ABOL) (Sigma-Aldrich, Saint Louis, MO) as described by Lin et al. [353] The 
reaction product was purified by dialysis (3.5 kDa cutoff) in acidic deionized water (pH 
4) and then lyophilized. The polymer was collected in its HCl-salt form (1.63 g, 33% 
yield), and its structure validated by 1H NMR (in D2O) on a Varian Mercury 300 MHz 
NMR Spectrometer. p(CBA-ABOL)/DNA nanocomplexes (polyplexes) were synthesized 
at a polymer:DNA mass ratio of 45:1, which was selected based on a preliminary 
optimization of GFP expression in primary mouse embryonic fibroblasts (PMEFs) 
(results not shown). Polyplexes were prepared by adding a HEPES buffer solution (20 
mM HEPES, 5 wt % glucose, pH 7.4) of p(CBA-ABOL) (900 μg/mL) to a HEPES buffer 
solution (20 mM HEPES, 5 wt % glucose, pH 7.4) of plasmid DNA (75 μg/mL), 
followed immediately by vortexing for 20 seconds. Reaction sizes ranged from 5 to 15 μg 
of plasmid DNA. Average p(CBA-ABOL)/pmax-BAM polyplex diameter was 102.5 nm 
± 3.7 nm, and zeta potential was +23.5 mV ± 1.5 mV (mean ± SEM, n = 3), as measured 
with a Zetasizer Nano ZS (Malvern Instruments Ltd, Malvern, UK).  
 
Cell culture and transfection 
40,000 cells (80,000 cells) passage six (eight) PMEF-HLs (Millipore, Billerica, 
MA) were seeded per well in 24-well TCPS plates (BD, Franklin Lakes, NJ) at 37 °C and 
5% CO2 in complete PMEF medium: Dulbecco’s Modified Eagle’s Medium with 4.5 g/L 
glucose (GIBCO 11960-044) (Invitrogen), 10% Premium Select FBS (Atlanta 
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Biologicals), 25 µg mL-1 gentamicin (Invitrogen), and 1x GlutaMAX, non-essential 
amino acids, sodium pyruvate, and β-mercaptoethanol (Invitrogen). In the case of 
electrophysiology and most immunofluorochemistry experiments, 12 mm BD BioCoat 
poly-D-lysine/laminin-coated glass coverslips were placed in the bottom of TCPS wells 
prior to cell seeding. 24 hours after seeding, PMEFs were transfected with either: reporter 
plasmids for flow cytometry, or pmax-BAM or pUNO-AM/pmax-B plasmid cocktails for 
induced neuronal transdifferentiation. BAM factor plasmids were delivered at an 
equimolar ratio in all cases. A 2:1 ratio of Lipofectamine 2000 (Invitrogen) volume (µL) 
to DNA mass (µg) was used for flow cytometry experiments, in accordance with the 
manufacturer’s protocol. All transfections were carried out in serum- and antibiotic-free 
OptiMEM (Invitrogen). OptiMEM was replaced with complete PMEF medium four 
hours after the onset of transfection. Serial transfections for neuronal transdifferentiation 
proceeded as depicted in (Figure 9). 48 hours after the final transfection was completed, 
PMEF medium was replaced with N3 neural induction medium containing: DMEM/F-12 
(Invitrogen), 25 μg mL-1 bovine insulin (Gemini Bio-Products, West Sacramento, CA), 
50 μg mL-1 human apo-transferrin, 30 nM sodium selenite, 20 nM progesterone, 100 µM 
putrescine (Sigma-Aldrich), 10 ng mL-1 human bFGF2 (Stemgent, Cambridge, MA), and 
25 µg mL-1 gentamicin (Invitrogen).  Transgenic PMEFs were dissected carefully away 
from neural tissue in E14.5 ‘NeuroD6-Cre’x‘LoxP-RFP’ (NC-Ai9 line, gift from Kristin 
Baldwin, TSRI), doublecortin-RFP (gift from Deborah Silver, Duke University), and 
TauEGFP (gift from Marius Wernig, Stanford University) mice, cultured, and transfected 
as described previously. 
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Viability assay 
 The quantification of PMEF viability following transfection was duplexed with 
flow cytometry experiments. 24 hours after the onset of the final transfection with pmax-
GFP, cells were incubated for four hours with fresh PMEF medium containing 
alamarBlue (Invitrogen) in accordance with the manufacturer’s protocol. Metabolic 
reduction of alamarBlue was monitored at 570 nm/590 nm excitation/emission using a 
BMG Labtech FLUOStar Optima plate reader (Ortenberg, Germany). AlamarBlue-
containing medium was then removed, and the cells were prepared for flow cytometry. 
 
Flow cytometry 
24 hours after completion of the final transfection with pmax-GFP, PMEFs were 
washed briefly with PBS without Ca2+ and Mg2+ (Mediatech, Washington, DC), and 
released from TCPS surfaces with 0.25% Trypsin-EDTA (Invitrogen). The trypsin was 
inactivated with serum-containing medium and the cells were centrifuged at 4 °C, 
resuspended in ice-cold PBS, centrifuged again, and resuspended in PBS containing 1% 
PFA (EMS, Hatfield, PA). Cells were then filtered through 40 μm nylon cell strainers 
(BD) and analyzed with a BD FACSCanto II flow cytometer. PMEFs transfected with the 
non-fluorescent VR1255C plasmid served as negative controls for each equivalent pmax-
GFP dose, with gates set such that 1% of these cells were considered GFP+. The recorded 
median fluorescent intensities of GFP+ cells (MFIGFP) were linearized according to an 
assumption of ideal logarithmic amplifier behavior, and normalized by the median 
fluorescent intensity of negative control cells (MFINC) to calculate the reported % MFI 
change: 100%*(MFIGFP - MFINC)/MFINC. 
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Real-time RT-PCR 
Comparative CT real-time RT-PCR was performed in 20 µL reactions using the 
QuantiTect SYBR Green RT-PCR Kit (QIAGEN) with 10 ng of starting mRNA isolated 
with RNeasy and QIAshredder kits (QIAGEN) from cells transfected with pmax-BAM 
factors. mRNA concentrations were quantified with a NanoDrop ND-1000 
Spectrophotometer (Thermo Scientific). PCR proceeded for 40 cycles in an ABI 7300 
Real-Time PCR System (Carlsbad, CA). Target mRNA levels were normalized to 
endogenous GAPDH references, and presented as a fold-change increase relative to 
expression levels from untransfected PMEF mRNA collected 48 hours after seeding. 
Correct RT-PCR target amplicon lengths for exogenous pmax-BAM factors were verified 
with gel electrophoresis in a separate experiment. Primers (IDT, Coralville, Iowa) were 
as follows: Ascl1 forward (GCTGCAAACGCCGGCTCAAC); Ascl1 reverse 
(GCGGATGTACTCGACCGCCG); Ascl1 Endo forward 
(TGGCGGGTTCTCCGGTCTCGT); Ascl1 Endo reverse 
(TCCCCATTTGACGTCGTTGGCGA); Brn2 forward 
(CCATCGTACATGCCGAGCCGC); Brn2 reverse 
(GCGCGGTGATCCACTGGTGAG); Myt1l forward 
(CGGGTGTGATGGAACCGGCC); Myt1l reverse (GCCCTGTGCAGCCTGGAGTG); 
GAPDH forward (ACGGCCGCATCTTCTTGTGCA); GAPDH reverse 
(TTCTCGGCCTTGACTGTGCCG). 
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Immunofluorochemistry and image analysis 
Transfected cells were washed briefly with PBS containing Ca2+ and Mg2+ 
(Mediatech), and fixed with 4% PFA (EMS) at RT for 20 minutes. Cells were then 
incubated for two hours at room temperature (RT) in blocking buffer containing 0.2% 
Triton X-100, 3% w/v BSA, 10% goat serum (Sigma-Aldrich), and combinations of the 
following primary antibodies with rabbit anti-Tuj1 (Covance, 1:500): mouse anti-MAP2 
(Sigma-Aldrich, 1:500), mouse anti-synaptophysin (BD, 1:100), or mouse anti-Tau (BD, 
1:50). The cells were then washed three times with PBS, and incubated for one hour at 
RT in blocking buffer containing Alexa Fluor 488 goat anti-mouse IgG and Alexa Fluor 
594 goat anti-rabbit IgG (Invitrogen), washed three times with PBS, and imaged with a 
Nikon Eclipse TE2000-U inverted fluorescence microscope (Tokyo, Japan) with a 
ProScanII motorized stage (Prior Scientific, Rockland, MA). 
To quantify the relationship between Tuj1+ cell generation and the number of 
serial BAM factor transfections, PMEFs were transfected in TCPS wells, stained for Tuj1, 
and scanned to produce large mosaic images of each complete culture area. These 
mosaics were processed with a FIJI (Fiji Is Just ImageJ, http://fiji.sc) macro to: 
automatically and uniformly threshold each image according to local contrast, exclude 
small debris, and to count the number of Tuj1+ cells in each well. These counts were then 
divided by the number of PMEFs seeded in each well to calculate % Tuj1+ cell 
generation efficiencies. 
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Electrophysiology 
Non-virally-induced neuronal cells cultured on poly-D-lysine/laminin-coated 
glass coverslips (BD) were identified for patch clamp analysis by synapsin promoter-
driven RFP expression [352] after 12-17 days of culture in N3 medium. One dose of 
p(CBA-ABOL)/BAM factors produced synapsin-RFP+ cells that were too sparse to find 
readily with the patch clamping apparatus, and five doses kept unconverted PMEFs in 
serum-containing medium for an additional 4 days compared to three doses, allowing a 
layer of cells to develop on the back of the coverslips, which made it more difficult to 
affix samples securely to our patching setup. So, we elected to patch cells that received 
three doses. Micropipettes had resistances between 3-7 MΩ, and were filled with internal 
solution containing: 130 mM KMeSO3, 10 mM HEPES, 10 mM sodium phosphocreatine, 
4 mM MgCl2, 4 mM Na2ATP, 0.4 mM Na2GTP, 3 mM sodium L-ascorbic acid, with pH 
7.24 and an osmolarity of 290 mM. The cells were perfused with artificial cerebral spinal 
fluid (ACSF) saturated with 5% O2 and 95% CO2 and containing: 130 mM NaCl, 2.5 mM 
KCl, 2 mM NaHCO3, 1.25 mM NaH2PO4, 25 mM glucose, 2 mM CaCl2, and 2 mM 
MgCl2. Giga-ohm membrane seals were formed under voltage-clamp conditions. Action 
potentials were then recorded using an Axon Multiclamp 700B Microelectrode Amplifier 
(Molecular Devices, Sunnyvale, CA) by stepwise whole-cell current clamp injections, 
and analyzed with custom in-house MATLAB programs. 
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3.4 Results 
Poly(CBA-ABOL)/DNA polyplexes mediate non-toxic and highly-efficient 
transfection of a GFP-reporter plasmid in PMEFs  
Of the three primary mouse embryonic fibroblast (PMEF) cell sources screened 
(PMEF-HL, PMEF-NL, and PMEF-CFL (Millipore)), we found PMEF HLs to be the 
most-efficiently transfected with p(CBA-ABOL)/DNA polyplexes (data not shown) and 
used them in all subsequent experiments. Fluorescence microscopy revealed that a 1.0 µg 
dose of pmax-GFP in p(CBA-ABOL) polyplexes produced high transfection efficiencies 
without noticeable toxicity (Figure 10a). 2.0 µg doses also gave high transfection 
efficiencies, with some visibly rounded and dead cells, and 4.0 µg was grossly toxic. 1.0 
µg of pmax-GFP delivered with p(CBA-ABOL) transfected cells more efficiently than 
the same dose delivered with Lipofectamine 2000.  
One and two doses of 1.0 µg pmax-GFP in p(CBA-ABOL) polyplexes were 
almost entirely nontoxic compared to untransfected controls, and a second transfection 48 
hours later did not compound toxicity up to 2.0 µg (Figure 10b). Lipofectamine 2000 was 
significantly more toxic than p(CBA-ABOL) when delivering the same DNA dose, and 
its toxicity compounded with a second serial dose. 
Flow cytometric quantification of GFP expression confirmed a high transfection 
efficiency for 1.0 and 2.0 µg pmax-GFP doses in p(CBA-ABOL) polyplexes, 
significantly higher than with Lipofectamine 2000 lipoplexes (Figure 10c). Further, a 
second dose maintained a high percentage of cells expressing GFP for an additional two 
days; without re-transfection, the percentage of GFP+ cells fell relatively by 15 and 28% 
for 1.0 and 2.0 µg pmax-GFP in p(CBA-ABOL) polyplexes, respectively (results not 
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shown). Though 1.0 and 2.0 µg doses of pmax-GFP in p(CBA-ABOL) polyplexes 
elicited similar percentages of GFP+ cells, the median fluorescence intensity (MFI) 
change of GFP+ cells over non-fluorescent negative controls revealed that cells 
transfected with a 2.0 µg DNA dose had significantly higher GFP expression levels 
(Figure 10d). 
 
Poly(CBA-ABOL)/DNA polyplexes elicit potent but transient expression of neuronal 
reprogramming factor mRNAs 
An equimolar ratio of 1.0 µg pmax-BAM neuronal reprogramming factors in 
p(CBA-ABOL) polyplexes was delivered to PMEFs according to the scheme in (Figure 
9). 24 hours after the initial transfection, each of the exogenous BAM factor transcripts 
were expressed at levels that were orders of magnitude higher than non-transfected 
PMEFs (Figure 11). Ectopic expression of pmax-BAM factors diminished by 
approximately two orders of magnitude by day 10 of culture in N3 medium as the 
plasmids were silenced and/or degraded, for both one and three doses. Endogenous Ascl1 
was activated in some cells by day 10 in N3 medium, as measured with primers targeted 
against an untranslated region (UTR) of the endogenous transcript not present in the 
exogenous transcript. Tuj1 and MAP2 transcripts were quantified but not detectably 
increased by transfection (results not shown). 
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Serial non-viral delivery of neuronal reprogramming factors generates Tuj1+ cells 
efficiently 
One dose of 1.0 µg pmax-BAM neuronal reprogramming factors in p(CBA-
ABOL) polyplexes produced rare and isolated Tuj1+ cells, while three and particularly 
five doses generated networks of Tuj1+ cells showing varying degrees of neuronal and 
fibroblastic morphologies (Figure 12a). Neuron-like Tuj1+ processes increased in length 
and complexity with increased culture time in N3 medium. Untransfected PMEFs were 
not reactive to antibodies against Tuj1. Automated microscopy and image analysis of 
large culture regions (Figure 12b) were used to quantify the efficiency of Tuj1+ 
conversion relative to the number of PMEFs seeded (Figure 12c). Five doses produced 
significantly more Tuj1+ cells than one or three doses. The increase in efficiency with 
dose is visually evident in the mosaic images of 24-well plates (Figure 12b). 
 
Non-virally-induced neuronal cells express pan-neuronal cytoskeletal and synaptic 
proteins 
After observing the feasibility of neuronal transdifferentiation using the BAM 
factors, we added an additional set of plasmids to give the best chance of producing NiNs 
with active membrane properties.  The CMV promoter is generally inactive in cortical 
neurons [354], and it is not known if or at what point this silencing could occur during 
neuronal transdifferentiation. We therefore added a parallel plasmid cocktail with serial 
transfections of 2.0 µg pUNO-AM/pmax-B factors, which utilize the EF1α/HTLV 
promoter for Ascl1 and Myt1l expression instead of the CMV promoter in pmax-BAM 
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plasmids, and would potentially take advantage of increased expression levels with 2.0 
µg of plasmid compared to 1.0 µg.  
Distal enrichment of tau (Figure 13, top row), characteristic of neurons, was 
visible for a subset of Tuj1+ cells (center and right panels). Tuj1+ cells with fibroblastic 
morphologies were not tau+ (red cells, left panel). Tuj1+ cells with neuronal morphology 
were also reactive to MAP2 antibodies (second row). Synaptophysin punctae were visible 
in a subset of Tuj1+ cells, a protein characteristic of synaptic vesicles (third row). 
Synapsin-RFP was also visible in long, branching processes. Synapsin-RFP+ cells were 
less common than any of those detected by immunofluorescence. Though comparatively 
uncommon, synapsin-RFP+ processes were present at sufficient densities and lengths to 
intersect with neighboring cells (fourth row), particularly for those transfected with the 
pUNO-AM/pmax-B cocktail (right panel). A worst case estimate of synapsin-RFP+ cells 
counted compared to Tuj1+ cells quantified in Figure 12c provides that approximately 
0.1% - 1% of Tuj1+ cells are also synapsin-RFP+ for three doses of 1.0 µg pmax-BAM 
factors. It is instructive to note that this is less efficient than our lentiviral derivation of 
iNs using the same TFs and cell source, with 66% synapsin-RFP+ cells generated from 
those plated, as detected by FACS (not shown). 
We also produced NiNs from three additional PMEF sources, which were 
dissected from E14.5 transgenic mice reporting NeuroD6, doublecortin (DCX), or tau 
promoter activity via GFP or RFP.  NeuroD6-RFP+ cells were observed as early as day 4 
in N3 medium, and rapidly increased in neurite complexity with further culture (Figure 
14a).  DCX-RFP+ cells (Figure 14b) also appeared at day 4 in N3 medium, and similarly 
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increased in complexity with time.  TauEGFP+ cells with clear neuronal morphology took 
longer to appear, at approximately day 12 of neurogenic culture. 
 
Non-virally-induced neuronal cells with synapsin I promoter activity are 
electrophysiologically active and complex 
Given the increased heterogeneity in maturity and completeness of NiNs 
compared to conventional iNs, we expected that upstream markers of neurogenesis, such 
as tau [251] or MAP2 promoter activity [257], would likely be less useful in NiNs for 
predicting active membrane properties. Accordingly, we transduced NiNs with a 
lentiviral reporter driving expression of RFP under the control of the highly neuron-
specific synapsin I promoter [355-356], in order to help us identify the most-mature NiNs 
for electrophysiological characterization. This lentivirus may have a natural tropism for 
excitatory cortical neurons [352], which are similar to the predominant subtype generated 
by ectopic BAM expression in PMEFs [251]. 
The presence of synapsin-RFP in long processes of NiNs was used to identify 
cells for electrophysiological recording. 12/13 synapsin-RFP+ cells produced with three 
doses of 1.0 µg pmax-BAM factors fired single action potentials in response to 
depolarizing current injection as shown in (Figure 15a,b). These cells had an average 
resting membrane potential of -46.3 ± 2.2 mV (mean ± SEM, n = 12), and an average 
input resistance of 1.7 ± 0.3 GΩ (mean ± SEM, n = 11). 12/13 synapsin-RFP+ cells 
produced with three doses of 2.0 µg pUNO-AM/pmax-B factors fired at least one action 
potential in response to depolarizing current injection. Further, 5/13 of these cells fired 
multiple action potentials as shown in (Figure 15c,d), and 7/13 fired single action 
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potentials. One cell was observed firing spontaneous trains of action potentials (Figure 
15d, 0 pA), and rebound action potentials were also recorded (Figure 15c,d). These cells 
had an average resting membrane potential of -41.7 ± 2.4 mV (mean ± SEM, n = 12), and 
an average input resistance of 1.5 ± 0.2 GΩ (mean ± SEM, n = 12). Results are for 
recordings with freely-fluctuating resting membrane potentials, though maintaining the 
cells at ~ -65 mV with holding current between recordings did occasionally result in 
more-clearly defined trains of action potentials. Qualitatively, we observed that cells 
firing trains of action potentials tended to be larger and expressed synapsin-RFP more-
intensely than those firing only once. 
 
3.5 Discussion 
Our aim in this study was to demonstrate direct neuronal transdifferentiation 
without viral delivery of TFs, in an effort to bring this exciting new field one step closer 
to clinical translation. We hypothesized that multiple doses of reprogramming factors 
would be required to generate non-virally-induced neuronal cells (NiNs) efficiently. 
Predicting that non-viral transdifferentiation would be less efficient than the viral systems, 
we elected to use primary mouse embryonic fibroblasts (PMEFs) as a starting material; 
PMEFs are putatively the somatic cell type most-susceptible to neuronal 
transdifferentiation [251, 260]. 
We delivered the three neuronal reprogramming factors Brn2, Ascl1, and Myt1l 
(BAM) in separate non-viral plasmids. Accordingly, we expect the proportion of cells 
that receive and express all three transgenes to be lower than that of those expressing 
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only one or two [357]. The fraction of cells co-expressing all three can be roughly 
calculated by considering the fraction of cells positive for a single reporter, and raising it 
to the power n = number of transgenes that must be co-expressed. This worst-case is 
mitigated somewhat by our inclusion of all three factors in the same polyplexes, such that 
they are co-endocytosed, but it is helpful to realize the large benefit high transfection 
efficiencies have on co-expression of multiple plasmids. For example, if a population is 
transfected with 20% efficiency for one of three separate genes, approximately 
100%*(0.2)3 = 0.8% will be positive for all three factors. An 80% transfection efficiency 
would produce 100%*(0.8)3 = 51% triple-positive cells (a 60-fold increase). This is 
particularly important if serial dosing is required, which will compound the effect. 
Previous reports have clearly demonstrated the importance of co-expression of all 
three BAM factors to produce iNs with mature electrophysiological phenotypes [251], 
which we expected to occur for a subset of cells transfected with our system. 
Improvement in transfection efficiency should result in nonlinear improvement in the 
appearance of NiNs firing multiple action potentials. p(CBA-ABOL) is a highly-efficient 
and non-toxic gene carrier that is rapidly degraded upon delivery to the reducing 
intracellular environment, for favorable unpacking of the polyplex [353]. In our hands, 
p(CBA-ABOL) outperforms most commercially-available transfection reagents in vitro. 
The high efficiency and low cytotoxicity of this gene carrier is key to the success of the 
current study, as serial multiple-plasmid transfections are helpful for efficient NiN 
generation. 
Optimization of PMEF transfection demonstrated that p(CBA-ABOL) polyplexes 
are nontoxic for doses that elicit very efficient transgene expression (Figure 10b,c). A 2.0 
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µg dose was identified as the highest dose suitable for serial delivery without toxicity 
concerns. p(CBA-ABOL) is more efficient and less toxic than Lipofectamine 2000, 
which we deemed to be inappropriate for multiple dose delivery due to its compounding 
toxicity. We have previously observed a sharp threshold for p(CBA-ABOL) efficacy, 
near 0.5 µg. To avoid inconsistent transfection and significant toxicity, our operating 
range for these experiments was therefore 1.0 to 2.0 µg. Maintenance of high transfection 
efficiencies upon administration of a second dose is likely due to re-transfection of 
fibroblasts silencing the transgene(s), as well as from transfection of newly-divided 
PMEFs replacing those lost to toxicity. The increase in expression levels for 2.0 µg 
compared to 1.0 µg (Figure 10d) is important, particularly if there is a threshold level of 
transcription factor that must be expressed in a given cell to “pioneer” heterochromatin or 
to outcompete a fibroblastic epigenetic program to “throw the switch” on 
transdifferentiation [358-359]. 
Using 1.0 µg of pmax-BAM factors, we observed dramatic ectopic expression of 
BAM factor mRNA (Figure 11) and endogenous activation of Ascl1, but no upregulation 
of MAP2 or Tuj1 mRNA. However, the presence of Tuj1 and MAP2 at the protein level 
(Figure 13) highlights the necessity of FACS enrichment via a neuronal reporter or 
single-cell PCR [360] when attempting to analyze iN mRNA amidst a background of 
unconverted cells. The exogenous BAM factors were silenced to a large extent by day 10 
in N3 medium, supporting the use of this technique as a transient expression system. 
Further transgene silencing is expected to continue with increased time in culture. 
Integration of non-viral DNA vectors occurs rarely [348, 350, 361], but direct 
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transdifferentiation is superior to iPSC systems in this regard, in that sporadic BAM 
factor reactivation would lead to growth arrest, rather than tumorigenic proliferation. 
The morphological heterogeneity of Tuj1+ cells generated by our technique 
(Figure 12a) is further confirmation of Tuj1+ as an early or promiscuous marker of 
induced neurogenesis [359]. However, a subset of these cells have more complete 
neuronal morphologies and phenotypes, and increasing the number of Tuj1+ cells is 
therefore likely predictive of an increased number of more-mature NiNs at downstream 
analysis points, and is hence useful for screening experiments without the use of 
transgenic neuronal reporter cells. The nonlinear improvement in the efficiency of Tuj1 
induction with an increasing number of serial transfections (Figure 12b,c) may be a 
consequence of the re-transfection of individual cells that did not initially express 
sufficient transcription factor to surpass the threshold required for transdifferentiation, 
and also of the potential continued proliferation and subsequent transfection of 
unconverted PMEFs. It seems likely that additional doses could further increase the 
efficiency of Tuj1+ cell generation. 
In accordance with the mixture of fibroblastic and neuron-like Tuj1+ cell 
morphologies, immunofluorochemistry revealed a similar heterogeneity in the expression 
of pan-neuronal markers (Figure 13). Delivering separate transcription factors with both 
pmax-BAM and pUNO-AM/pmax-B plasmids resulted in some more-mature NiNs that 
expressed MAP2, distal tau enrichment, Tuj1, synaptophysin punctae, and had synapsin 
promoter activity, as well as some less-mature cells that expressed a subset of these 
markers. These less-complete neuron-like cells may have received an inappropriate 
timing, amount, or mixture of transcription factors, or may have been on their way to 
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becoming fully-reprogrammed NiNs. The initiation of transgenic NeuroD6 and DCX 
reporter activity was rapid and co-incident with a rapid increase in arbor complexity 
(Figure 14), commensurate with their normal developmental roles in axo- and 
neurogenesis, respectively [362].  Though heterogeneous on the population level, the 
presence of non-virally-induced markers of maturing neuronal cells (persistent transgenic 
reporter activation, synapsin promoter activity, synaptophysin punctae) indicated the 
likely neuronal electrophysiological properties of these cells. 
The synapsin-RFP reporter was excellent at predicting which cells would fire 
action potentials, with 24/26 patched cells firing at least once (Figure 15). These cells had 
heterogeneous resting membrane potentials, action potential thresholds, action potential 
amplitudes, and number of action potentials. We observed action potentials after 
hyperpolarization (Figure 15c), and spontaneous action potentials (Figure 15d) for NiNs 
generated with 2.0 µg pUNO-AM/pmax-B factors. These heterogeneous active 
membrane properties are likely a consequence of the myriad combinations of BAM 
factors the cells receive during non-viral transdifferentiation, producing NiNs in different 
stages of maturity and completion. 
NiNs generated with pmax-BAM factors were electrophysiologically similar to 
iNs produced with lentiviral transduction of Ascl1 only [251]. Ascl1 is the only member 
of the BAM factors that is able to generate cells with active membrane responses on its 
own. As such, if a population of cells tends to receive a supra-threshold dose of only one 
of the transcription factors, Ascl1+ cells may be the only ones detected as synapsin-RFP+. 
pmax-BAM vectors may be silenced before an expression time has been reached that is 
sufficient for Brn2 or Myt1l to act, or more-prevalent pmax-Ascl1 transcript may have 
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out-competed pmax-Brn2 and -Myt1l for translational machinery [363]. The 2.0 µg dose 
of pUNO-AM/pmax-B factors may have elicited higher (or more balanced) overall 
expression levels compared to 1.0 µg of pmax-BAM factors. The use of separate 
plasmids would allow simple alteration of BAM plasmid ratios to correct such an 
imbalance, if necessary. 
 
3.6 Conclusion and future perspectives 
These results are the first example of non-viral direct neuronal transdifferentiation. 
We believe this method will prove useful in the non-viral production of other subtypes of 
neuronal cells, as well as to provide an accessible means of generating iNs without 
lentivirus. Lentiviral protocols have demonstrated that adult human cells may be 
intrinsically more resistant to neuronal transdifferentiation than are mouse fibroblasts, 
and as such our non-viral approach can benefit from further increases in efficiency as it is 
deployed in human cells. The effectiveness of the non-viral technique may improve as 
polycistronic vectors for iN generation become more readily available [257, 259], which, 
by removing redundant plasmid backbone sequences could increase the effective dose of 
each factor, and ensure co-expression of all factors in transfected cells. The recent 
discovery that small molecules can greatly boost the efficiency of neuronal 
transdifferentiation is also expected to help reach this goal [364]. Subtype-specific human 
NiN generation will likely require a longer pulse of ectopic expression [254], which may 
further rely on the unique non-toxicity of p(CBA-ABOL). Though the non-integrative 
requirement for ex vivo generation of non-proliferative therapeutic NiNs is relaxed 
compared to iPSCs, mRNA vectors will be of interest, and may need to be delivered even 
more frequently to maintain a sufficient duration and levels of ectopic expression.  The 
reduced risk of insertion mutagenesis with non-viral reprogramming approaches should 
lower the entry barrier for cell therapy against a variety of neurological diseases. Further, 
our demonstration of NiN generation suggests that other forms of non-viral inter-lineage 
transdifferentiation may be feasible [340-344]. 
 
3.7 Figures 
 
 
Figure 8. Non-viral vectors generated for direct reprogramming of fibroblasts to glutamatergic 
neurons 
Coding sequences for mouse Ascl1, Brn2, and Myt1l (BAM) transcription factors were inserted into the 
pmax and pUNO backbones, under control of the CMV and EF1α-HTLV promoters, respectively.  
Cocktails of BAM factor-encoding plasmids were delivered at an equimolar ratio. 
 
 
Figure 9. Non-virally-induced neuron (NiN) generation scheme 
On day zero, PMEFs were seeded on TCPS wells or poly-D-lysine/laminin-coated glass coverslips in 
complete medium containing serum. 24 hours later, the first transfection was performed. One to four 
additional doses were then administered every 48 hours. Beginning 48 hours after administration of the 
final dose, the cells were cultured for a minimum of 10 additional days before assay in serum-free N3 
neural induction medium containing FGF2, which was replaced every 48 hours, or every 24 hours beyond 
day 10 in N3 for longer-term experiments. 
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Figure 10. Optimization of non-viral GFP reporter plasmid transfection in PMEFs 
(a) Fluorescence micrographs of PMEFs transfected with increasing doses of DNA in p(CBA-
ABOL)/pmax-GFP polyplexes (500 µm scale bars), with 1.0 µg of pmax-GFP delivered with 
Lipofectamine 2000 (LF2k) included for comparison. Images were taken 24 hours after transfection. (b) 
AlamarBlue toxicity assay multiplexed with (c) flow cytometric measurement of GFP transfection 
efficiency and (d) % median fluorescence intensity increase of GFP+ cells compared to non-fluorescent 
control transfections for one and two doses of p(CBA-ABOL)/pmax-GFP polyplexes, assayed 24h after 
transfection. 1.0 µg of pmax-GFP delivered with Lipofectamine 2000 (LF2k) is again included for 
comparison. Error bars represent SEM of three separate experiments performed in triplicate. Two-way 
ANOVA were performed with P < 0.05 considered significant. The main effect of DNA mass was 
significant in (b-d), and the main effect of DNA dose # was significant in (b). Letters (x,y,z) not shared 
between columns denote significant comparisons between DNA masses by Tukey post-hoc tests (P < 0.05) 
of one-way ANOVA across DNA masses, with data from one and two doses pooled in (c) and (d), due to 
absence of a main effect of dose # by two-way ANOVA. All comparisons of viability (b) across DNA mass 
within a given dose # were significant, other than those between 0.5 and 1.0 µg pmax-GFP in p(CBA-
ABOL) polyplexes (marked ns – not significant). 
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Figure 11. Ectopic and endogenous reprogramming factor transcript in transdifferentiating PMEFs 
PMEFs were transfected with one or three doses of 1.0 µg pmax-BAM (Brn2, Ascl1, Myt1l) factors 
complexed with p(CBA-ABOL), and total mRNA was collected 24h after transfection (day 2) or after 10 
days of culture in N3 and analyzed with RT-qPCR. Error bars represent the range of transcript produced by 
the standard deviation about a mean CT value (n = 3).  
 
 
Figure 12. Tuj1 induction in cells transfected with multiple doses of reprogramming factors 
(a) Tuj1 stain of cells transfected with one to five doses of 1.0 µg pmax-BAM factors in p(CBA-ABOL) 
polyplexes after a minimum of 14 days in N3 medium following transfection. 200 µm scale bars. (b) Large 
mosaic images of the entire culture area (2.5 mm scale bar) acquired for image analysis-based 
quantification of the number of Tuj1+ cells normalized to the number of PMEFs seeded (c), after a 
minimum of 10 days in N3 following transfection. Letters (x,y) not shared between columns denote 
significant comparisons by Tukey post-hoc tests of a one-way ANOVA (P < 0.05). Error bars represent the 
SEM of three separate experiments performed in triplicate. 
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Figure 13. Neuron-specific immunofluorochemistry and synapsin reporter activity in NiNs 
All scale bars are 50 µm. Tau stain (first row): three doses of 1.0 µg pmax-BAM factors, ≥ 10 days in N3 
medium, on TCPS. MAP2 stain (second row): three doses of 1.0 µg pmax-BAM factors (left panel), or 2.0 
µg pUNO-AM/pmax-B factors (center and right panels), 16 days in N3, on poly-D-lysine/laminin-coated 
coverslips. Synaptophysin stain (third row): five (left and center panels) or three (right panel) doses of 1.0 
µg pmax-BAM factors, 17 days in N3, on PDL/laminin-coated coverslips. Expression of RFP under control 
of the synapsin promoter (fourth row): three doses of 1.0 µg pmax-BAM factors (left and center panels), or 
2.0 µg pUNO-AM/pmax-B factors (right panel), ≥ 10 days in N3, on PDL/laminin-coated coverslips. 
Synapsin-RFP images have not been false-colored red, in order to maximize visual contrast for thin cellular 
processes. Arrows indicate synapsin-RFP+ cell bodies. 
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Figure 14. Transgenic PMEF reporter activation in NiNs 
(a) RFP+ NiN at day four of culture in N3 following transfection of NeuroD6 Cre-loxP RFP PMEFs with 
pUNO-AM/pmax-B.  An increase in neurite extension and complexity was observed with each subsequent 
day in culture.  Images depict a single representative NiN imaged repeatedly over seven days.  (b) Neurite 
complexity in NeuroD6 Cre-loxP RFP+, DCX-RFP+, or Tau-EGFP+ NiNs at day 10, 8, and 18, respectively.  
Contrast has been enhanced to reveal dim GFP+ neurites in Tau-EGFP+ NiN neurites (small arrows) 
emerging from a brighter GFP+ soma (large arrow). 
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Figure 15. Current clamp response in the whole-cell configuration of synapsin-RFP+ NiNs 
(a) and (b) are traces of cells that received three doses of 1.0 µg pmax-BAM factors, after 16-17 days of 
culture in N3 medium, on poly-D-lysine/laminin-coated coverslips. (c) and (d) are traces of cells that 
received three doses of 2.0 µg pUNO-AM/pmax-B factors, on day 12 of culture in N3, on poly-D-
lysine/laminin-coated coverslips. 
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Chapter 4: Non-viral Neuronal Reprogramming can be 
Enhanced with Small Molecules and Chronic 
Depolarization 
 
4.1 Summary 
 Since Wernig’s original description of lentiviral direct reprogramming of 
fibroblasts to functional glutamatergic neurons in 2010 [251], the field has expanded to 
include the generation of neural and oligodendroglial progenitors [267-268], 
photoreceptors [365], dopaminergic [253, 255-256, 366], GABAergic [273], and spinal 
motor neurons [258, 295], and many others, from a variety of human and murine cell 
types of various ages and disease states.  As applied to future cell therapies against 
myriad intractable neurodegenerative diseases, each of these techniques share a strong 
impetus for increased reprogramming efficiency. To that end, small molecule cocktails 
have been tested in and demonstrated to greatly enhance the efficiency of viral neuronal 
reprogramming [364].  In an effort to improve the clinical translatability of neuronal 
reprogramming, we have previously developed a safer non-integrative, non-viral method 
based on nanoparticulate transfection of lineage-instructive transcription factor-encoding 
plasmids, to produce functional neurons from mouse fibroblasts [281].  In this report we 
extend our non-viral technique by the use of small molecules and chronic depolarization 
to double our yields of glutamatergic neurons, as well as to enable the non-viral induction 
of a neuronal phenotype in human fibroblasts. We also report the first non-virally induced 
dopaminergic neuron-like cells that co-express tyrosine hydroxylase, TUJ1, and MAP2.  
We provide evidence that chronic depolarization can improve both dopaminergic and 
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pan-neuronal conversion efficiencies, but that small molecular inhibition of GSK-3β and 
SMAD signaling may increase pan-neuronal reprogramming efficiency particularly in 
reprogramming cocktails containing Ascl1.  The use of chronic depolarization to guide 
direct reprogramming is a new strategy that may find general application in other 
subtypes of neuronal transdifferentiation.  Each of these advances brings the goal of safe, 
efficient, autologous cell therapies for human neurodegenerative diseases closer to reality. 
 
4.2 Rationale and Significance 
Our success in Chapter 3 suggested that the generation of human NiNs, mouse 
NiDAs, and mouse NiMNs would be possible to some extent when our non-viral BAM 
NiN transdifferentiation protocol is respectively applied to human fibroblasts, or to 
mouse fibroblasts with a dopaminergic or motor neuron transcription factor cocktail.  It is 
important to consider, however, that lentiviral protocols have demonstrated that human 
cells are inherently more resistant to neuronal transdifferentiation than are embryonic 
mouse cells [367], and as such our non-viral approach may require further increases in 
efficiency as it is deployed therein. Similarly, dopaminergic iN generation requires a 
longer pulse of ectopic TF expression than does glutamatergic iN creation [254], which 
may further benefit from the unique non-toxicity of p(CBA-ABOL) for serial transfection.  
When the scalability of p(CBA-ABOL) synthesis is taken together with successful 
demonstration of iMN [258] and iDA [254] engraftment and iDA functional 
improvement in animal models of Parkinson’s disease [255-256], the goal of various cell-
replacement therapies using iNs for a variety of neurodegenerative diseases seems 
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attainable.  Parkinson’s disease is particularly focal and gradual, and is therefore 
attractive target for cell therapy, due to the relatively small quantity of iDAs that would 
be required to produce a therapeutic benefit. For example, if a non-viral method could 
produce functional dopaminergic neurons with five 1 µg doses at a 7.5% efficiency, only 
~ 0.5% of a typical p(CBA-ABOL) synthesis and ~ 1% of a Plasmid Giga Kit product 
would be required to generate enough neurons to produce phenotype correction in a 
Parkinsonian rat [255]. The benefit-to-risk ratio of neuroprotective AAV gene therapy to 
combat PD is already deemed high enough to warrant clinical trials in humans [339], so 
the introduction of an ethically and technically viable autologous non-viral source of 
neuronal cells would be of great therapeutic value. 
We hypothesized the effectiveness of the non-viral technique would improve with 
use of polycistronic vectors for iN generation [257, 259], which by removing redundant 
plasmid backbone sequences could increase the effective dose of each factor, and ensure 
co-expression of all factors in transfected cells.  Consistent with the heterogeneity in 
neuronal properties observed in SA2, we have observed wide cell-to-cell differences in 
expression of reporter plasmids co-transfected into PMEFs.  To ensure co-expression of 
all necessary dopaminergic transcription factors in each cell transfected, we used an 
Ascl1-Lmx1b-Nurr1 polycistronic insert that has been proven in lentiviral dopaminergic 
transdifferentiation of mouse astrocytes and fibroblasts [257], in our non-viral system.   
We also chose to evaluate recently-discovered small molecules which can greatly 
boost the efficiency of lentiviral glutamatergic iN [364] and iMN [295] reprogramming. 
This approach draws on previous results that demonstrate inhibition of SMAD and GSK-
3β signaling drives more-efficient neuronal differentiation of hES and iPSCs [368-369].  
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Adding small molecules SB-431542, CHIR-99021, and noggin for 2 weeks increased the 
purity and efficiency of neuronal transdifferentiation in human fibroblasts by 17- and 25-
fold, respectively [364].  The addition of FSK and DM to iMN reprogramming media 
also reduces the number of transcription factors required from seven [258] to one [295], 
making the approach significantly more amenable for a non-viral transfection strategy, as 
it does not rely on rare co-expression of many plasmids in single cells. 
We further proposed to utilize chronic depolarization of transdifferentiating 
neuronal cells in an effort to encourage their survival and/or dopaminergic specification. 
This is a new strategy that is informed by many developmental examples that indicate an 
intimate connection between electrochemical stimulation and neuronal development in 
general [313-314, 319], and dopaminergic specification in particular [317].  We were 
interested to determine if these interactions are also applicable in direct neuronal 
reprogramming, which appears to co-opt some of the biochemical circuits utilized in 
normal development [285].  The use of chronic depolarization and small molecular 
enhancers of reprogramming to boost the efficiency of our non-viral system will push iN 
yields towards therapeutically-useful levels. Further, generalizing the technique to other 
neuronal subtypes will extend the impact of non-viral neuronal reprogramming, and 
further develop our understanding of the relative importance of general barriers to 
delivery compared to barriers that are highly specific for a particular transcription factor 
cocktail or reprogramming target. 
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4.3 Methods 
Plasmids, molecular cloning, and plasmid purification. 
The reporter vectors pmax-GFP (3486 bp, Amaxa, Cologne, Germany) and 
VR1255C (6413 bp, Vical, San Diego, CA), which respectively express GFP and 
luciferase under control of the CMV promoter, were used as a positive transfection 
control (GFP), and a no-reprogramming negative control (pLuc).  
pEF-Ascl1 (6539 bp), pEF-Lmx1b (6947 bp), pEF-Nurr1 (7625 bp), and pEF-
polyALN (9560 bp) which carry human ORFs, or a polycistronic 2A-linked cassette with 
all three ALN factors, were expressed under control of the EF1α promoter in the pEF-
DEST51 vector, and were gifts from Russ Addis (University of Pennsylvania, PA).  
When used together, the separate ALN-expressing vectors are abbreviated pEF-ALN.  
pUNO1-mAscl1 (3892 bp, InvivoGen, San Diego, CA, expressing mouse Ascl1 and 
under control of the EF1α/HTLV promoter, was occasionally used in conjunction with 
pEF-Lmx1b and pEF-Nurr1, and when used together are abbreviated as pEF-(A)LN.  A 
summary of these dopaminergic plasmid cocktails is presented in Figure 16. 
pCIG2-mNgn2-6XMyc (7282 bp), which expresses myc-tagged mouse Ngn2 
followed by IRES-GFP under control of the CAG promoter, was a gift from Franck 
Polleux (The Scripps Research Institute, CA).  pmax-Ngn2 (3683 bp), which expresses 
mouse Ngn2 under control of the CMV promoter, was generated by excision of the Ngn2 
ORF from pCIG2-mNgn2 digested with PstI and EcoRI (NEB, Ipswich, MA), and 
ligation into pmaxCloning (Amaxa) digested with PstI and EcoRI. 
Plasmids were propagated in Escherichia coli DH5α (Invitrogen, Carlsbad, CA) 
and purified with EndoFree Plasmid Mega and Maxi kits (QIAGEN). Plasmid DNA 
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concentrations were quantified by measurement of absorbance at 260 nm with a 
NanoDrop ND-1000 Spectrophotometer (Thermo Scientific, Waltham, MA). 
 
Poly(CBA-ABOL) synthesis and polyplex formation 
Poly(CBA-ABOL) was synthesized by Michael polyaddition of 3.67 g N,N-
cystaminebisacrylamide (CBA) (Polysciences, Warrington, PA) and 1.26 g 4-amino-1-
butanol (ABOL) (Sigma-Aldrich, Saint Louis, MO) as described by Lin et al [353]. The 
reaction product was purified by dialysis (3.5 kDa cutoff) in acidic deionized water (pH 
4) and then lyophilized. The polymer was collected in its HCl-salt form (1.63 g, 33% 
yield), and its structure validated by 1H NMR (in D2O) on a Varian Mercury 300 MHz 
NMR Spectrometer. p(CBA-ABOL)/DNA nanocomplexes (polyplexes) were synthesized 
at a polymer:DNA mass ratio of 45:1, which was selected based on a preliminary 
optimization of GFP expression in primary mouse embryonic fibroblasts (PMEFs) 
(results not shown). Polyplexes were prepared by adding a HEPES buffer solution (20 
mM HEPES, 5 wt % glucose, pH 7.4) of p(CBA-ABOL) (900 μg/mL) to a HEPES buffer 
solution (20 mM HEPES, 5 wt % glucose, pH 7.4) of plasmid DNA (75 μg/mL), 
followed immediately by vortexing for 20 seconds. Reaction sizes ranged from 5 to 15 μg 
of plasmid DNA. 
 
Cell culture and transfection 
PMEF CD1s were dissected carefully away from neural tissue in E14.5 mice. 
80,000 PMEF-HLs (Millipore, Billerica, MA) or PMEF-CD1s, or 60,000 MRC-5 fetal 
human fibroblasts (ATCC) were seeded per well in 24-well TCPS plates (BD, Franklin 
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Lakes, NJ) at 37 °C and 5% CO2 in complete PMEF medium: Dulbecco’s Modified 
Eagle’s Medium with 4.5 g/L glucose (GIBCO 11960-044) (Invitrogen), 10% Premium 
Select FBS (Atlanta Biologicals), 25 µg mL-1 gentamicin (Invitrogen), and 1x GlutaMAX, 
non-essential amino acids, sodium pyruvate, and β-mercaptoethanol (Invitrogen).  For the 
ECM study, PMEF-HLs were additionally seeded on BD BioCoat poly-D-lysine/laminin 
or human fibronectin-coated plates.   
PMEFs were transfected with either: GFP as a positive transfection control, pLuc 
as a no-reprogramming control, or pUNO-AM/pmax-B, pEF-ALN, pEF-polyALN, pEF-
(A)LN, pCIG2-mNgn2-6XMyc, or pmax-Ngn2 plasmid cocktails for induced neuronal 
transdifferentiation. Separate BAM and ALN factor plasmids were delivered at an 
equimolar ratio in all cases. All transfections were carried out in serum- and antibiotic-
free OptiMEM (Invitrogen). OptiMEM was replaced with complete PMEF medium four 
hours after the onset of transfection. Serial transfections were performed every 48 hours, 
with complete PMEF media between.  
48 hours after the final transfection was completed, complete PMEF medium was 
replaced with neurogenic medium.  BAM-transfected cells were placed in N3 neural 
induction medium containing: DMEM/F-12, 1x N2 supplement, 1x B27 supplement 
(Invitrogen), 10 ng mL-1 human bFGF2 (Stemgent, Cambridge, MA), and 25 µg mL-1 
gentamicin (Invitrogen).  ALN-transfected cells were placed in dopaminergic induction 
medium containing: DMEM/F-12, 1x N2 supplement, 1x B27 supplement (Invitrogen), 
and 25 µg mL-1 gentamicin (Invitrogen), with 10 ng mL-1 human bFGF2 (Stemgent) and 
25 ng mL-1 FGF8 (R&D) for 1 week, followed by withdrawal of bFGF and FGF8.  Ngn2-
transfected cells were placed in C2 neural induction medium containing: 
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DMEM:F12:Neurobasal (2:2:1), 0.8% N2 supplement, 0.4% B27 supplement 
(Invitrogen), 1 μM dorsomorphin, 10 μM forskolin (Stemgent), and 25 µg mL-1 
gentamicin (Invitrogen). 
For chronic depolarization experiments, OptiMEM from the final transfection was 
replaced with PMEF medium containing an additional 30 mM KCl or NaCl, or 1 mM 
TEACl (Sigma), and two days later were maintained in neurogenic media containing 
these factors for the remainder of the experiments.  For small molecular inhibition of 
GSK-3β and SMAD signaling, OptiMEM from the final transfection was replaced with 
PMEF medium containing 10 μM SB-431542, 0.5 μM LDN-193189 (Sigma), and 2 μM 
CHIR99021 (Stemgent), and two days later were maintained in neurogenic media 
containing these factors for 10 days, followed by their withdrawal. 
 
Immunofluorochemistry 
Transfected cells were washed briefly with PBS containing Ca2+ and Mg2+ 
(Mediatech), and fixed with 4% PFA (EMS) at RT for 20 minutes. Cells were then 
incubated for 2 hours at room temperature (or 18 hours at 4C for Ascl1) in blocking 
buffer containing 0.2% Triton X-100, 3% w/v BSA, 10% goat or fetal bovine serum 
(Sigma-Aldrich), and combinations of the following primary antibodies: rabbit anti-Tuj1 
(Covance, 1:500), mouse anti-MAP2 (BD, 1:500), goat anti-Ascl1 (Santa Cruz 48449, 
1:500), rabbit anti-Ngn2 (Millipore AB5682, 1:500), FITC-conjugated mouse anti-V5 
(Life Technologies R963-25, 1:500), rabbit anti-TH (Pel-Freez, 1:500).  The cells were 
then washed three times with PBS, and if necessary incubated for one hour at RT in 
blocking buffer containing appropriate AlexaFluor 488 or 594 secondary antibodies 
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(1:200, Invitrogen), washed three times with PBS, and imaged with a Nikon Eclipse 
TE2000-U inverted fluorescence microscope (Tokyo, Japan) with a ProScanII motorized 
stage (Prior Scientific, Rockland, MA). 
 
Image analysis 
To quantify Tuj1+, MAP2+, and TH+ cell generation, PMEFs were transfected in 
TCPS wells, stained, and scanned to produce large mosaic images of each complete 
culture area. Tuj1 and MAP2 mosaics were processed with a FIJI (Fiji Is Just ImageJ, 
http://fiji.sc) macro to: automatically and uniformly threshold each image according to 
local contrast, exclude small debris, overlay thresholded TUJ1 and MAP2 channels, and 
to count the number of double-positive cells in each well.  Because TH+ cells were 
present at a frequency similar to that of debris particles indistinguishable via automated 
ImageJ analysis, large well scans were counted manually in their entirety for TH+ cells 
with neuronal morphology by an experimenter blinded to the experimental condition. 
 
4.4 Results 
NiN yield is increased with exposure to chronic depolarization during 
reprogramming 
 In PMEF CD1s transfected with three 1 µg doses of pUNO-AM/pmax-B, a 
greater number of TUJ1+, MAP2+, and double-positive cells were each evident with KCl 
exposure at N3 day 10, and neurite complexity was not evidently affected (Figure 17).  
To quantify this effect, we performed large area automated image analysis (Figure 18a) to 
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count the number of total cells (Figure 18b) (including unconverted PMEFs), and 
MAP2+TUJ1+ double-positive NiNs (Figure 18c) at N3 day 10.  The total final cell 
number was unchanged with 30 mM KCl or non-depolarizing 30 mM NaCl osmotic 
control, compared to normal N3 media formulation (Figure 18b).  TUJ1+MAP2+ NiN 
yield was more than doubled with 30 mM KCl exposure compared to normal media, and 
was unchanged with 30 mM NaCl (Figure 18c).  Unlike PMEF CD1s, exposure to 30 
mM KCl was toxic to PMEF HLs during transfection with a 1 µg dose of pUNO-
AM/pmax-B, diminishing the number of surviving cells at N3 day 10 by half compared 
to normal media (Figure 19a).   Depolarization instead with 1 mM TEACl, a K+ channel 
blocker, rescued a 30% enhancement in NiN yield from PMEF HLs, compared to normal 
media (Figure 19b). 
 
NiN yield is increased with exposure to small molecular inhibitors of GSK-3β and 
SMAD signaling during reprogramming 
The yield of NiNs generated from PMEF HLs with a 1 µg dose of pUNO-
AM/pmax-B was increased by reprogramming in the presence of small molecules LDN-
193189, CHIR-99021, and SB-431542 small molecules (SMs) inhibiting GSK-3β and 
SMAD signaling for 10 days immediately following non-viral transfection (Figure 20).  
A greater number of TUJ1+, MAP2+, and double-positive cells were each evident with 
SM exposure at N3 day 14, and neurite complexity was not evidently affected.  To 
quantify this effect, we performed large area automated image analysis to count the 
number MAP2+TUJ1+ double-positive NiNs at N3 day 14 (Figure 21a).  NiN yield was 
more than doubled with exposure to SMs compared to normal media, and PMEF HLs 
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transfected with luciferase (pLuc) did not express neuronal markers (Figure 21b).  
Exposure to the SM cocktail doubled the efficiency of NiN generation when PMEF HLs 
were transfected with a 1 µg dose of pUNO-BAM on TCPS, PDL/laminin-, or human 
fibronectin-coated substrates, and analyzed for MAP2 and TUJ1 positivity at N3 day 10 
(Figure 22).  Human fetal lung fibroblasts (MRC-5) transfected with a 1 µg dose of 
pUNO-AM/pmax-B adopted neuronal morphology and co-expressed TUJ1 and MAP2 at 
N3 day 14, only if reprogrammed in the presence of SMs for ten days (Figure 23); 
neuronal markers were not expressed in the absence of SMs during reprogramming, or in 
pLuc-transfected MRC-5s. 
 
Non-viral induction of TH+ cell yield is inefficient, but can be improved with chronic 
depolarization 
 PMEF CD1s transfected with three 1 µg doses of polycistronic ALN (pEF-poly 
ALN) or separate ALN factors (pEF-ALN) both generated rare TH+ cells (Figure 24).  
pEF-poly ALN cells were rarely MAP2+ and had atypically large and multinuclear 
“soma”, whereas pEF-ALN TH+ cells were generally also MAP2+ and exhibited a soma 
and mononuclear phenotype more typical of published iDAs.  Addition of 30 mM KCl 
did not evidently alter NiDA morphology in either case (Figure 24), but more than 
doubled the yield of TH+ cells generated from pEF-ALN transfected cells (Figure 25). 
 
Ascl1 is sensitive to 3’ modification when used for neuronal reprogramming 
 PMEFs transfected with individual ALN factors carrying a 3’ V5 tag fusion were 
stained with an anti-V5 antibody, revealing the expected proper nuclear localization of 
  115  
 
 
Lmx1b-V5 and Nurr1-V5, whereas Ascl1-V5 was sequestered in bright punctae near the 
nuclear envelope (Figure 26).  Delivery of a tagless wild-type Ascl1 via the pUNO-Ascl1 
construct restores an even nuclear expression localization of Ascl1.  Replacement of pEF-
Ascl1-V5 with pUNO-Ascl1 in the ALN cocktail, denoted as pEF-(A)LN, produced an 
order of magnitude improvement in the yield of TUJ1+ cells detected at N3 day 10 
(Figure 27).  The number of rare TH+ and double-positive cells was also increased, but to 
a lesser extent than TUJ1.  Untransfected PMEFs did not express detectable TH or TUJ1. 
 
Pan-neuronal but not TH+ cell yield is increased by inhibition of GSK-3β and 
SMAD during reprogramming with ALN factors 
The yield of TUJ1+ cells generated with a 1 µg dose of pEF-(A)LN plasmids 
could be increased over 80% by reprogramming in the presence of small molecules LDN-
193189, CHIR-99021, and SB-431542 (SM) inhibiting GSK-3β and SMAD signaling for 
10 days immediately following non-viral transfection, but the number of TH+ cells was 
not affected (Figure 29).  Neurite complexity was reduced at this timepoint because the 
small molecules were not yet withdrawn (Figure 28). 
 
Non-viral neuronal reprogramming does not depend exclusively on Ascl1 
PMEFs transfected with a plasmid expressing Neurogenin 2 (Ngn2) under control 
of either the CMV (Figure 30, left column) or CAG promoter (Figure 30, right column) 
expressed abundant Ngn2 at day 2 following transfection (Figure 30, top row), but 
comparatively rare MAP2+TUJ1+ NiNs converted and survived to day 11 of culture in 
iMN media containing FSK, DM, and neurotrophic factors (Figure 30, bottom row).  
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CAG-driven Ngn2 expression did not guarantee neuronal conversion in surviving cells at 
day 11, as evident by the presence of IRES-GFP+TUJ- cells. 
 
4.5 Discussion 
In PMEF CD1s collected freshly from embryos, addition of 30 mM KCl did not 
impair BAM NiN neurite outgrowth (Figure 17) and was not toxic to the starting 
fibroblasts (Figure 18a), but dramatically improved the yield of NiNs collected at the end 
of the experiment, compared to normal N3 medium (Figure 18b).  Non-depolarizing 
NaCl did not produce a difference in NiN yield.  This suggests depolarization by elevated 
[Ca2+] (which continues as long as high [K+] is present [318]), rather than elevated 
osmotic pressure or [Cl-], mediated an increase in either reprogramming efficiency or 
NiN survival after conversion.   
 We are currently unable to distinguish between these potential impacts on 
survival or conversion efficiency, but both are supported by the literature.  For instance, 
depolarization can increase the survival of neural progenitors following injury [370].  
Chronic depolarization can also dissociate repressive REST from target loci in 
differentiating dopaminergic progenitors, and can increase the yield of dopaminergic 
neurons produced [317].  Direct knockdown of REST has also recently been shown to be 
sufficient to reprogram fibroblasts into functional neurons [264].  Increased intracellular 
Ca2+, as can occur via depolarization of voltage-gated Ca2+ channels, is a well-known 
improver of primary neuron survivability both in vitro [320, 322-324] and in vivo [371]. 
Activity also continues to control the identity of neurons post-natally - in one example, 
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acting as a switch to induce a dopaminergic phenotype in the brain of adult rats [372].  
Perhaps most strikingly, increased intracellular Ca2+ entry (as occurs through voltage-
gated Ca2+ channels with depolarization) has recently been shown to activate calcineurin 
to dephosphorylate and inhibit SMAD1/5/8 (the same targets of the small molecules 
shown to improve viral iN yield [364]), thereby increasing neural induction from NPCs 
[373]. Taking all of these precedents together, we believe chronic depolarization 
contributes to increased NiN yield via either: a switch to a subtype that better survives 
low density cultures, improved survivability without a concurrent subtype switch, an 
increased number of initial successfully-converted neurons, or a combination thereof. 
A commercial fibroblast source (PMEF HLs) was sensitive to increased osmotic 
pressure – KCl toxicity significantly reduced the number of surviving cells at the end of 
the reprogramming experiment (Figure 19a).  Interestingly, despite the sensitivity to high 
[KCl], depolarization of these cells with TEACl (a K+ channel blocker) during 
reprogramming with BAM factors recovered an enhancement of BAM factor NiN yield 
(Figure 19b).  We are interested therefore to evaluate KCl and TEACl for improved NiN 
generation in additional PMEF sources, particularly for those collected at various 
developmental stages, with an aim to correlate the degree of improvement afforded by 
chronic depolarization to concurrent epigenetic or developmental events.   
Electrical activity acts as a critical switch to stop neuron migration and 
differentiate to a mature "GABA-inhibitory" phenotype, via increased expression of a Cl- 
channel [374].  Various fibroblast sources may be more or less epigenetically-primed to 
track these normal expression patterns neurons follow in development, and presumably 
when induced in vitro. These differences would likely affect intracellular Ca2+ levels, and 
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consequently the sensitivity to, and utility of, chronic depolarization.  It may also be 
possible to further delineate the relative contribution of depolarization to NiN induction 
and survivability by adding and withdrawing KCl at various stages of the reprogramming 
process, while continuously monitoring the induction kinetics of transgenic markers such 
as NeuroD6- or DCX-RFP, as described in Chapter 3.  We also intend to re-evaluate the 
electrophysiological competence of these cells.  Chronic depolarization can retard 
synaptic network formation in primary neuron cultures, but which can then recover and 
develop normally upon withdrawal of high [KCl] [320]. 
We next evaluated a slightly modified version of a small molecule cocktail with 
published success improving viral iPSC and neural induction [302, 375] and viral iN 
[364] derivation from PMEF sources for its ability to increase BAM NiN generation 
efficiency in PMEF HLs.  These molecules inhibit BMP- and TGFβ-dependent EMT 
pathways in normal development via inhibition of SMAD and GSK-3β signaling.  The 
details of their mechanisms of action in direct reprogramming are unclear, but they are 
generally believed to destabilize EMT differentiation programs, leaving MET and 
neuronal differentiation more likely [285].  Furthermore, Ascl1 may be inhibited via a 
GSK-3β phosphorylation site [285]; inhibition of GSK-3β may therefore act to directly 
de-repress Ascl1.  As previously reported, it was necessary to withdraw the small 
molecules for four days to de-restrict neurite branching via CHIR [364].  With small 
molecule withdrawal, neurite complexity was similar to that observed in normal N3 
medium (Figure 20).  The addition of small molecules more than doubled BAM NiN 
yield at the end of the reprogramming period (Figure 21).   
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 The production of BAM NiNs in the presence or absence of small molecules was 
not affected by PDL/laminin- or fibronectin-coated surfaces (Figure 22).  We stopped 
these experiments at an earlier timepoint due to the known pro-survival effects ECM can 
have on neurons [376], in an effort to focus on the induction phase of iN generation.  As 
such, it appears the early stage of NiN reprogramming may be more potently affected by 
GSK-3β and SMAD signaling than substrate ECM.  Based on reports of enhanced 
transfection on hFN surfaces [69, 82-83], and our own experience, we expected that the 
PMEFs on hFN would be transfected to a greater extent and efficiency than on uncoated.  
Though GFP controls were qualitatively more transfected on hFN than TCPS (results not 
shown), the efficiency of iN generation was unaffected. As such, further improving 
transfection of the already-efficient pCBA-ABOL particles in PMEFs may not be as 
significant a barrier to reprogramming in the BAM NiN system as those barriers 
surmounted by the small molecule cocktail.  This may not be the case for more difficult 
transfection targets, such as primary human fibroblasts. 
We also observed that the improvement in BAM NiN yield from PMEFs with 
small molecule exposure was recapitulated in primary human fibroblasts.  Without SMs, 
we observed no co-expression of TUJ1 and MAP2 from fetal lung fibroblasts transfected 
with the BAM factors, but 10 days of small molecule exposure was sufficient to induce at 
least immature human NiNs (Figure 23).  To our knowledge this is the first report of non-
viral human neuronal reprogramming.  We next intend to evaluate the 
electrophysiological competence of these hNiNs, and to reprogram adult human 
fibroblasts.  This effort may also benefit from possible synergy between the KCl- and 
small molecule-mediated improvements in NiN yield. 
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We next moved on to determine if the enhancements provided by the SMs and 
depolarization could be translated to more efficient production of NiDAs, which was 
expected to be more difficult than BAM NiN production, as dox-withdrawal experiments 
have shown that a longer pulse of ectopic dopaminergic factors is required for successful 
reprogramming [254].  The small molecule cocktail may encourage all forms of neuronal 
reprogramming, or operate specifically on one or more of the BAM factors, or their 
downstream targets.  We began with a polycistronic dopaminergic vector that expresses 
Ascl1, Lmx1b, and Nurr1 from a single ORF, with transcription factor coding regions 
linked by 2A sequences, which release as individual proteins at nearly stoichiometric 
levels during translation [377-378].  These linker sequences are generally superior to the 
use of internal ribosomal entry sites (IRES), which drive significantly lower expression 
than from typical 5’ cap initiation of translation.  We hypothesized this would reduce 
some of the heterogeneity observed in Chapter 3, by ensuring co-expression of all three 
ALNs in every transfected cell. 
Both polycistronic ALN and separate ALN factors were able to induce tyrosine 
hydroxylase (TH, an enzyme required for biosynthesis of dopamine) expression and 
morphological changes in transfected PMEFs (Figure 24).  Surprisingly, the polycistronic 
ALN construct produced TH+ cells that generally did not also express MAP2, and also 
had large multinuclear “soma”, with thin neurite-like processes.  The lack of MAP2 
expression in these cells suggested they were not fully reprogrammed neurons, and that 
potentially only the dopaminergic transcription factors Lmx1b and Nurr1 were at work in 
these cells.  Considering the potent and rapid growth arrest observed with Ascl1 
expression in fibroblasts destined to become BAM factor neurons [251-252], the 
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appearance of multinuclear soma may further suggest reduced activity of Ascl1 as 
delivered via the polycistronic ALN construct.  Separate ALN plasmids, on the other 
hand, produced iDA-like cells that expressed MAP2 and had more compact and 
mononuclear soma.   
The efficiency of TH+ cell production was improved by chronic KCl 
depolarization from PMEFs transfected with separate ALN plasmids, but the efficiency 
of the polycistronic vector was unaffected (Figure 25).  The overall efficiency of NiDA 
generation was one to two orders of magnitude lower than that of BAM NiN generation. 
The polycistronic ALN construct may be less efficient due to lower overall expression 
levels and efficiency due to more difficult nuclear entry of large plasmids – an effect 
previously noted for a large polycistronic construct producing decreased iPSC-derivation 
efficiency compared to separate factors [379].  These results may imply that co-
transfection is less of a barrier than are low overall expression levels.  This result is 
despite the observation that viral delivery of the same construct is able to efficiently 
induce iDA formation from PMEFs and astrocytes [257]. 
 We next worked to determine the source of the apparently impaired function of 
Ascl1 in the polycistronic ALN vector.  We began by staining for proper nuclear 
localization of the separate ALN vectors, each of which carried a 3’ V5 fusion tag.  
Lmx1b-V5 and Nurr1-V5 were localized to the nucleus, whereas Ascl1-V5 appeared to 
be sequestered in punctae near the nuclear envelope (Figure 26).  The tagless Ascl1 
vector used for BAM NiN in Chapter 3 was more efficient at transfecting PMEFs, and 
expressed Ascl1 throughout PMEF nuclei.  Replacement of the V5-tagged Ascl1 with 
untagged Ascl1 produced an order of magnitude greater induction of TUJ1 in ALN-
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transfected cells (Figure 27).  When taken with the published success of the polycistronic 
ALN vector (with a 3’ 2A sequence on Ascl1) delivered from lentivirus, we believe 3’ 
Ascl1 fusions are functional but less stable or active than native Ascl1, and that when 
combined with lower expression duration or levels with non-viral delivery, may be 
accordingly less able to reprogram PMEFs.  The reduction in Ascl1 transfection 
efficiency from pEF compared to pUNO, despite sharing the same promoter, may also be 
a consequence of the larger size of the pEF backbone.  In all subsequent experiments we 
designed plasmids that were as small as possible. 
 The persistent difficulty of activating highly efficient TH+ expression with the 
separate (A)LN factors presented us with an opportunity to study whether the 
improvements observed with GSK-3β and SMAD inhibition in BAM NiNs could be 
generalized to improve the efficiency of NiDA generation.  Small molecules increased 
the yield of TUJ1+ cells to the same extent we previously observed, but did not similarly 
improve the yield of TH+ or TUJ1+TH+ cells (Figure 28, Figure 29).  This suggests that 
the small molecule cocktail may be impacting Ascl1 or its downstream pan-neuronal 
targets independent of the dopaminergic transcriptional networks activated by the 
dopaminergic lineage-instructive Lmx1b and Nurr1 factors.  This notion of transcription-
factor-specific small molecule interactions is further supported by a recent report of a 
unique and synergistic interaction between Ngn2, forskolin, and dorsomorphin for viral 
iMN induction; no improvement or similar interaction was observed with Ascl1 [295].  
These specific interactions may reflect various supportive and cross-repressive soluble 
cues in the maturation of the myriad neural subtypes in normal development. 
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Next, we set out to determine if the powerful pioneer activity of Ascl1 [282] and 
uniquely brief period of its ectopic expression required for neuronal conversion [252] are 
solely responsible for the success of our non-viral BAM iN system.  We chose to evaluate 
the most efficient currently published lentiviral system that does not use Ascl1 – the 
reprogramming of PMEFs and human fibroblasts to iMNs with Ngn2 in the presence of 
forskolin, dorsomorphin, and neurotrophic factors [295].  We were able to induce robust 
nuclear non-viral expression of Ngn2, but only relatively rare MAP2+TUJ1+ cells 
appeared (Figure 30).  This is the first example of non-viral neuronal reprogramming 
without Ascl1.  With an IRES-GFP construct we were able to monitor live iN 
arborization as it matured rapidly and extensively at approximately day 6, followed soon 
thereafter by cell death in the next few days.  We were therefore unable to culture 
putative NiMNs long enough to observe maturation of motor neuron-specific markers 
such as Isl1/2 and Hb9.   
Considering the excellent survival and high yields we can produce with the non-
viral BAM factors, our iMN results suggest that each iN subtype may be variably 
sensitive to extended culture.  One potential explanation may be differential expression of 
ion channels one neuronal subtype relative to another; motor neurons may be particularly 
susceptible to death by excitotoxicity.  Or, iMNs may be more prone to programmed 
death by apoptosis, as occurs to a great extent in normal development to maintain a 
proper innervation density [318-319].  The higher efficiency viral iMN cultures may also 
secrete and benefit from neuroprotective autocrine effects.  We and many others have 
observed improved culture viability and iN complexity with half-volume rather than full-
volume media changes, which potentially maintains the presence of some as-yet 
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undescribed critical conditioned media component(s).  Culturing NiMNs in glia- or 
neuron-conditioned media may help to improve survivability. 
 
4.6 Conclusion and future perspectives 
Our aim was to extend our success producing BAM NiNs to a human cell source, 
as well as to other neuronal subtypes, and to determine if the efficiency of these processes 
could be improved with small molecules and chronic depolarization, towards the 
production of iNs that are therapeutically attractive.  The use of chronic depolarization to 
improve NiN induction and/or survivability is a new technique that can be readily 
evaluated in any lab performing neuronal reprogramming.  In accordance with the many 
neural subtypes that depend on depolarization for accurate specification and survival 
during normal development, we observed an improvement in both dopaminergic and pan-
neuronal marker expression with culture in medium containing high KCl; this may 
suggest the technique can be further generalized to other forms of neural reprogramming.  
We look forward to evaluating the technique in lentiviral systems that suffer from 
unexplained low efficiencies.  To delineate the contribution of KCl to the neural 
induction versus survival phases of the experiments, we will use PMEF reporter lines as 
described in Chapter 3, add and remove KCl at various times, and employ longitudinal 
single-cell imaging. 
We have demonstrated that Brüstle's cocktail of small molecules [364] can also be 
used to greatly improve the yield of TUJ1+MAP2+ NiNs, in particular for cocktails 
including Ascl1.  It remains for us to evaluate potential synergy between chronic 
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depolarization and small molecules for NiDA induction with the (A)LN cocktail; KCl 
may act on the dopaminergic TFs Lmx1b and Nurr1 to improve TH+ induction, and the 
small molecules on Ascl1 for general enhancement of neural induction and survival.  
With further increases in NiDA efficiency we will be able to evaluate the functional 
characteristics of these cells.  The small molecules also enabled us to produce the first 
human BAM NiNs, which is a significant proof-of-concept advance that brings us closer 
to the goal of transformative autologous cell therapies for neurodegenerative disease. 
A critical finding of this chapter is that the successful deployment of each 
transcription factor cocktail seems to require the surmounting of a mixture of shared and 
unique barriers.  To over-simplify for the purpose of illustration: all forms of non-viral 
neuronal reprogramming can benefit from the high transfection efficiencies afforded by 
pCBA-ABOL, a large subset may benefit from pro-survival effects of chronic 
depolarization, NiMNs may benefit from NMDAR inhibitors to prevent excitotoxicity, 
and potentially only NiN cocktails including Ascl1 may benefit from inclusion of GSK-
3β and SMAD inhibitors.  Rapid development of the field will require an understanding 
and ability to detect and circumnavigate each of the potential barriers. 
The most poorly-understood of these barriers may be the variable epigenetic 
availability of critical target loci in the starting cell source.  There has been a recent 
attempt to mechanistically describe the difference in BAM iN induction efficiency 
between various cell sources, which finds that the susceptibility to reprogramming by 
Ascl1 appears to depend on a complex trivalent chromatin state [282].  Each target iN 
type may have a similar “ideal” set of chromatin marks that may previously exist and/or 
appear gradually in reprogramming cells.  
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Each of the endogenous BAM factor genes activate in around 48 hours of 
lentiviral induction [380], which is also readily achieved with non-viral delivery.  If 
kinetically-limited epigenetic changes are required to allow stable activation of 
endogenous gene circuits, transient transfection may be less-readily able to achieve 
efficient reprogramming (for example in non-viral dopaminergic neuron 
reprogramming).  Slow epigenetic or stochastically-unlikely pioneer events may be 
responsible for the differences in reprogramming speed and efficiency reported for 
various forms of reprogramming.  iPSCs for example, require perhaps the longest 
continuous induction of ectopic factors, presumably because their epigenetic landscape 
must be reverted to the greatest extent to prime for the rapid induction that occurs with 
subsequent differentiation into all possible lineages.   
Difficult forms of non-viral reprogramming may therefore benefit from 
CRISPR/Cas9-based synthetic transcription factor activation of endogenous loci, which 
appear to have pioneer activity of their own [298], which some natural lineage-instructive 
TFs may lack in a fibroblastic context (Brn2 in the absence of Ascl1, for example 
[282]).  This approach could make the largest impact in low-efficiency reprogramming 
cocktails that include transcription factors with demonstrable difficulty binding to their 
targets in the starting cell source.  Future dCas9 systems carrying chromatin-remodeling 
enzymes may also help to precisely define and surgically excise the epigenetic barriers to 
reprogramming without repeated and laborious protein engineering, potentially providing 
a strong therapeutic rationale for the nascent field of "epigenetic editing" [381-382]. 
A current restriction on the full potential of CRISPR/Cas9-based epigenetic 
modifiers for reprogramming may be the generally-desired single-site specificity of 
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dCas9 targeting; ideally the epigenetic modifiers could be simultaneously targeted with a 
library of gRNAs across all of the consensus binding sites for the lineage-specifying 
transcription factors.  This could speed slow forms of reprogramming by specifically 
removing repressive marks on all target loci, thereby allowing the ectopic (or dCas9-
activated endogenous) transcription factors to act on their targets freely.  Transfection of 
gRNA libraries into transgenic reporter PMEFs, followed by FACS purification of 
rapidly- or completely-reprogrammed cells, and a compilation of the gRNAs sequenced 
from those successful cells may identify epigenetic “hot spots” that are particularly 
critical for successful reprogramming. 
Having demonstrated the large impact chemical microenvironments can exert on 
NiN generation, and our lab’s experience with the power substrate topography can have 
on cell phenotype, we were also interested to determine if the physical microenvironment 
might have a positive effect on non-viral transfection, and direct neuronal reprogramming.  
We have considered this question in two independent parts, in order to isolate the relative 
contribution of topography to each.  In Biomaterials, we recently demonstrated that 
substrate topography can encourage the viral neuronal reprogramming of fibroblasts to 
neurons [383].  Briefly, we found that viral reprogramming of PMEFs with the BAM 
factors on micron-scale gratings could increase iN yields by 35-60%, as well as affect 
neurite branching and global gene expression patterns.  These effects may be transduced 
by mechanotransductive modulation of GSK-3β [384] and SMAD activity by YAP/TAZ.  
In Chapter 5, we go on to demonstrate that substrate topography can also increase non-
viral transfection efficiency in fibroblasts more generally, which could be applied to any 
form of plasmid-based non-viral reprogramming. 
4.7 Figures 
 
 
Figure 16. Non-viral vectors generated for direct reprogramming of fibroblasts to dopaminergic 
neurons 
Coding sequences for human Ascl1, Lmx1b, and Nurr1 (ALN) transcription factors were inserted into the 
pEF-DEST1 backbone, under control of the EF1α promoter, either separately or as a single polycistronic 
2A-linked construct (pEF-poly ALN), with 3’ V5 tags.  pUNO-Ascl1 was used with pEF-Lmx1b and pEF-
Nurr1 as a tagless version of Ascl1, denoted pEF-(A)LN.  The separate ALN factor-encoding plasmid 
cocktails (pEF-ALN and pEF-(A)LN) were delivered at equimolar ratios. 
 
 
Figure 17. NiNs produced with and without chronic exposure to depolarizing concentrations of KCl 
The appearance of NiNs at N3 day 10 produced with three 1 µg doses of pUNO-AM/pmax-B with and 
without exposure to 30 mM KCl immediately following non-viral transfection, for the duration of 
reprogramming. 
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Figure 18. Quantification of NiN yield from PMEFs with and without chronic depolarization by KCl 
(a) Large area scans of TUJ1 expression at N3 day 10 following three 1 µg doses of pUNO-AM/pmax-B in 
PMEFs (2.5 mm scale bar).  (b) Total final cell number with 30 mM KCl or non-depolarizing 30 mM NaCl 
osmotic control, compared to normal N3 media formulation.  (c) TUJ1+MAP2+ NiN yield was more than 
doubled with 30 mM KCl exposure compared to normal media, and was unchanged with 30 mM NaCl.  
Cell counts were generated with large area image analysis; bars represent mean ± SEM of three separate 
experiments performed in triplicate. 
 
 
Figure 19. Quantification of NiN yield from a commercial MEF source with and without chronic 
depolarization by TEACl 
(a) Number of surviving PMEF HLs at N3 day 10 following a 1 µg dose of pUNO-AM/pmax-B, in the 
presence or absence of 30 mM KCl. (b) NiN yield at N3 day 10 following reprogramming in the presence 
or absence of 1 mM TEACl (K+ channel blocker). Cell counts were generated with large area image 
analysis, error bars represent SEM, n = 3. 
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Figure 20. NiNs produced with and without inhibition of GSK-3β and SMAD signaling 
The appearance of NiNs at N3 day 14 generated with a 1 µg dose of pUNO-AM/pmax-B in the presence or 
absence of small molecules LDN-193189, CHIR-99021, and SB-431542 (SM) for 10 days immediately 
following non-viral transfection. 
 
 
Figure 21. Quantification of NiN yield with and without inhibition of GSK-3β and SMAD signaling 
(a) Large area scans of TUJ1 expression at N3 day 14 following a 1 µg dose of pUNO-AM/pmax-B in 
PMEFs (2.5 mm scale bar).  (b) TUJ1+MAP2+ NiN yield at N3 day 14 with exposure to LDN-193189, 
CHIR-99021, and SB-431542 (SM) compared to normal media.  Cell counts were generated with large area 
image analysis; bars represent mean ± SEM of three separate experiments performed in triplicate. 
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Figure 22. Quantification of NiN yield on various substrate ECMs with and without inhibition of 
GSK-3β and SMAD signaling 
NiN yield at N3 day 10 from PMEFs transfected with 1 µg pUNO-BAM when reprogrammed on TCPS, 
PDL/laminin, or human fibronectin, in the presence or absence of LDN-193189, CHIR-99021, and SB-
431542 (SM).  Cell counts were generated with large area image analysis, error bars represent SEM, n = 3. 
 
 
Figure 23.  Expression of neuronal markers in human NiNs produced with inhibition of GSK-3β and 
SMAD signaling 
Expression of TUJ1 and MAP2 at N3 day 14 in NiNs produced from human fetal fibroblasts (MRC-5) 
transfected with a 1 µg dose of pUNO-AM/pmax-B and reprogrammed in the presence of LDN-193189, 
CHIR-99021, and SB-431542 (SM) for ten days. 
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Figure 24. Expression of tyrosine hydroxylase (TH) in PMEFs transfected with a cocktail of ALN 
plasmids, or a polycistronic ALN construct 
Induction of TH+ cells at iDA medium day 10 in PMEF CD1s transfected with three 1 μg doses of 
polycistronic ALN (pEF-poly ALN) or separate ALN plasmids (pEF-ALN). pEF-poly ALN-transfected 
cells were generally not MAP2+. 
 
 
Figure 25. Quantification of TH+ cells produced with separate or polycistronic ALN factors in 
presence of KCl 
TH+ yield at iDA medium day 10 following three 1 µg doses of pEF-poly ALN or pEF-ALN in PMEF 
CD1s, with or without 30 mM KCl.  Cell counts were generated with large area image analysis, error bars 
represent SEM, n = 3. 
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Figure 26. Localization of Ascl1, Lmx1b, and Nurr1 with 3’ V5 tags, and tagless Ascl1 
Staining in PMEFs two days after transfection with V5-tagged (top left) or wild-type Ascl1 (top right), and 
V5 tagged Lmx1b and Nurr1 (bottom row).  V5 stains were performed with an anti-V5 antibody, and wild-
type Ascl1 stain with an anti-Ascl1 antibody. 
 
 
Figure 27. Quantification of cells expressing TUJ and TH upon removal of V5 tag from Ascl1 
Yield of TH+ and TUJ1+ cells from V5-tagged ALN factors (pEF-ALN) or ALN factors with tagless Ascl1 
(pEF-(A)LN) at N3 day 10.  Cells were counted with large area image analysis, error bars represent SEM, n 
= 3. 
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Figure 28. TH and TUJ1 expression in (A)LN-transfected PMEFs with and without exposure to small 
molecules inhibiting GSK-3β and SMAD signaling 
The expression of TUJ1+ and TH+ in PMEF HLs transfected with a 1 µg dose of pEF-(A)LN plasmids by 
reprogramming in the presence of small molecules LDN-193189, CHIR-99021, and SB-431542 (SM) 
inhibiting GSK-3β and SMAD signaling for 10 days immediately following non-viral transfection. 
 
 
Figure 29. Quantification of TUJ1+ yield in pEF-(A)LN transfected PMEFs with or without exposure 
to small molecular inhibitors of GSK-3β and SMAD signaling 
TUJ1+ and TH+ cell yield in PMEF HLs transfected with a 1 µg dose of pEF-(A)LN plasmids with or 
without exposure to LDN-193189, CHIR-99021, and SB-431542 (SM).  Cell counts were generated with 
large area image analysis, error bars represent SEM, n = 3. 
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Figure 30. Transgene and neuronal marker expression in PMEFs transfected with Neurogenin 2 
Expression of Neurogenin 2 (Ngn2) and GFP in PMEFs transfected with a plasmid expressing Ngn2 under 
control of the CMV (top left) or CAG promoter (top right) and stained two days following transfection.  
MAP2 and TUJ1 expression at day 11 of culture in iMN medium (bottom row). 
  135  
 
 
  136  
 
 
Chapter 5: High-Throughput Screening of Microscale 
Pitted Substrate Topographies for Enhanced Non-viral 
Transfection Efficiency in Primary Human Fibroblasts 
 
A portion of Chapter 5 appears in: High-throughput screening of microscale pitted 
substrate topographies for enhanced nonviral transfection efficiency in primary human 
fibroblasts. Adler AF, Speidel AT, Christoforou N, Kolind K, Foss M, Leong KW. 
Biomaterials. 2011 May;32(14):3611-9. 
 
5.1 Summary 
Optimization of non-viral gene delivery typically focuses on the design of 
particulate carriers that are endowed with desirable membrane targeting, internalization, 
and endosomal escape properties. Topographical control of cell transfectability, however, 
remains a largely unexplored parameter. Emerging literature has highlighted the 
influence of cell-topography interactions on many cell phenotypes, including protein 
expression and cytoskeletal behaviors implicated in endocytosis, the principal means of 
nanoparticulate gene carrier internalization. Using high-throughput screening of primary 
human dermal fibroblasts cultured on a combinatorial library of microscale topographies, 
we have demonstrated an improvement in non-viral lipoplex transfection efficiency for 
cells cultured on dense micropit patterns compared to smooth substrates, as verified with 
flow cytometry. A 25% increase in GFP transfection efficiency was observed, 
independent of proliferation, accompanied by SEM and confocal microscopy to help 
explain the phenomenon qualitatively. This improvement was also observed in a reverse 
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transfection format, as well as in cells transfected with cationic polyplexes.  Further, the 
micropit-mediated enhancement of siRNA knockdown and low-dose plasmid delivery 
was evaluated.  These findings encourage researchers to investigate substrate topography 
as a new design consideration for the optimization of non-viral transfection systems. 
 
5.2 Rationale and Significance 
We have previously presented a method whereby physical substrate topography 
could be used to increase the yield of NiNs produced from PMEFs with lentiviral 
delivery of the BAM factors, either by encouraging the reprogramming process itself, or 
by improving iN survival [383].  We expect a similar improvement may be possible with 
NiN reprogramming.  Here, we use similar micropatterned substrates in an attempt to 
increase the efficiency of transfection – the first step of non-viral reprogramming, in adult 
human fibroblasts, the eventual cell source needed for transdifferentiation-based cell 
therapies.  Beyond neuronal reprogramming, topographical cues influence many cell 
phenotypes including proliferation, spreading, cytoskeletal organization, and endocytosis 
[108-110]. We hypothesize therefore that substrates with nano- and micropatterned 
topographies may also influence the transfectability of interacting cells. We endeavor to 
understand the functional relationship between substrate topography, focal adhesion 
formation, cytoskeletal tension, endocytosis, and transfectability. We demonstrate 
topographical control of transfection in this chapter, first with bolus delivery of 
Lipofectamine 2000 (LF2k) complexes to primary normal dermal human fibroblasts 
(NHDFs) cultured on a combinatorial library of well-defined micropitted topographies.   
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Topography-mediated enhancement of non-viral gene transfer can find utility in 
transfected cell arrays, ex vivo cell therapy approaches, and in the intelligent design of 
gene-eluting scaffolds.  Cell culture substrates for in vitro use are typically smooth by 
default, whereas implantable gene-eluting scaffolds often impart tunable porosity (and 
therefore topography) via electrospinning [385], polymer chemistry, or porogen inclusion 
[386] to promote cell penetration and enhance mass transfer of entrapped therapeutics.  
The microenvironment at implant surfaces is critically important to efficient 
transfection; the inclusion of soluble factors, adsorption of ECM molecules, modulation 
of cell-cell interactions, and tuning of mechanical stress are all currently leveraged 
towards the improvement of transfection efficiency [387]. Scaffold surface topography is 
an additional design parameter that may be optimized to bolster in situ genetic 
manipulation of infiltrating cells.  
The use of pitted topography may also facilitate maintenance of a detectable level 
of knockdown with a diminished dose of siRNA or pDNA in transfected cell arrays. Even 
modest improvements in transfected cell array efficiency and miniaturization can 
significantly reduce the cost and quantity of reagents and cells required to perform these 
assays, encouraging researchers to embrace the technology to accelerate discovery.  
Topographically-enhanced transfection is particularly attractive for ex vivo cell therapy 
systems (such as direct neuronal reprogramming), where increases in transfection 
efficiency will translate to improved therapeutic benefit in the form of more successfully-
transdifferentiated cells. 
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5.3 Methods 
Preparation of 13 x 13 pattern topographical library 
Topographical libraries (arrays) were prepared as described in [388], using a 
standard lithography process. Briefly, a resist without hard bake was etched with Cl2, 
HBr and NF3 to produce sidewall angles of 85° with etch rate non-uniformity of 2–3% 
(max–min). After removal of the resist and cleaning, the surface was sputter- coated with 
100 nm of tantalum at a rate of 50 nm min-1, producing a 13 x 13 master library of post 
topographies. To create substrates for cell culture, Sylgard 184 polydimethylsiloxane 
(PDMS) (Dow Corning, Midland, MI) was mixed at a curing agent/base ratio of 1.05/10 
w/w, degassed in a vacuum chamber, cast onto the metal master, and cured overnight at 
47°C. PDMS arrays were peeled from the metal master and used for cell culture. These 
arrays were composed of 10 distinct pit morphologies (A-J) with: pit size (X) and edge-
to-edge spacing (Y) iterated combinatorially through values of 1, 2, 4, and 6 µm (Figure 
31), a uniform depth of 2.4 µm, and with 3×3 mm2 patterned area for each. Pattern K did 
not support robust NHDF adhesion, and was excluded from all analyses. Smooth control 
regions were present in the middle of the array, and in the boundaries between patterns. 
Large area (2×2 cm2) metal masters of the single patterns F(X,Y) = F(1,4) and F(4,1) 
were also produced following the same lithographical process to facilitate analysis by 
flow cytometry and luciferase assay. Pitted PDMS replicates of these “single-pattern” 
substrates, as well as smooth PDMS substrates produced from smooth silicon wafers, 
were stamped into 2 cm2 circular disks, affixed to the bottom of 24-well tissue culture 
plates (Falcon, Heidelberg, Germany) with 50 µL PDMS, and cured overnight. 
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Cell culture 
 Adult normal human dermal fibroblasts (NHDFs) (Lonza, Basel, Switzerland) 
were cultured in high glucose Dulbecco’s Modified Eagle’s Medium (GIBCO 11960-
044) (Invitrogen, Carlsbad, CA) supplemented with 20% Premium Select FBS (Atlanta 
Biologicals, Lawrenceville, GA), 25 µg mL-1 gentamicin (Invitrogen), and 1x GlutaMAX, 
non-essential amino acids, sodium pyruvate, and β-mercaptoethanol (Invitrogen), at 37°C 
and 5% CO2. NHDFs were passaged a maximum of six times prior to experimentation. 
PDMS substrates were washed with 70% ethanol and air-dried twice, then washed with 
sterile deionized (DI) water and air-dried twice again. 25 µg mL-1 human plasma 
fibronectin (BD, Franklin Lakes, NJ) in DI water was adsorbed to PDMS substrates for 1 
hour at room temperature (RT) before seeding NHDFs at a density of 7,500 cells cm-2 for 
quantitative analyses, and 3,750 cells cm-2 for visualization by SEM and confocal 
microscopy. 
 
Plasmid DNA 
 pmaxGFP (Amaxa, Cologne, Germany) and VR1255 (Vical, San Diego, CA) 
plasmids expressing green fluorescent protein (GFP) and luciferase reporters under 
control of the CMV promoter were propagated in Escherichia coli DH5α and purified 
with the EndoFree Plasmid Giga Kit (Qiagen, Hilden, Germany). Plasmid DNA 
concentrations were quantified by measurement of absorbance at 260 nm with a 
NanoDrop ND-1000 Spectrophotometer (Thermo Scientific, Waltham, MA). 
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Transfection protocol 
 24 hours after seeding on topographical libraries or single-pattern substrates, 
NHDFs were transfected with a 2:1 ratio of Lipofectamine 2000 (Invitrogen) volume 
(µL) to pmaxGFP or VR1255 DNA mass (µg) at a dose of 1 µg plasmid cm-2 in serum- 
and antibiotic-free OptiMEM (Invitrogen), according to the manufacturer’s protocol. 
Transfection medium was replaced with complete medium 4 hours after the onset of 
transfection. Mass ratio and DNA dose were selected based on a preliminary optimization 
of luciferase expression levels in NHDFs cultured on smooth substrates (results not 
shown). 
 
Proliferation assay 
Proliferation of cells on topographical libraries was quantified with the BrdU (5-
bromo-2-deoxyuridine) incorporation assay, which labels the nuclei of cells that have 
undergone mitosis. Following removal of the transfection medium, cells were incubated 
for 20 hours with 15 μM BrdU (Invitrogen) in complete media. Cells were then washed 
briefly with Cellgro phosphate-buffered saline (PBS) containing Ca2+ and Mg2+ 
(Mediatech, Washington, DC), and fixed with 4% paraformaldehyde (PFA) (EMS, 
Hatfield, PA) at 4°C for 30 minutes. Genomic DNA was denatured with 2M HCl (Sigma-
Aldrich, Saint Louis, MO) for 10 minutes at RT and 20 minutes at 37°C, immediately 
followed by a 5 minute wash with 0.1 M borate buffer (Thermo Scientific), and a 30 
minute RT incubation in blocking buffer containing 0.2% Triton X-100, 3% w/v BSA, 
and 10% goat serum (Sigma-Aldrich). BrdU incorporation was detected by 12 hour 
incubation at 4°C with anti-BrdU-AF594 mAb (1:100 dilution, Invitrogen), and 15 
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minute RT DAPI counterstain (1:5000, Invitrogen). Between each staining step, cells 
were washed three times for five minutes at RT with PBS containing 0.2% Triton X-100 
and 1% BSA.  
 
Automated fluorescence imaging and analysis of topographical library 
 24 hours after the onset of transfection, NHDFs were washed briefly with PBS 
containing Ca2+ and Mg2+, and fixed with 4% PFA (EMS) at 4°C for 30 minutes. Cell 
spreading was visualized with a 30 minute RT phalloidin-AF594 (1:200, Invitrogen) stain, 
and nuclei with 15 minute DAPI (1:5000, Invitrogen) stain at RT, with three five-minute 
PBS washes before and after each. Following staining, arrays were mounted face-down 
on Nunc single-well OmniTrays (Thermo Scientific) with Fluoro-Gel (EMS). 
Transfection efficiency (GFP, green), cell spreading (phalloidin, red), and cell 
number (DAPI, blue) data were collected from three independent arrays, while 
proliferation data (BrdU, red; DAPI, blue) were collected from another three, using a 
Nikon Eclipse TE2000-U fluorescence inverted microscope fitted with appropriate filters 
and ProScanII robotic stage and autofocus controllers (Prior). Each array was scanned 
automatically using NIS-Elements software (Nikon, Tokyo, Japan), with autofocus 
performed in every field, and a constant exposure time for each channel within a given 
array, producing large high-resolution composite images for each fluorophore. 
Adobe Photoshop CS3 (Adobe Systems, San Jose, CA) was used to overlay a 
black grid onto an image of an array, outlining the boundaries of each patterned region 
within that array (Figure 32). This masked image was then used to define regions of 
interest (ROIs) in ImageJ (NIH). First, a threshold was set to differentiate the background 
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in each region from the black mask. The “Analyze particles” command was then used to 
detect and store each patterned area as a unique ROI. The original (unmasked) images 
were then re-thresholded and analyzed with a custom ImageJ macro, which sequentially 
stepped through each ROI and utilized the “Analyze particles” command to count the 
number of BrdU+ nuclei, DAPI+ nuclei, and GFP+ cells, or quantified the area fraction of 
each region stained with phalloidin. Particles that were significantly smaller than cells or 
nuclei were excluded from the relevant quantifications with the “Particle size” setting 
within “Analyze particles”. 
 
Flow cytometry of cells on single-patterned substrates 
 24 hours after the onset of transfection with pmaxGFP-containing complexes (48 
hours after cell seeding), NHDFs cultured on F(1,4), F(4,1), and smooth PDMS 
substrates in quadruplicate were washed briefly with PBS containing Ca2+ and Mg2+, 
released from substrate surfaces with 0.25% Trypsin-EDTA (Invitrogen), centrifuged, 
and resuspended in propidium iodide (PI) (1:1000, Invitrogen) to stain dead cells. Cells 
were then filtered through 40 μm nylon cell strainers (BD) and analyzed with a BD 
FACSCanto II flow cytometer. Single-positive PI+ and GFP+ cells were used to adjust 
spectral compensation. Non-transfected NHDFs cultured on smooth PDMS served as 
negative control, with 1% of these cells considered GFP+. 
 
Luciferase assay 
 24 hours after the onset of transfection with VR1255-containing complexes, 
NHDFs cultured on F(1,4), F(4,1), and smooth PDMS substrates in triplicate were 
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washed briefly with PBS containing Ca2+ and Mg2+, and lysed with: 500 μL Glo Lysis 
Buffer (Promega, Fitchburd, WI), a -80°C freeze-thaw cycle, and scraping. Non-
transfected cells served as negative control. 100 μL of each lysate was then combined 
with 100 μL Steady-Glo Luciferase Assay Substrate (Promega) in an opaque 96-well 
plate (Thermo Scientific). Luminescence signals were normalized to the total dsDNA 
content in each lysate measured by Quant-iT PicoGreen assay (Invitrogen), according to 
the manufacturer’s protocol. A standard curve of cell number to PicoGreen signal was 
linear in the required dynamic range. Luminescence integrated over 7 seconds 
(luciferase) and fluorescence (PicoGreen) values were collected at RT following 5 minute 
incubations using a BMG Labtech FLUOStar Optima plate reader. 
 
Confocal laser scanning microscopy 
To visualize NHDFs protruding into pits, the cells were stably transduced with 
fluorescent cytoskeletal fusion proteins Lifeact-mRFPRuby (F-actin) [389] and -actinin-
GFP [390] (Addgene plasmid 11908) which were previously cloned into the lentiviral 
vector FUGW, and delivered with replication-deficient 2nd generation lentiviruses 
(packaging vectors psPAX2 (Addgene plasmid 12260) and pMD2.G (Addgene plasmid 
12259)). Lentiviral transduction was used in place of immunohistochemistry to minimize 
sample handling. The stably-transduced NHDFs were cultured on patterns F(1,4) and 
F(4,1) for 24 hours, washed with PBS containing Ca2+ and Mg2+, fixed for 20 minutes in 
4% PFA at 4°C, mounted face-down in Fluoro-Gel (EMS) on #1.5 coverslips (VWR, 
West Chester, PA), and visualized with the 63× oil immersion objective of a Zeiss LSM 
510 inverted confocal microscope. 
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SEM 
 Cells cultured on single-pattern substrates were washed briefly with PBS 
containing Ca2+ and Mg2+, and dehydrated with a graded ethanol series. The cell samples 
were then dried with a Pelco CPD2 critical point drier, and sputter coated with a 10 nm 
layer of gold using a Denton Desk IV Vacuum Sputter Unit. Single-pattern substrates 
without cells were cleaned with 70% ethanol, freeze-fractured with liquid nitrogen, and 
sputter-coated with 10 nm of gold. All samples were then examined with an FEI XL30 
scanning electron microscope. 
 
Real-time RT-PCR 
Comparative CT real-time RT-PCR was performed in 20 µL reactions using the 
QuantiTect SYBR Green RT-PCR Kit (QIAGEN) with 10 ng of starting mRNA isolated 
with RNeasy and QIAshredder kits (QIAGEN) from cells cultured on smooth or 
micropitted substrates. mRNA concentrations were quantified with a NanoDrop ND-1000 
Spectrophotometer (Thermo Scientific). PCR proceeded for 40 cycles in an ABI 7300 
Real-Time PCR System (Carlsbad, CA). Target mRNA levels were normalized to 
endogenous GAPDH references, and presented as a fold-change increase on topography 
relative to smooth substrates, collected 48 hours after seeding. Primers used (IDT, 
Coralville, Iowa) were as follows: CAV1 forward (TGG GCC CAG GAC GCG TTT TC), 
CAV1 reverse (GAT GTC CCT GCG CAG CTC CC), CLTC forward (CCA TAA CCC 
CCG ACA GCG CC), CLTC reverse (CCC ACC ACA CGA TTT TGC TGT GC), 
ITGB1 forward (TGT CTG TGC TGA GCA TAA AGA ATG TGT), ITGB1 reverse 
(GCG TGT CCC ATT TGG CAT TCA TTT), ITGAV forward (CTT AAA GGC AGA 
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TGG CAA GG), ITGAV reverse (AAA TGG TGA TGG GAG TGA GC), HSPG2 
(perlecan) forward (CAC AGC AAG CCA AAT GCG CTG G), HSPG2 reverse (ACT 
CCA GCG TGT CTA CCA CAG CC), GAPDH forward (CGT ATT GGG CGC CTG 
GTC ACC), GAPDH reverse (TGG CAT GGA CTG TGG TCA TGA GT). 
 
Statistics 
 Statistical treatment and graphing of data were performed using Prism (GraphPad 
Software, La Jolla, CA). For comparisons of multiple pairs, ANOVA with Tukey post-
test was performed, with p-values < 0.05 considered significant. For post-normalization 
comparisons to smooth substrates, one-sample t-test was performed, with p-values < 0.05 
considered significant. Error bars represent the standard deviation of three independent 
experiments. 
 
5.4 Results 
Transfection efficiency, morphology, and proliferation of fibroblasts on 
topographical libraries 
 High-throughput parallel screening of 160 pitted topographies revealed a 
significant 25% enhancement of GFP transfection efficiency for cells cultured on patterns 
with small interfeature spacings (Y = 1, 2 μm) compared to smooth regions (Figure 34a). 
This enhancement decreased and disappeared as the pits became spaced further apart; that 
is, as they more closely approximated a smooth surface. Regions with large pits (X) 
increased transfection efficiency more modestly, while patterns with small pits supported 
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identical transfection efficiencies as smooth regions. Pit morphologies A-J had no 
significant impact on transfection efficiency (results not shown). Topography-mediated 
enhancement of transfection was significant compared to smooth regions within each 
array, as well as between the averages of three normalized arrays presented in Figure 34. 
Examples of these differences are visible in representative widefield fluorescence images 
presented in Figure 33. 
 Cell spreading was quantified as the area occupied by actin on each pattern 
normalized by the number of cells in that region (Figure 34b). Spreading showed a trend 
opposite that observed for transfection efficiency; NHDFs on large, closely spaced pits 
were significantly less spread than those on small, distal pits, and on smooth regions. 
Regions with large, closely-spaced pits were also observed to encourage cell alignment. 
The strong influence of pitted topography on NHDF morphology is also evident in Figure 
33. 
 Pit size had no effect on the number of cells in each patterned region after 
transfection. However, features with closely-spaced pits had slightly but significantly 
fewer cells than those with large interfeature distances (Figure 34c). No combination of 
pit size or spacing supported a significantly different number of cells than found on 
smooth regions. No significant differences in proliferation rates were observed for 
NHDFs cultured on topographical libraries (Figure 34). 
 
Flow cytometry on single-patterned substrates 
Refer to Figure 35 for freeze fracture cross sections of F(1,4) and F(4,1), the 
topographies selected for this experiment.  Without normalization, an average of 55.0 ± 
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3.5% NHDFs cultured on smooth PDMS were GFP-positive following non-viral 
transfection, whereas an average of 68.3 ± 2.7% of cells cultured on pattern F(4,1) and 
57.8 ± 3.6% on pattern F(1,4) were successfully transfected across all three experiments 
(95% confidence intervals).  Normalization to the transfection efficiency of cells on 
smooth PDMS in each experiment gives a significant 24.4% average enhancement of 
transfection efficiency for cells cultured on F(4,1), compared to F(1,4) and smooth 
substrates (Figure 36a).  Reverse transfection with Lipofectamine 2000 was also 
increased 35% (Figure 36b), and forward transfection with pCBA-ABOL/DNA 
nanoparticles was increased 15% by culture on F(4,1) compared to F(1,4) and smooth 
substrates (Figure 37). 
 
Luciferase assay 
 Luciferase activity normalized to total cellular DNA was not significantly 
different for NHDFs transfected on smooth, F(1,4), or F(4,1) patterned topographies (data 
not shown). Cells transfected with luciferase were 4,000 times more luminescent than no-
transfection negative controls. 
 
SEM 
 Inspection of NHDFs cultured on pitted topography with SEM revealed NHDFs 
cultured on pattern F(4,1) were less spread, and more aligned than those on pattern F(1,4) 
(Figure 39). The cells were also observed to drastically deform the walls of the 4 µm pits, 
sometimes with a single thin process. For both patterns, cells could be seen extending 
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portions of their membrane over the edge of open pits. Freeze fracture of the patterns 
revealed a uniform pit depth of 2.4 µm (Figure 35). 
 
Confocal microscopy 
 Cytoskeletal fusion proteins expressed in NHDFs were observed protruding 2.4 
µm below the rest of the basal membrane plane from cells cultured on both 4 and 1 µm 
pits (Figure 40). Cells cultured on 4 µm pits appeared as “waves” in the XY and XZ 
planes, because both the apical and basal membrane descended into pits. This is in 
contrast to cells on 1 µm pits, which only extended their basal membrane to pit bottoms. 
Further, in many of the cells cultured on 1 µm pits, there were no protrusions visible. 
 
siRNA knockdown in cells transfected on micropits 
Positive controls (GFP DNA only, on TCPS) were 20% and 7% GFP+ for 
adsorbed 500 µg cm-2 and bolus 75 ng cm-2 doses, respectively (not shown). 4 μm pits 
increased the fraction of GFP+ cells co-transfected with bolus lipoplexes containing GFP 
pDNA and non-targeted negative control siRNA by 44% (Figure 38, solid bars). α-GFP 
siRNA was efficient at knocking down GFP expression on all substrates (Figure 38, 
hatched).  
 
qPCR comparison of cells on micropits versus smooth topography 
A preliminary screen of transcript expression of genes implicated in endocytosis 
reveals cells cultured on micropitted topography upregulate integrin αv and possibly β1 
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(Figure 41), components of the vitronectin receptor (vitronectin is a principal ECM 
component in serum) αvβ3, and fibronectin receptor α5β1 respectively.   
 
5.5 Discussion 
In this study, our goal was to test the hypothesis that substrate topographies, 
which have been shown to affect many cell phenotypes, also have an influence on 
transfectability. High-throughput microscopy of primary NHDFs cultured on 
topographical arrays revealed that cells on large, closely spaced pits were transfected a 
significant 25% more efficiently than those on smooth surfaces, while small, distally-
spaced pits did not significantly alter GFP expression (Figure 34a). Flow cytometric 
analysis of NHDFs cultured on single patterns verified the prediction made by screening 
(Figure 36). When taken with the increased GFP expression, total siRNA-mediated 
knockdown was greater on 4 µm pits than on 1 µm pits or smooth substrates (Figure 38). 
These effects are applicable to scaffold-mediated gene delivery, which can be thought of 
as a mixture of bolus- and substrate-mediated delivery, and to reverse-transfected cell 
arrays.  The bolus LF2k delivery used previously (Figure 36a) was an optimized dose (1 
μg); it is interesting to note that transfections with a lower (suboptimal) dose of plasmid 
(150 ng) are enhanced to a greater extent by micropitted topography (Figure 38).  pCBA-
ABOL is an extremely efficient gene carrier - as such it may not benefit as greatly from 
topographical enhancements if the transfection is already nearly "saturated" on smooth 
substrates (Figure 37).  To our knowledge, these results represent the first demonstration 
of a topographic control of transfection. 
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 Additional experiments and measurements were performed in an effort to 
understand why cells cultured on patterned topography were transfected more efficiently. 
NHDFs that were least-spread were most efficiently transfected (Figure 33, Figure 34a,b). 
Visible deformation of pattern F(4,1) but not of pattern F(1,4) implies cells may 
experience a different effective surface stiffness and intracellular tension on each 
topography (Figure 39). 
Cytoskeletal tension and cell spreading have been repeatedly demonstrated to 
modulate genome-wide changes in protein expression levels and patterns, including many 
involved in endocytosis, including: clathrin, epsin 2, caveolin-1, REP-2, and integrins 
[133-134, 137, 391]. Actin contraction, a process required for formation and 
strengthening of focal adhesions on integrin ligands during spreading, has been suggested 
to drive the internalization of cholesterol-rich lipid rafts containing cationic complexes 
bound to proteoglycans [163]. 
Emerging research suggests cell spreading may have a direct impact on endocytic 
processes. The formation, maturation, contraction, and disassembly of focal adhesions 
allow cells to spread over and move across their substrates. The speed of this cycle is 
controllable with substrate topography, as mediated through the heterogeneous spatial 
availability of adsorbed integrin ligands [89, 148]. A loss of integrin-mediated adhesion 
results in dramatic internalization of caveolae [152]. Disassembly of focal adhesions is a 
clathrin-dependent endocytic process; clathrin colocalizes with focal adhesions as 
nucleated by actin fibers, and knockdown of clathrin activity results in diminished 
integrin internalization [90]. These studies demonstrate strong links between integrin 
function and caveolae- and clathrin-mediated trafficking. These links could manifest as a 
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coincident uptake of complexes or as a downregulation of particle uptake through 
competition for the endocytic machinery by altered integrin presentation and 
internalization on patterned topographies. As such, enhanced transfection efficiency of 
NHDFs cultured on patterned topography may be a downstream consequence of altered 
endocytic uptake and/or intracellular trafficking. 
 Substrate stiffness has been previously demonstrated to control transfectability, 
with stiffer substrates supporting more efficient transfection, putatively a consequence of 
enhanced proliferation on stiff surfaces [392]. Similarly, dense presentation of integrin 
ligands has also been shown to improve gene transfer through increased proliferation 
[393]. In our study however, neither pit spacing nor size had a significant impact on cell 
density or proliferation compared to smooth substrates (Figure 34c,d), indicating 
differences in cell division are not responsible for the enhanced transfection efficiency. 
Regions with large pit spacing had a greater number of cells than those with small 
spacing after transfection (Figure 34c); when taken with the observation that proliferation 
is unchanged this suggests either decreased initial attachment, or survival, during 
transfection on more discontinuous surfaces. 
 Luciferase expression levels were not detectably altered with transfection on the 
patterns that increased the percentage of GFP-expressing cells. This result may reflect the 
difference in how the reporter signals are weighted in each case - weakly GFP+ cells are 
counted with equal importance as those that saturate the photodetectors when quantified 
with thresholded fluorescence microscopy or flow cytometry. In contrast, luciferase 
assays weight highly-expressing cells more heavily than weakly-positive cells. Therefore, 
patterned topography may be exerting its influence on cells that express only a few copies 
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of reporter - that is, on cells that are very near to the positive/negative threshold. 
Alternatively, luciferase expression could be more toxic than GFP in NHDFs, leading to 
greater cell death in luciferase-positive cells. Increased transfection efficiency without an 
associated increase in transfection level is desirable at times, particularly for transfected 
cell arrays, where over-expression can be a significant problem if it doesn’t reflect a 
natural phenotype in vivo [394]. 
 Detailed microscopic examination of cells cultured on patterned topography 
reveals more possibilities to explain the increase in transfection efficiency. SEM images 
demonstrate NHDFs stretch their membrane over open pits as they move across their 
substrates, thereby exposing their basal surface to complex-containing medium (Figure 
40). It is reasonable to expect this process to occur more often, and for a larger proportion 
of the cell membrane, on surfaces with large, dense pits. Including sidewall surfaces, 
dense pits have an increased effective surface area than sparse patterns or smooth 
surfaces; pattern F(4,1) has ~ 2.4× and 1.8× greater effective surface area than smooth 
and F(1,4) substrates, respectively. This potentially increases the amount of fibronectin 
that is able to adsorb to pitted surfaces, and the amount of non-viral vector that can 
adsorb during transfection. Substrate-mediated gene delivery has at times been 
demonstrated to be more effective than bolus delivery [68-70]; if cells can interact with 
this increased substrate surface area, they may have access to a larger amount of 
complexes, increasing their probability of being successfully transfected. Confocal 
microscopy revealed that NHDFs were indeed capable of reaching the bottom of both 1 
and 4 µm pits, though the cells were more able to do so for 4 μm pits, which may have 
contributed to their enhanced transfection. 
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qPCR also demonstrated that integrin αv expression is upregulated in NHDFs on 
pitted topographies (Figure 41).  This may be a compensatory mechanism for diminished 
attachment, or a response to increased availability of the ligands through increased 
effective surface area.  Perlecan, a matrix heparan sulfate proteoglycan (HSPG), is 
expressed by dermal fibroblasts [395], and can bind to integrin β3 and β1 through an RGD 
domain in its core protein [396].  HSPGs are polyanionic, and serve as nonspecific 
receptors for cationic gene carriers [397].  Integrin αvβ5 functions in endocytosis and 
degradation of matrix-bound vitronectin by human skin fibroblasts [398], a process that is 
inhibited by heparin (a soluble anionic HSPG competitor), suggesting integrin receptors 
and HSPGs are involved in endocytosis of vitronectin [399].  Syndecan-1 (a 
transmembrane HSPG) expression increases transfection efficiency [400], co-precipitates 
with integrin β5 [401], and acts as a co-receptor with αvβ3 to initiate cell spreading [402].  
Further, engagement of integrin subunits through adsorbed antibodies against the 
dominant integrins expressed by a cell subtype increase transfection efficiency of 
adsorbed Lipofectamine 2000 [83].  Non-viral gene therapy approaches have also 
targeted the αv family in biomimetic approaches mimicking the natural hijacking of these 
integrins by AAV in receptor-mediated endocytosis to infect cells [403].  Taken together, 
these links suggest altered integrin expression on microtopography may be affecting the 
endocytosis of co-receptor HSPGs and any associated cationic nanoparticulate cargo. 
Cell culture substrates for in vitro use are typically smooth by default, whereas 
implantable gene-eluting scaffolds often impart tunable porosity (and therefore 
topography) via electrospinning [385], polymer chemistry, or porogen inclusion [386] to 
promote cell penetration and enhance mass transfer of entrapped therapeutics. The 
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microenvironment at implant surfaces is critically important to efficient transfection; the 
inclusion of soluble factors, adsorption of ECM molecules, maintenance of cell-cell 
interactions, and tuning of mechanical stress are all currently leveraged towards the 
improvement of transfection efficiency [387]. Scaffold surface topography is an 
additional design parameter that may be optimized to bolster in situ genetic manipulation 
of infiltrating cells. 
Ultimately, our goal is to understand the functional relationship between substrate 
topography, focal adhesion formation, cytoskeletal tension, endocytosis, and 
transfectability. We elected to take the first step with demonstration of the most 
downstream effect, transfectability, using bolus delivery of ubiquitous Lipofectamine 
2000 complexes to primary human fibroblasts cultured on a combinatorial library of well-
defined pitted topographies. Transfection is a multi-step process with many known and 
unknown modulators, including some that are evidently tunable with substrate 
topography. Discovery of topographies that increase transfection efficiency in primary 
human fibroblasts is another example of the power of high-throughput screening, 
complimenting the previous use of this technique to discover substrates with desirable 
stem and progenitor cell maintenance [114] or differentiation [388] effects and 
cytoskeletal changes in primary fibroblasts [404]. 
 
5.6 Conclusion and future perspectives 
 We have performed a systematic screen of non-viral transfection efficiency on 
microtopographic substrates, and discovered a significant enhancement of transfection 
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efficiencies for primary human fibroblasts cultured on densely-pitted surfaces compared 
to smooth. This improvement could not be attributed to an altered proliferation rate for 
cells on pitted substrates, and represents the first demonstration of a topographic 
influence on non-viral gene transfer. Topographic modulation of transfection is a new 
and therefore under-appreciated factor to consider when creating gene delivery systems. 
Understanding the mechanism responsible for this enhancement could allow us to 
determine the generality of the effect.  Substrate topography may enhance transfection 
efficiency by encouraging the endocytic uptake of nanoparticulate carriers.  This effect 
could be quantified by transfection of NHDFs with rhodamine-labeled GFP-encoding 
DNA.  And, to begin to determine the relative contribution of endocytosis, protein 
synthesis/degradation, and exocytic processes in topography-mediated transfection, the 
experiments could be repeated by first transfecting cells on topography, then trypsinizing 
and replating onto smooth substrates, and analyzing with flow cytometry a day later. 
Our main future interest in topography-mediated transfection is to apply the 
technology to a therapeutic system, such as NiN generation.  Combination of topography-
mediated transfection with topography-mediated enhancement of the iN reprogramming 
process [383] could lead to a synergistic improvement in NiN yields.  Heirarchical 
topographies, which include both nano- and microtopographical features [331], could 
simultaneously take advantage of the neuro-inducing effects nanotopography has on 
progenitor and stem cells [330], as well as of the improvements in transfectability and iN 
survival and/or induction efficiency on microtopography [383].  Synthesizing the results 
of Chapters 3-5, we can conclude that physical and chemical microenvironmental factors 
each have an important place in the design of effective non-viral direct neuronal 
reprogramming strategies. 
 
5.7 Figures 
 
Figure 31. Topographical library details 
10 pit morphologies (A–J) were replicated with 16 different combinations of size (X, 1–6 μm) and spacing 
(Y, 1–6 μm), giving 160 unique patterned PDMS substrates for cell growth, each with a uniform pit depth 
of 2.4 μm. Smooth regions were present in the center of the array (SM), and in the regions between patterns. 
Pattern K was excluded due to poor cell attachment. 
 
 
Figure 32. Fluorescence micrographs of NHDFs transfected on topographical libraries 
Masked large-area scans of transfected topographical arrays, with visible GFP transgenic protein (green), 
actin (phalloidin stain, red), and nuclei (DAPI, blue). 
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Figure 33. Fluorescence micrographs of NHDFs transfected on topographical libraries (detail) 
Patterns with small interfeature spacing (B(6,1)) supported higher transfection efficiency, greater alignment, 
and less spreading than those with large interfeature spacing (B(1,6)). 
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Figure 34. Transfection, spreading, attachment, and proliferation of NHDFs on topographical 
libraries 
(a) Transfection efficiency, (b) spreading, (c) cell number, and (d) proliferation of NHDFs cultured on 
topographical PDMS libraries as normalized to values taken from smooth regions in each array. Data are 
grouped across pit morphologies A-J by pit spacing (Y). Error bars represent the SEM of three independent 
experiments. Letters above bars (w-z) denote significance between columns by Tukey post-hoc testing of 
one-way ANOVA (P < 0.05) and symbols (#) denote significance compared to smooth regions by single 
sample t-test (P < 0.05). (a) Small interfeature spacing (Y = 1 μm) produced a 25% increase in transfection 
efficiency compared to smooth regions. (b) Pits spaced far apart (large Y) supported the highest levels of 
spreading. (c) Patterns with large interfeature spacing (Y = 6 μm) contained 25% more cells than those with 
small interfeature spacing (Y = 1 μm). (d) No significant dependence of proliferation on feature spacing 
was detected, suggesting increased cell number on features with large interfeature spacing may reflect 
increased initial attachment or survival. 
 
 
Figure 35. Freeze fracture SEM of patterns used for flow cytometry experiments 
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Figure 36. Flow cytometric quantification of transfection on micropits 
(a) Flow cytometry corroborates the results presented in FIGURE XXX; F(4,1), a pattern with small 
interfeature spacing (1 μm), supported 25% higher transfection efficiency than smooth PDMS and F(1,4), a 
substrate with large interfeature spacing (4 μm).  (b)  Reverse transfection is enhanced to an even greater 
extent on dense micropits.  Error bars represent SEM (n = 3).  Letters (a,b) not shared between columns 
denote significant comparisons between pitted substrates by Tukey post-hoc tests (P < 0.05) of one-way 
ANOVA, and symbols (#) denote significant differences compared to smooth substrates by single sample t-
test (P < 0.05). 
 
 
Figure 37. Microtopographical increase of pCBA-ABOL polyplex transfection efficiency in PMEFs 
Dense micropits (F(4,1)) significantly increase the efficiency of pCBA-ABOL transfection in PMEFs.  
Error bars represent SEM (n = 3).  Symbols (#) denote significant differences compared to smooth 
substrates by single sample t-test (P < 0.05). 
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Figure 38. Microtopographical increases in siRNA knockdown 
The transfection efficiency of low doses of DNA (solid bars), and siRNA knockdown (difference between 
solid and hatched bars) are enhanced by patterned topographies with small interfeature spacing ((F(4,1)) 
compared to smooth substrates.  Error bars represent SEM (n = 3).  Symbols (#) represent significant 
comparisons between substrates by Tukey post-hoc testing following one-way ANOVA (P < 0.05). 
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 than those cultured on F(4,1). Regions 
of the cell membranes were stretched over open pits on both patterns. Cells cultured on F(4,1) dramatically 
deform pit sidewalls. 
Figure 39. SEM of NHDFs interacting with pitted topography 
As imaged with 30° tilt. NHDFs cultured on F(1,4) are more spread
 
Figure 40. Confocal microscopy of NHDFs interacting with pitted topography 
NHDFs explore the bottom of 1 and 4 μm diameter pits, with visible α-actinin (green), actin filaments (red), 
and nuclei (blue).  The appearance of “holes” in the cell membrane of cells cultured on pattern F(4,1) is a 
ereas cells on F(1,4) consequence of the apical and basal cell surfaces bending below the focal plane, wh
only reached the bottom of pits with their basal membrane. 
 
 
Figure 41. mRNA expression of NHDFs on micropits compared to those on smooth substrates 
Preliminary RT-qPCR quantification of mRNA transcript from cells cultured on F(4,1) compared to 
smooth patterns, normalized to GAPDH.  Integrin α  expression was elevated on micropitted topographies.  
 1 
about 
V
No significant changes were detected for the endocytic genes clathrin heavy chain (CLTC), caveolin
(CAV1), or perlecan.  Error bars represent the range of transcript produced by the standard deviation 
a mean CT value (n = 3). 
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Significant Barrier to the Direct Reprogramming of 
Fibroblasts to Oligodendrocyte Progenitor Cells 
 
6.1 Summary 
Demyelinating diseases are a devastating burden on human health and healthcare, 
with currently no curative therapeutic options.  Autologous replacement of 
oligodendrocyte progenitor cells (OPCs) derived via direct reprogramming has the 
potential to drastically improve therapeutic outlook [268-269].  Ideally, integrative 
transcription factor delivery methods can be replaced with safer non-viral methods. As 
such, we delivered combinations of transcription factors expressed during OPC 
development: Sox10, Olig2, and ZFP536 (SOZ factors) to fibroblasts via transfection 
with pCBA-ABOL, or dox-inducible lentiviruses (as a positive control), in an effort to 
produce iOPCs capable of proliferating in response to PDGF, and of differentiating to 
oligodendrocytes.  Cells expressing the SOZ factors were cultured for a period of one to 
three weeks in OPC proliferation media, and then stained for the proliferative OPC 
markers S100β and O4, or differentiated with T3 for one week to oligodendrocyte-like 
cells and stained for myelin proteins MBP and MOG.  During this process we discovered 
that the cytoplasmic sequestration of wildtype Olig2 in PMEFs is a critical barrier to the 
induction of an OPC phenotype in fibroblasts. We appended the SV40 nuclear 
localization sequence (NLS) to the N-terminus of Olig2, which redistributed the 
transcription factor from the cytoplasm to the nucleus. When delivered in the SOZ factor 
cocktail virally and non-virally, Olig2-NLS produced a many-fold improvement in the 
Chapter 6: Cytoplasmic Sequestration of Olig2 is a 
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number of cells expressing iOPC markers over wildtype Olig2, and induced a vast 
ction.  
amming is 
expected to make derivation of human iOPCs more achievable, and to serve as a template 
approach for other forms of reprogramming that may suffer from cytoplasmic 
sequest
e 
ying 
f the 
aintained 
improvement in the number of myelin-producing iOLs generated by viral transdu
Our discovery and surmounting of this previously-unknown barrier to reprogr
ration of a lineage-instructive transcription factor. 
 
6.2 Rationale and Significance 
 Much like Alzheimer’s and Parkinson’s diseases, and ALS (against which we ar
working to develop non-viral strategies to produce autologous replacements for d
cortical, dopaminergic, and motor neurons respectively), MS is a crippling and deadly 
neurodegenerative disease with currently no curative treatment options for the most 
common progressive forms [176], though immunomodulation can modestly slow the 
deterioration in relapsing-remitting cases [177-179].  MS is caused by the autoimmune 
attack of myelin sheath-producing oligodendrocytes (OLs), leading to deterioration o
insulating myelin layer on axons throughout the CNS and eventual neuron death.  
 Two reports have recently appeared which describe the generation of induced 
oligodendroglial progenitor cells (iOPCs) with lentiviral delivery of OPC lineage 
specifying factors [268-269].  With mitogenic stimulation these iOPCs can be m
and expanded in a proliferative phenotype for many passages, and can then be 
differentiated with T3 into oligodendrocytes capable of compactly myelinating axons of 
dorsal root ganglia collected from shiverer mice (which are incapable of producing 
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y, 
tion for 
med iOPCs would have the 
advantage of being syngenic with the patient, and not derived from potentially 
teratogenic pluripotent intermediates [405]. 
 The generation of autologous OPCs from adult human sources is particularly 
ays (in 
ion to 
ortunately 
lly, 
normal myelin sheaths due to deletion of a portion of the MBP gene). Encouragingl
OPCs differentiated from human iPSCs have been shown to migrate through and 
myelinate the brains of mice with congenital hypomyelination (shiverer) with a single 
intracranial injection, without tumor formation or heterotropic nonglial differentiation 
[220], thereby firmly establishing cell replacement as a promising treatment op
MS.  Compared to iPSC-derived OPCs, directly-reprogram
attractive for human cell therapy, because the proliferative pre-differentiation phase of 
iOPCs could be exploited to increase the amount of cells that can be produced from 
however many cells are initially reprogrammed. This is particularly true for non-viral 
iOPC generation; regardless of the initial reprogramming efficiency, the proliferative 
phase could be used to generate a sufficiently large source of safer autologous OLs.  
Compared to iPSCs, autologous OPCs are expected to be less tumorigenic due to their 
exclusive commitment to the glial lineage and reliance on PDGF for continued 
proliferation.  Furthermore, OPC generation from iPSCs currently takes 110-150 d
addition to the time required to generate the iPSCs) [220] – a daunting prospect for 
clinical scale-up.  iOPCs, on the other hand, require less than a month from induct
differentiation into oligodendrocytes [268-269]. 
Non-viral induction of myelin genes has been previously attempted, unf
with no activation of endogenous myelin gene expression [406]. However, the 
researchers: attempted to simultaneously deliver seven transcription factors non-vira
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.2, 
ly 
d 
al 
lig2, and 
viral iOPC production in the PMEFs that we 
t of 
o 
6.3 Methods 
, Amaxa, Cologne, Germany) and 
VR125
ion 
, 
only allowed the cells to reprogram for seven days before analysis, and included Nkx2
which is dispensable for and may unpredictably affect iOPC generation [268] via 
complex suppression/activation of Olig2 [407-408], and Ascl1, which may have strong
arrested cell division in this context [409] as it is now known Ascl1 levels need to 
oscillate to maintain the proliferative phenotype observed in Ascl1+ NPCs [410].  Arme
with the knowledge that iOPCs may require at least 14 days to reprogram in the lentivir
system, as well as with a smaller list of essential transcription factors (Sox10, O
ZFP536) we also ambitiously attempted non-
are able to transfect very efficiently with pCBA-ABOL [281].  As we discussed in 
Chapter 4, we were aware that each direct reprogramming cocktail may face unique 
barriers that may hinder complete conversion to the desired fate; this awareness 
sensitized us to recognize a previously undescribed but evidently critically important 
barrier to both viral and non-viral iOPC generation: cell type-dependent nuclear impor
Olig2 – one of the master regulators of iOPC generation that is shared between the tw
currently known iOPC cocktails. 
 
Plasmids, molecular cloning, and plasmid purification. 
The reporter vectors pmax-GFP (3486 bp
5C (6413 bp, Vical, San Diego, CA), which respectively express GFP and 
luciferase under control of the CMV promoter, were used as a positive transfect
control (GFP), and a no-reprogramming negative control (pLuc). pORF-Sox10 (4642 bp)
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 Tet-O-
ed 
he 
AG 
se PCR 
 
s presented in Figure 42.   
lasmids were propagated in Escherichia coli DH5α (Invitrogen, Carlsbad, CA) 
and purified with EndoFree Plasmid Mega and Maxi kits (QIAGEN). Plasmid DNA 
concentrations were quantified by measurement of absorbance at 260 nm with a 
, Waltham, MA). 
 
pORF-Olig2 (4213 bp), and pORF-ZFP536 (7150 bp), which carry mouse ORFs under 
control of the EF1α promoter, were generated by digestion of Tet-O-FUW-Sox10,
FUW-Olig2, and Tet-O-FUW-ZFP536 (gifts from Marius Wernig, Stanford University) 
with EcoRI (NEB), and ligation into pORF-mcs (Invivogen, San Diego, CA) digest
with EcoRI. 
pORF-Olig2-NLS (4237 bp) was generated by PCR-amplification of Olig2 from 
TetO-FUW-Olig2, with primers that added flanking 5’ and 3’ EcoRI restriction enzyme 
sites, as well as a 5’ Kozak sequence followed by an ATG start codon and SV40 NLS 
sequence (NLS sequence: 5’-CCC AAG AAG AAG AGG AAG GTG GGC-3’).  T
forward PCR primer sequence was 5’-CAG CAG GAA TTC GCC ACC ATG CCC A
AAG AAG AGG AAG GTG GGC GAC TCG GAC GCC AGC-3’ and the rever
primer sequence was 5’-CAG CAG GAA TTC TCA CTT GGC GTC GGA G-3’.  Tet-O-
FUW-Olig2-NLS was produced by digestion of pORF-Olig2-NLS with EcoRI, and 
insertion into Tet-O-FUW-Ascl1 digested with EcoRI.  A summary of the non-viral SOZ
and SOZ-NLS plasmid cocktails i
P
NanoDrop ND-1000 Spectrophotometer (Thermo Scientific
Poly(CBA-ABOL) synthesis and polyplex formation 
Poly(CBA-ABOL) was synthesized by Michael polyaddition of 3.67 g N,N-
cystaminebisacrylamide (CBA) (Polysciences, Warrington, PA) and 1.26 g 4-amino-1-
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meter. p(CBA-ABOL)/DNA nanocomplexes (polyplexes) were synthesized 
at a pol
fer 
, MA), or 40,000 PMEF-HLs 
for vira  
 4.5 
a 
ential 
mino acids, sodium pyruvate, and β-mercaptoethanol (Invitrogen).   
sitive transfection control, pLuc 
as a no
butanol (ABOL) (Sigma-Aldrich, Saint Louis, MO) as described by Lin et al.[353] The 
reaction product was purified by dialysis (3.5 kDa cutoff) in acidic deionized water (pH 
4) and then lyophilized. The polymer was collected in its HCl-salt form (1.63 g, 33% 
yield), and its structure validated by 1H NMR (in D2O) on a Varian Mercury 300 MHz 
NMR Spectro
ymer:DNA mass ratio of 45:1, which was selected based on a preliminary 
optimization of GFP expression in primary mouse embryonic fibroblasts (PMEFs) 
(results not shown). Polyplexes were prepared by adding a HEPES buffer solution (20 
mM HEPES, 5 wt % glucose, pH 7.4) of p(CBA-ABOL) (900 μg/mL) to a HEPES buf
solution (20 mM HEPES, 5 wt % glucose, pH 7.4) of plasmid DNA (75 μg/mL), 
followed immediately by vortexing for 20 seconds. Reaction sizes ranged from 5 to 15 μg 
of plasmid DNA. 
 
Cell culture and transfection or transduction 
80,000 PMEF-HLs for non-viral (Millipore, Billerica
l were seeded per well in 24-well TCPS plates (BD, Franklin Lakes, NJ) at 37 °C
and 5% CO2 in complete PMEF medium: Dulbecco’s Modified Eagle’s Medium with
g/L glucose (GIBCO 11960-044) (Invitrogen), 10% Premium Select FBS (Atlant
Biologicals), 25 µg mL-1 gentamicin (Invitrogen), and 1x GlutaMAX, non-ess
a
PMEFs were transfected with either: GFP as a po
-reprogramming control, or cocktails of pORF-Sox10, pORF-Olig2, pORF-
ZFP536 (SOZ factors) for induced oligodendroglial progenitor transdifferentiation.  
  169  
 
 
 
after 
nt 
t-O-
F medium containing 2 μg mL-1 doxycycline (Sigma). 
48 hours after the final transfection was completed, or 48 hours after viral 
ced with OPC proliferation medium: 
DMEM
TF, 10 ng mL-1 
PDGF-
Cocktails containing Olig2 with the SV40 NLS sequence have “-NLS” appended to their
name (SOZ-NLS, for example). SOZ factor plasmids were delivered at an equal mass 
ratio in all cases. All transfections were carried out in serum- and antibiotic-free 
OptiMEM (Invitrogen). OptiMEM was replaced with complete PMEF medium four 
hours after the onset of transfection. Serial transfections were performed every 48 hours, 
with complete PMEF media between.  
Viral transduction of the SOZ or SOZ-NLS factors was performed 24 hours 
PMEF seeding in medium with 8 μg mL-1 sequabrene (Sigma), using replication-deficie
2nd generation lentiviruses (packaging vectors psPAX2 (Addgene plasmid 12260) and 
pMD2.G (Addgene plasmid 12259)), in combination with Tet-O-FUW-Sox10, Te
FUW-Olig2, and Tet-O-FUW-ZFP536.  24 hours after transduction, PMEF medium was 
replaced with PME
transduction, complete PMEF medium was repla
 11960 (Invitrogen) containing 100 μg mL-1 human transferrin, 100 μg mL-1 
bovine serum albumin, 16 μg mL-1 putrescine, 60 ng mL-1 progesterone, 40 ng mL-1 
sodium selenite, 5 μg mL-1 N-acetyl-L-cysteine, 10 ng mL-1 D-biotin (Sigma), 4.2 μg mL-
1 forskolin (Stemgent), 5 μg mL-1 bovine insulin (Gemini Biosystems), 1x B27 
supplement without vitamin A, 1x GlutaMAX, 1x sodium pyruvate, 25 µg mL-1 
gentamicin (Invitrogen), 1x Trace Elements (Cellgro), 10 ng mL-1 CN
AA, and 1 ng mL-1 NT-3 (PeproTech). After 21 days of culture in proliferation 
medium, iOPCs were switched to differentiation medium.  Differentiation medium was 
the same as proliferation medium, with addition of 40 ng mL-1 triiodothyronine (T3, 
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MS) at RT for 15 minutes. Cells were then 
permea  
c-17342, 
1:500), 9, 
 
 
, 
r 
 area. 
Sigma) and absence of PDGF-AA and NT-3.  Viral OPC proliferation and differentiation 
medium contained 2 μg mL-1 doxycycline (Sigma). 
  
Immunofluorochemistry 
Transfected cells were washed briefly with PBS containing Ca2+ and Mg2+ 
(Mediatech), and fixed with 4% PFA (E
bilized for 10 minutes in 0.2% Triton X-100, washed twice, blocked for an hour in
10% donkey, goat, or fetal bovine serum, and incubated for 2 hours at room temperature 
(or 18 hours at 4C for myelin antibodies) in blocking buffer containing 10% goat or fetal 
bovine serum (Sigma-Aldrich) and combinations of the following primary antibodies: 
mouse IgM anti-A2B5 (R&D MAB141, 1:200), mouse IgM anti-O4 (R&D MAB1326), 
rabbit anti-S100β (Abcam ab52642, 1:500), goat anti-Sox10 (Santa Cruz s
 goat anti-Olig2 (Santa Cruz sc-19969, 1:500), rat anti-MBP (Abcam ab734
1:100), goat anti-MOG (R&D AF2439, 1:50).  The cells were then washed three times
with PBS, and incubated for one hour at RT in blocking buffer containing appropriate
AlexaFluor 488 or 594 anti-IgG or anti-IgM secondary antibodies (1:500, Invitrogen)
washed three times with PBS, and imaged with a Nikon Eclipse TE2000-U inverted 
fluorescence microscope (Tokyo, Japan) with a ProScanII motorized stage (Prio
Scientific, Rockland, MA). 
 
Image analysis 
To quantify S100β+ and O4+ cell generation, PMEFs were transfected in TCPS 
wells, stained, and scanned to produce large mosaic images of each complete culture
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h image according to local contrast, 
xclude mall debris, overlay thresholded S100β and O4 channels, and to count the 
le-positive cells in each well. 
6.4 Results 
lig2.  
+
 
LS 
aged at 
artitioned virtually all visible Olig2 from the cytoplasm to the 
ucleus (Figure 43, right).  The same repartitioning was observed when Olig2 or Olig2-
red with lentiviral transduction (not shown). 
 
S100β and O4 mosaics were processed with a FIJI (Fiji Is Just ImageJ, http://fiji.sc) 
macro to: automatically and uniformly threshold eac
e  s
number of single- and doub
 
Olig2 requires a synthetic nuclear localization sequence to efficiently traffic to the 
nucleus in fibroblasts 
 To check expression, transfection efficiency, and proper nuclear localization of 
the master OPC transcription factors Sox10 and Olig2 cloned into the non-viral pORF 
vectors, PMEFs were transfected using pCBA-ABOL with pORF-Sox10 or pORF-O
PMEFs were then stained at day two post transfection for Sox10 and Olig2 expression.  
Sox10 was located in the nucleus, whereas Olig2 was largely cytoplasmic, with some 
nuclear expression.  A subset of Olig2  cells excluded Olig2 from their nuclear 
compartment, evident as a “hole” coincident with DAPI staining of the nucleus (Figure
43, left).  To determine the effect on nuclear localization from addition of the SV40 N
to Olig2, pORF-Olig2-NLS and pORF-Olig2 were transfected into MEFs, and im
day 2.  Addition of NLS rep
n
NLS were delive
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tails, 
 days, and exposed to T3-
containing media for 7 days. A subset of PMEFs transfected with equimolar mixtures of 
SOZ factors drastically altered their morphology and expressed OPC lineage markers 
(Figure 44). SOZ-NLS qualitatively produced the highest efficiency of S100β induction 
anel). 
O 
r 
F-SOZ 
d with luciferase (pLuc) 
id not express OPC markers. 
 
The addition of NLS to Olig2 dramatically increases the expression of OPC mar
in PMEFs expressing ectopic SOZ factors 
 PMEFs were transfected with 1 µg of pORF-SOZ and pORF-SOZ-NLS cock
cultured in OPC proliferation media for a period of 7 to 21
at day 14 in OPC proliferation medium, and produced the most compact O4+ cells 
(Figure 44, lower right p
The increase in S100β and O4 positivity was significant as measured by large area 
image analysis (Figure 45).  Without the addition of SV40 NLS to Olig2, both pORF-S
and pORF-SOZ factor cocktails were ineffective at generating O4+ and S100β+ cells 
compared to delivery of Sox10 alone.  ZFP536 increased the expression of S100β in all 
cases tested.  The fusion of SV40 NLS to Olig2 increased the expression of S100β ove
15-fold, O4 5-fold, and double-positive cells 20-fold for the pORF-SO and pOR
factor cocktails. 
The number of S100β+ and O4+ cells increased from day 7 to day 14 in OPC 
proliferation media for all combinations of SOZ factors other than pORF-Olig2 delivered 
alone (Figure 46).  SOZ factor combinations with the highest fraction of Sox10 produced 
the greatest number of O4+ cells.  Olig2 and Olig2-NLS were unable to induce OPC 
marker expression in the absence of Sox10.  PMEFs transfecte
d
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 NLS 
lusters of iOLs arising from colonies proliferated from 
single s
6.5 Discussion 
lia-committed phenotype simultaneously diminishes their potential for 
tumorig
68] 
heir complete recapitulation of all measured functions of 
ona-fide OLs, but the efficiency of iOPC generation is markedly lower than neuronal 
Addition of NLS to Olig2 increases the yield of iOLs produced with viral delivery of 
SOZ factors 
Rare PMEFs transfected non-virally with pORF-SOZ-NLS factors and exposed to 
T3 for 7 days expressed MOG, but the morphology and expression pattern of these 
MOG+ cells was not typical of primary oligodendrocytes (Figure 47).  PMEFs virally 
transduced and differentiated in parallel with SOZ or SOZ-NLS factors co-expressed 
MBP and MOG with the stellate morphology expected of primary myelinating 
oligodendrocytes.  Large area image analysis reveals that viral SOZ factors without
produced what appeared to be c
uccessfully-reprogrammed iOPCs, while inclusion of Olig2-NLS produced a 
much denser field of iOLs (Figure 48). 
 
iOPCs are an attractive target for viral and non-viral reprogramming.  Their 
proliferative yet g
enicity compared to iPSCs, while being expandable to provide a therapeutic 
quantify of cells for transplantation.  In a pioneering description of iOPC generation from 
fibroblasts, Wernig et al. demonstrated SO and SOZ efficiently activate OPC markers 
with lentivirus, but SOZ was the only combination that produced myelinating OLs [2
– as such, we focused on this combination.  Both of the currently-published iOPC 
protocols are encouraging for t
b
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on-viral generation of OPCs; successful non-viral OPC reprogramming 
will be
ing 
BP, 
y OPCs.  Accordingly, O4+ NiOPC-like cells did 
not proliferate significantly in response to mitogen stimulation following FACS 
purification (not shown).  Furthermore, MBP+ and MOG+ cells were exceedingly rare, 
and also had morphologies that were dissimilar to that of primary OLs (Figure 47).  
MBP+ a se 
e 
 
tic 
reprogramming protocols.  This presents a particularly exciting opportunity and steep 
challenge for n
 more difficult than non-viral neuronal reprogramming, but any successfully-
reprogrammed cells could be greatly expanded for therapeutic deployment.   
OPCs express a variety of lineage-specific markers throughout their normal 
development and differentiation.  Fast-dividing early OPCs express A2B5, slow-divid
late OPCs express S100β and begin to express O4 [411].  Mature OLs express M
MOG, and may continue to express O4 [411].  We were able to detect each of these 
markers with immunostaining in non-viral iOPC-like cells transfected with the SOZ 
factors.  However, for the most part NiOPC-like cells had abnormally large, spread 
morphologies when compared to primar
nd MOG+ NiOPC-like cells were never double-positive.  Taken together, the
results suggest these NiOPC-like cells are only partially reprogrammed. 
Considering the incomplete reprogramming of these NiOPC-like cells, it is 
surprising to note the gradual appearance of O4+ and S100β+ cells between days seven 
and 14 post-transfection (Figure 46) – a period during which the ectopic SOZ factors ar
expected to be silenced.  These cells may gradually find a pseudostable fate that is neither
OPC nor PMEF, and may be entirely synthetic.  It is important to keep this “synthe
cell” possibility in mind when determining the “success” of reprogramming based on 
appearance of markers that are exquisitely unique to the target cell type in normal 
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Indeed,
o 
OG+ 
PCs 
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PCs (Figure 43, 
left).  O th 
 
development – these markers may appear during reprogramming as direct or indirect 
transactivants of the ectopic transcription factors, and waves of downstream markers ma
appear at the “normal” point they would be expected in vivo, in cells that are neverth
unable to perform the required therapeutic function (myelination of axons, in 
 single-cell expression analysis of iPSCs in the process of converting have 
revealed that many distinct intermediate stages can exist between starting fibroblasts and 
the final reprogrammed phenotype, each with a different resistance to proceeding on t
the next [293].  These intermediates are a (meta)stable fate in their own rite, and can 
persist for some time without fully committing to the desired final functional form. 
Viral iOPCs, on the other hand, were A2B5+, S100β+, O4+, and MBP+ and M
upon differentiation with T3, and single cells were generally co-stained for all markers 
analyzed.  Viral iOPCs and iOLs assumed morphologies typical of proliferative O
and myelinating primary OLs, respectively.  We generated iOPCs with SOZ factors at a
efficiency that was comparable to that which has been previously reported [268-269]
During validation of molecular cloning of the non-viral SOZ factors, we observe
a cytoplasmic localization of Olig2 that is not typical of that in primary O
lig2 has a cryptic NLS which is only exposed and active upon interaction wi
chaperone proteins, none of which are normally expressed in fibroblasts [407].  
Considering the central importance of Olig2 in both published iOPC derivation protocols,
and the fact that transcription factors must be physically located in the nucleus to initiate 
or repress transcription on target genomic DNA, we hypothesized cytoplasmic 
sequestration of Olig2 may be a previously unknown barrier to iOPC generation.   
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lineage-specific markers (Figure 44, Figure 45).  The additional activation afforded by 
With an aim to translocate Olig2 to the nucleus in PMEFs, we first considered
small molecules which can globally inhibit the active export of transcription factors from 
the nucleus (leptomycin B, for example).  However, Sox10 activity is known to be 
dependent on continuously active nucleoplasmic shuttling [412].  An indiscriminate 
inhibitor of nuclear export would likely therefore impair the activity of Sox10, the 
master regulator of OPC reprogramming.  Adding chaperone transcription factors to the 
cocktail is another possibility to carry ectopic Olig2 into the nucleus, but this is not ideal
for non-viral reprogramming, as it diminishes the total mass of the other plasmids tha
can be delivered in the cocktail.  We had already noted that co-delivery of three plas
es the mass of Sox10 plasmid to levels near the cutoff threshold of its ability to 
induce O4 positivity in PMEFs (not shown).  Furthermore, the Olig2 chaperone 
transcription factor Nkx2.2 may inhibit viral iOPC generation [268]; other chaperone 
proteins may have similarly unpredictable and undesirable side effects. 
Transgenic mice with an N-terminal Olig2 fusion have been previously describ
velopmentally normal [410]; this suggests the function of Olig2 may not critically 
depend on interactions at the N-terminus.  We therefore elected to append the strong 
SV40 NLS to the N-terminus of Olig2 to encourage nuclear entry without the assistance
of chaperone proteins.  With addition of the NLS, Olig2 delivered both virally an
virally to PMEFs was repartitioned from the cytoplasm almost exclusively to the nucleus 
(Figure 43, right).  Consequently, the number of S100β+ and O4+ cells was dramatically 
increased at day 14 post introduction of the SOZ factors with non-viral (and vira
shown) delivery of cocktails containing Olig2-NLS, as well as expression of other O
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6.6 Conclusion and future perspectives 
 
 localization of Olig2 was not sufficient to induce complete reprogramming of 
NiOPCs as measured by MBP and MOG positivity, but the yield of MBP+ viral OLs was 
increased markedly (Figure 48). We were unable to increase the number of non-vira
induced MBP+MOG+ cells with three serial transfections of SOZ-NLS factors, nor w
further addition of miRNAs highly and uniquely expressed in OPCs, or reprogramming 
in the presence of small molecules that remove repressive epigenetic marks from mature 
myelin genes [406] (results not shown).  Non-viral transfection with SOZ factors in 
general, or with the EF1α promoter specifically, may produce expression that is current
of an insufficient duration, stability, and/or intensity to completely reprogram PMEs to 
iOPCs.  The addition of NLS to the non-viral SOZ cocktail may lower the barrier of 
conversion from fibroblasts to an intermediate fate [293], through which viral SO
transduced cells can pass on to the iOPC fate efficiently, but non-virally transfected ce
cannot. 
 
 We have demonstrated that relief of cytoplasmic sequestration of Olig2 is 
sufficient to dramatically increase the non-virally-induced expression of OPC lineage 
markers, and to increase viral iOL yield.  To our knowledge this is the first demonstration 
of a strongly repressive host cell context "in trans", which can be circumvented during 
direct reprogramming via the intelligent reengineering of a master transcription factor. 
Therefore, the failure of a cell to reprogram may not always be a consequence of 
insurmountable epigenetic barriers, but also potentially due to the absence of critical 
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 bind to its genomic targets during BAM NiN generation [282], and that the 
ability of Ngn2 to reprogram cells in vivo has been shown to depend on the local milieu 
of growth factors [311]. 
Our present inability to fully convert iOPCs without lentivirus implies there are 
ly a 
y 
 
t non-
c 
cofactors [283].  The generation of fibroblast-OPC heterokaryons could be instructive 
determine which genes are not transactivated in the fibroblast nuclei.  Manipulation of the 
ground state of starting cell sources is an almost completely unsolved barrier to direct 
reprogramming in the CNS [285]. 
Optimistically, the increased yield of viral iOLs with the use of Olig2-NLS may 
help to allow iOPC reprogramming from human fibroblast sources for the first time.  
These results serve not only as a specific notice to researchers performing any form o
direct reprogramming to ensure proper nuclear localization of transcription factors rather 
than only expression by Western blot, but also more broadly to consider other potential 
cell-type-specific contextual inhibitors of transcription factor function such as post-
translational modifications, chaperone interactions, and extracellular signaling. Two 
related examples are the demonstrated requirement for Ascl1’s pioneer activity before 
Brn2 can
one or more additional barriers preventing non-viral iOPC generation.  This is like
consequence of delivery, as the viral and non-viral experiments were performed entirel
in parallel from an identical cell source.  Minicircle vectors avoid silencing and may help 
to maintain longer-term expression [351].  The use of orthogonally-inducible lentiviral 
systems could also help determine the order, duration, and level of TF expression that is
required for complete iOPC reprogramming, and to better predict whether transien
viral transfection will be able to achieve the required thresholds.  Assuming epigeneti
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repression in cis is a barrier to non-viral iOPC generation, CRISPR/Cas9 synthetic TFs 
[298] should also be evaluated for their ability to activate more stable expression from the 
endogenous SOZ loci than ectopic factors delivered via plasmid DNA. 
Appending a strong NLS to
d” synthetic transcription factor for use in reprogramming - there are many other 
design possibilities that remain to be explored in the context of direct reprogramming.
For example, appending VP16/64/160 transactivation domains to increase transcription
factor potency (as has been done to enhance iPSC reprogramming [413]), or specifically 
mutating or applying directed evolution to wild-type transcription factors to alter known
or as-yet-undiscovered critical post-translational modification sites (such as those us
for inhibitory SUMOylation of Sox10 [305]), may further improve the efficiency of t
difficult forms of direct reprogramming.  Interestingly, VP16-Olig2 fusions act as 
dominant-negative mutants, presumably because of Olig2's normal role as a 
transcriptional repressor [408].  OPCs also respond strongly to topographical cues, even 
in the absence of biochem
tiation and myelination of nanofibers [414].  The stage is therefore well-set to 
explore a rich parameter space of intra- and extracellular microenvironmental factors to
push non-viral iOPC generation over its remaining barriers to complete conversion, 
towards deployment in safer future cell replacement therapies against MS.   
 
6.7 Figures 
 
Figure 42. Non-viral vectors for direct reprogramming of fibroblasts to oligodendroglial progenitors 
Coding sequences for mouse Sox10 (S), Olig2 (O), and ZFP536 (Z) transcription factors were inserted into
the pORF backbone under control of the EF1α-HTLV promoter, or the dox-inducible Tet-O-FUW lentiviral 
backbone.  The SV40 nuclear localization sequence was cloned 5’ of the coding sequence of Olig2, 
 
 
producing Olig2-NLS. Cocktails of SOZ factor-encoding plasmids were delivered at an equimolar ratio. 
 
Figure 43. Olig2 expression in fibroblasts transfected with and without 5’ addition of the SV40 NLS 
Olig2 transfected into PMEFs is primarily located in the cytoplasm, and is excluded from the nucleus
exclusively to the nucleus in PMEFs. 
Olig2 expression as visualized by immunofluorochemistry at day 2 post-non-viral transfection.  Wild-type 
 in 
some cells (left).  5’ addition of the SV40 nuclear localization sequence (NLS) repartitions Olig2 
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Figure 44. OPC marker expression in PMEFs non-virally transfected with SOZ factors 
S100β (red) and O4 (green) expression as visualized by immunofluorochemistry at day 14 OPC 
proliferation media, following non-viral transfection of 1 μg pORF-SOZ or pORF-SOZ-NLS factors, with 
DAPI-labeled nuclei (blue).  A subset of PMEFs transfected with equimolar mixtures of Sox10 (S), Olig2-
NLS (O-NLS), and ZFP536 (Z) plasmids drastically altered their morphology and expressed OPC lineage 
markers. SOZ-NLS produced the highest efficiency of S100β induction at day 14 in OPC proliferation 
medium, and produced the most compact O4+ cells (lower right panel).   
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Figure 45. Quantification of OPC marker expression in PMEFs non-virally transfected with SOZ 
and SOZ-NLS factors 
Large area scans of S100β and O4 expression at day 14 in OPC proliferation media following a 1 µg dose 
of pORF-SOZ or pORF-SOZ-NLS in PMEFs (2.5 mm scale bar).  (b) Quantification of S100β+ and O4+ 
cells at day 14 of OPC proliferation media culture. Without the addition of SV40 NLS to Olig2, both 
combinations of OPC transcription factors were ineffective at generating O4+ and S100β+ cells compared to 
usion of NLS 
EFs 
delivery of Sox10 alone.  ZFP536 increased the expression of S100β in all cases.  (c) The incl
increased the expression of S100β over 15-fold, O4 5-fold, and double-positive cells 20-fold. PM
transfected with luciferase (pLuc) did not express OPC markers.  Cell counts were generated with large 
area image analysis; bars represent mean ± SEM of three separate experiments performed in triplicate. 
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Figure 46. Time course of OPC marker expression one to two weeks following SOZ factor 
transfection 
Quantification of the increase in S100β+ and O4+ cells between day seven and 14 of culture in OPC 
proliferation medium.  Combinations with the highest fraction of Sox10 produced the greatest number of
O4+ cells.  Olig2 and Olig2-NLS were unable to induce OPC marker expression in the absence of Sox10
 
.  
MEFs transfected with luciferase (pLuc) did not express OPC markers.  Cell counts were generated with 
large area image analysis. 
 
P
 
Figure 47. Expression of MOG in PMEFs transfected with SOZ-NLS factors and exposed to T3 
MOG expression as visualized by immunofluorochemistry in PMEFs non-virally transfected with SOZ-
NLS, cultured in OPC proliferation medium for 21 days, and exposed to T3 differentiation medium for 7 
days. 
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Figure 48. Myelin protein expression in PMEFs virally transduced with SOZ and SOZ-NLS factors 
Large area scans of MBP expression at day seven of culture in T3 differentiation media following viral 
transduction of SOZ or SOZ-NLS factors and 21 days of culture in OPC proliferation medium (2.5 mm 
scale bar).  Figure produced in equal collaboration with Karina Kulangara.
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Chapter 7: Summary and Synthesis 
7.1 Non-viral direct neuronal reprogramming 
 In Chapter 3, we provided data that strongly supports Hypothesis 1: Non-viral 
neuronal transdifferentiation of fibroblasts into neuronal cells that fire trains of action 
lentiviral BAM-factor iN generation protocols, and a proportion of those NiNs went on to 
mature into an electrophysiologically-active phenotype.  To our knowledge this is the 
first demonstration of non-viral direct somatic reprogramming across germ layers 
(complete myoblast reprogramming with MyoD is restricted to mesodermal starting cells), 
and is therefore an important proof-of-concept which demonstrates the feasibility of safer 
non-integrative direct neuronal reprogramming. If the history of the iPSC field is 
predictive of future iN developments, the safety profile of iN generation can and will be 
improved even further by replacement of plasmid DNA (which integrates very rarely) 
with completely non-integrative mRNA, siRNA, miRNA, protein-transduction, and 
entirely small molecule-based techniques.  
 NiN generation with BAM factors is an accessible technique; though pCBA-
ABOL transfection improves the yield of iNs compared to commercial carriers, labs with 
non-viral transfection experience should be able to rapidly produce neurons from MEF 
sources with their transfection reagent of choice.  This advance over viral delivery will 
lower the barrier to entry for many biomaterials labs, which already have experience 
potentials can be achieved.  With multiple transfections of transcription factor-encoding 
plasmids we produced immature NiNs at an efficiency similar to that of published 
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studying the differentiation of ESCs and iPSCs into CNS lineages in a variety of 
a formation may have lacked 
ation of successful NiN 
reprogramming can therefore act as a bridge between the neurobiologists who are now 
delving into the biology of direct reprogramming, and the tissue- and bio-engineers who 
are well-equipped to deploy these cells in their most translatable forms.  Non-viral 
neuronal reprogramming may also re-invigorate the design of non-viral transfection 
agents with a new question: What can be done to re-transfect partially-converted 
intermediate cell fates stuck between fibroblast and neuronal phenotypes, particularly 
those which may have arrested division?  Subsequent mRNA/miRNA/siRNA 
transfections, which do not depend on nuclear entry, may be a good answer to this open 
question. 
 Gene-eluting implantable scaffolds for nerve regeneration in the PNS and CNS 
are just two examples which could be modified from a neuro-protective to a cell-
replacement paradigm with substitution of the plasmids delivered.  We expect there will 
be an explosion of work performed to study the interaction of iNs, iNPCs, and iOPCs 
with biomaterials, both to improve the efficiency of their generation, as well as to deliver 
the cells in a supportive context in vivo.  We have provided the first examples of these 
microenvironmental mediators of transfection and iN generation and/or survivability in 
Chapters 4-6. 
 
microenvironmental contexts, but due to the risk of teratom
a strong therapeutic rationale for the near future.  Our demonstr
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 In Chapter 4 we provided evidence in support of Hypothesis 2: 
Microenvironmental factors can improve iN yield.  We demonstrated that defined 
chemical microenvironments can improve the yield of non-viral iNs for both a 
glutamatergic and dopaminergic cocktail of transcription factors, either by inducing 
chronic depolarization, or by manipulating SMAD and GSK-3β signaling with small 
molecules.  Chemical control of microenvironment with these same approaches elicits 
similar pro-survival and pro-neuronal changes in normal development and in 
differentiating iPSCs.  This adds to growing support across the field of direct neuronal 
reprogramming that seems to suggest emerging iNs may be subject to some of the same 
developmental cues and controls as newborn primary neurons.  We expect that our 
extension of these techniques to non-viral neuronal reprogramming will provoke any 
translational bioengineers who adopt our NiN production scheme in Chapter 3 to look 
towards normal neurodevelopment to discover new means to further improve and instruct 
NiN reprogramming, especially for difficult target subtypes that may nevertheless be 
particularly attractive for cell replacement therapies. 
 The physical microenvironment imparted by substrate topography is another 
powerful mediator of cell phenotype in vitro, but its role in normal development is 
difficult to study in vivo.  Cell replacement strategies for neurodegenerative diseases 
typically enjoy the benefit of a slow disease progression, and may therefore readily adopt 
ex vivo iN generation schemes, which could potentially gain from topographical 
7.2 Extracellular microenvironment and non-viral direct 
reprogramming 
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 or in vivo 
 surface topographies that encourage transfection and iN 
conversion and survival. In Chapter 5 we go on to show that microtopography can 
improve the non-viral transfection efficiency of fibroblasts, in support of Hypothesis 3: 
High-throughput screening will identify micropitted topographies that enhance 
transfection compared to smooth substrates.  Our lab has also further demonstrated that 
microtopographies can enhance both the yield and purity of iNs produced with lentiviral 
transduction.   
 We are currently investigating potential synergy between these substrate-mediated 
effects on transfection and iN generation via non-viral direct neuronal reprogramming on 
patterned micro- and nanotopographies.  Topography could also be intelligently designed 
to guide neurite extension of iNs in such a way that they are more likely to encounter 
desirable circuits in vivo or other converting iNs in vitro, to encourage a particular 
electrical microenvironmental connectivity that might enhance subtype specification, 
integration, or survival, potentially via some of the same beneficial depolarization-
mediated effects we described in Chapter 4. 
 
 Drawing a distinction between extra- and intracellular microenvironment may be 
largely semantic – extracellular signaling is transduced and reflected inside the cell, and 
cells actively secrete and modify extracellular factors.  In this case however, we use 
enhancements of this process.  Similarly, implantable scaffolds for iN delivery
induction could include
7.3 Intracellular microenvironment and non-viral direct 
reprogramming 
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al 
 generation, and may therefore suffer from 
dditional barriers to complete reprogramming. We found that the published iOPC 
generation protocols indeed suffer from a lack of chaperone factors to carry Olig2 into 
fibroblastic nuclei.  We relieved this barrier via fusion of a constitutive NLS to Olig2, 
 the induction of OPC markers.  The appended NLS was 
“intracellular microenvironment” as shorthand to encapsulate the overall epigenetic and 
transcriptional phenotype of naïve and mid-reprogramming fibroblasts, which ma
impermissive to completion of the transdifferentiation process.  To this point, resea
have largely ignored the status of the starting cell type, which may drastically impact 
reprogramming.  Consideration of the differences in efficiency for various startin
target cell types highlights perhaps the most exciting and fundamental questions in the 
field of direct reprogramming: What keeps somatic cell fates stable, and how can we 
precisely break 
needed for therapeutic cell replacement?  For the most part, all cells contain the same 
genomic DNA, so the most fundamental “switch” in a reprogrammed cell occurs at the 
epigenetic level.  However, it is generally unclear whether resistance to reprogramming is 
principally a consequence of epigenetic silencing in cis, insufficient transgene delivery
levels or duration, or the presence (absence) of suppressive (supportive) trans-acting
factors. 
 We investigated this idea in Chapter 6 with Hypothesis 4: Viral and non-vir
iOPC generation is inefficient compared to iN
a
which greatly improved
sufficient to greatly improve the yield of oligodendrocytes from a lentiviral 
reprogramming approach, but one or more barriers to non-viral iOPC generation remain. 
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ation of these 
of starting cell programs which have evolved to resist change.  We must be willing and 
 Our discovery of a strongly repressive fibroblastic intracellular context will not 
only improve iOPC derivation efficiencies specifically, but can also serve as a general 
notice to the field to search for other non-permissive intracellular contexts, whether they 
be acting in cis or trans.  We have demonstrated proof-of-concept that trans repressors
transcription factor function can be overcome via protein engineering.  Currently, the 
strategies for overcoming epigenetic cis repressors are generally limited to global 
epigenetic modifiers, or biasing stochastic epigenetic changes towards a desired fate w
supraphysiological levels of ectopic transcription factor expression.  In the future, the 
nascent field of “epigenetic editing” may be able to more-precisely manipulate epigenetic 
marks at the loci most critical for successful reprogramming.  Safe translation of these 
techniques as deployed against neurodegenerative disease can draw benefit from 
consideration of the enhanced non-viral transfection and reprogramming methods we 
have developed in this dissertation. 
 
 Safe direct reprogramming of readily-obtained somatic cells to the neuronal a
glial cell types lost in neurodegenerative disease could provide patients with the most 
realistic hope for curative therapies to date. The direct conversion of fibroblasts to 
neurons and glia is not likely a naturally-occurring process, but it does appear to f
some of the normal “rules” of development.  In the pursuit of efficient gener
cells, we should therefore look to and respect development, while remaining suspicious 
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able to re-engineer the intracellular and extracellular contexts before, during, and after 
reprogramming, to allow the desired natural transcriptional programs to take hold and 
remain healthy.  The most permissive microenvironments for iN conversion and survival 
may be quite similar to those encountered by primary progenitors, neurons, and glia 
during their journey through development.  In this dissertation we have demonstrated t
such physical and chemical microenvironments can be potently repressive, or wiel
encourage the direct reprogramming of neurons and glia.  This sets the stage for a new 
field of therapeutically-fruitful research, which can draw equally from neurobiology an
bioengineering: the development of in vitro and in vivo systems for close recapitulation 
of dynamic developmentally-inspired soluble and biophysical cues during non-integrati
direct neuronal and glial reprogramming. 
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